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Carbapenem antibiotics were thought to be the ultimate ß- lactams, 
combining the action of a ß- lactam with that of a ß- lactamase inhibitor in a 
single molecule. These compounds are very effective antimicrobials and are 
currently licensed for use as last line treatments in Intensive Therapy 
Units (ITUs) and remain active against organisms producing extended 
spectrum TEM- and SHV- derived enzymes which are able to hydrolyse 
third generation cephalosporins. 
In this thesis a study of imipenem resistant Bacteroides fragilis clinical 
isolates from several sources including the Public Health Laboratory 
Service in Cardiff and the Scottish Anaerobe Reference Laboratory was 
undertaken. Three of these isolates were found to have Minimum Inhibitory 
Concentrations (MIC's) of imipenem greater than the breakpoint set by the 
NCCLS of 16mg/l. In all cases, the isolates were found to produce an 
imipenem hydrolysing ß- lactamase. Biochemical analysis has shown that 
these strains each produce a single ß- lactamase with a substrate and 
inhibitor profile similar to that of the CfiA metallo- ß- lactamase previously 
described from a Bacteroides fragilis isolate. 
Whilst attempting to optimise the assay conditions for these enzymes, it 
was discovered that the concentration of zinc sulphate present during the 
preparation procedure and during the assay significantly affected the 
specific activity and substrate profile of these enzymes. By splitting a 
single culture of a metallo -ß- lactamase producing strain, it was possible to 
demonstrate that this effect was a direct result of the zinc sulphate 
concentration present during the preparation and assay of these enzymes. 
It was noted that these enzymes were inhibited by the presence of excess 
zinc sulphate, and that this inhibition was reversible and substrate specific, 
affecting carbapenem hydrolysis more than any other substrate. This 
observation was found to extend to several other metallo- ß- lactamases. 
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Abstract 
A survey of Bacteroides clinical isolates from the Edinburgh Royal 
Infirmary was also undertaken to determine the frequency of resistance to 
several antimicrobials. The rate of imipenem resistance was found to be 
0.6% (n = 166). 
Imipenem resistant isolates from several species including Burkholderria, 
Enterobacter and Stenotrophomonas were examined for carbapenemase 
production. Only the Stenotrophomonas isolates were found to produce a 
ß- lactamase capable of hydrolysing imipenem. 
Ten clinical isolates from the genus Flavobacterium were examined for 
carbapenemase production. All isolates were found to hydrolyse imipenem, 
although in three isolates, the rate was very low. The addition of the metal 
ion chelator EDTA was found to inhibit both the nitrocephin and imipenem 
hydrolysis of all but two of these isolates. Two strains were also identified 
each of which produced a novel metallo -ß- lactamase, and the ß- lactamases 
of one of these ( Flavobacterium spiritivorum NCTC 11388) were 
characterised in greater detail. 
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BFR0 BFR, BFR1000 
[Chapter 5] 
Glossary. 
The rate of hydrolysis of substrate by the tested 
ß- lactamase in the presence of no ZnSO4 supplement. 
This term relates only to data presented in Chapter 5. 
The subscripts 0, 1 and 1000 denote the concentration of 
zinc sulphate (in µM) present during the 13-lactamase 
preparation, in this case BFR (Batt. fi,agilis). 
ID60 Concentration of inhibitor required to inhibit hydrolytic 
activity by 50 %. 
Minimum inhibitory concentration at which 50% of the 





Minimum inhibitory concentration at which 90% of the 
tested isolates were found to be sensitive. 
Chapters in brackets denote the first occurrence of each term. 
All other terms are standard scientific notation and are quoted in standard 
units. 
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Chapter 1: Introduction 
CHAPTER ONE 
Introduction.. 
Few developments in the history of medicine have had such a profound 
effect upon man and society as the development of the power to control 
infections due to micro -organisms. Developed countries have been able to 
control and treat many bacterial infections which previously devastated 
populations. The threat of death from infection has diminished to such an 
extent that it is now the exception, rather than the expected outcome of a 
diagnosed infection. 
1.1. Antimicrobial Agents: A Brief History. 
The use of poultices and tinctures for the treatment of infections and 
general malaise have been documented for thousands of years. These 
remedies were passed down from generation to generation and improved 
over the centuries. Many of these treatments can be shown to contain 
compounds which give them a sound pharmacological basis, although the 
reason for activity was not necessarily understood at the time. 
Mercuric chloride was used by Arabian physicians in the middle ages for 
preventing sepsis on open wounds. Antiseptics came into general medical 
use in the nineteenth century, although these early attempts were not 
generally accepted until Pasteur's publication in 1863 of the microbial origin 
of putrefaction. The problem was to discover compounds having a selective 
action against the microbial cell compared with the cells of the host animal. 
Following the success by Lindgard in the treatment of trypanosomiasis with 
arsenous oxide, Ehrlich attempted to make other related arsenicals which 
were less toxic. He found that these compounds were active against the 
causative agent of syphilis, and in 1907 he discovered salvarsan which soon 
1 
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became the standard treatment for syphilis. This was later coupled with 
bismuth therapy, and was used until superseded by penicillin in 1945. 
Ehrlich was probably the first person to encounter the problem of 
resistance to chemotherapeutic compounds by the observation that 
trypanosomes could become resistant to certain treatments, and that this 
resistance extended to chemically related compounds, but that there was no 
cross resistance between compound groups [1,2]. 
Other attempts at producing antimicrobials were unsuccessful and no 
practical progress was made until 1935 when Domagk reported the activity 
of Prontosil rubrum against animal infections. Trefouel showed that 
Prontosil was metabolised in the body to sulphanilamide, the active 
antibacterial compound. This was the first sulphonamide identified, and 
their development would have been more extensive had it not been for the 
advent of penicillin and other antibiotics so soon afterwards. The only 
synthetic compounds widely used apart from sulphonamides are 
trimethoprim, the quinolones and metronidazole [1]. 
1.2. The Penicillins. 
1.2.1. The Discovery of Penicillin. 
In 1929 Fleming reported that a mould growth contaminating one of his 
plates seeded with Staphylococcus aureus was able to inhibit the growth of 
this bacterium. This mould was identified as Penicillium notatum. He later 
showed that this mould produced a freely diffusible substance which he 
named penicillin. This compound was highly active against Gram positive 
bacteria, and he found that when injected into animals, broth containing 
this compound was no more toxic than broth alone. Unfortunately this 
mould did not produce penicillin in sufficient quantities for the drug to be 
successfully purified and tested, and little work was conducted on penicillin 
until 1940. In this year, Florey and Chain re- examined the mould described 
by Fleming. They succeeded in producing a solid preparation containing 
partially purified penicillin [3,4]. Large scale fermentation techniques and 
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the later discovery of Penicillium chiysogenum which produced penicillin in 
significantly greater quantities than Penicillium notatum allowed large 
scale penicillin production to become both practical and affordable. 
It was found that the addition of various adjuncts to the fermentation 
medium could determine the side chain added to the penar nucleus and 
thereby the ß- lactam produced would be predominantly a single compound 
[5]. Benzylpenicillin (Penicillin G) was produced by the addition of 
phenylacetic acid to the fermentation medium. Similarly, the addition of 
phenoxyacetic acid led to the production of the first penicillin variant, 
phenoxymethylpenicillin (Penicillin V) [6]. This compound had significantly 
increased acid stability which led to a decreased loss of the active compound 
owing to the low pH of the stomach when given orally. 
1.2.2. 6- Aminopenicillanic Acid. 
The elucidation of the structure of 6- aminopenicillanic acid (6 -APA) [7] 
facilitated the formation of many semi - synthetic penicillin derivatives with 
varying spectra of activity. 6 -APA is the condensation reaction product of 
alanine and ß- dimethylcysteine and is shown in Figure 1.1 below. 
Figure 1.1: Structure of 6- Aminopenicillanic Acid. 
COO - 
II I 
ß- lactam Thiazolidine 
Ring Ring 
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1.2.3. Classification of Penicillins. 
Modification of the acyl side -chain of 6 -APA results in the steric protection 
of the ß- lactam ring and thus protects it from attack and hydrolysis by 
several ß- lactamase enzymes whilst also defining its spectrum of activity 
and pharmacokinetic properties. Many such modifications have been made, 
and examples of the resulting compounds are shown in Table 1.1 below. 
Table 1.1: Classification System for Penicillins. 
Penicillin Group 
Natural Penicillins Anti Broad Compounds 
Staphylococcal Spectrum active against 
Penicillins Penicillins P. aeruginosa 
Benzylpenicillin (G) Methicillin (amino -) Temocillin 
Phenoxymethyl- Nafcillin Ampicil hint (acylureido -) 
penicillin (V) (isoxazolyl -) Amoxycillin Azlocillin 
Cloxacillin Ciclacil in Mezlocillin 
Dicloxacillin Amdinocillin Piperacillin 
Flucloxacillin (carboxy -) 
Oxacillin Carbenicillin 
rl`icarcillin 
¡ and derivatives. 
Adapted from [8]. 
(italics) denote the structural family of the compounds listed. 
1.2.3.1. Natural Penicillins. 
These compounds exhibited activity against almost all Gram positive 
organisms, Gram negative cocci and some Gram negative bacilli. These 
compounds rapidly penetrate most tissues but are hydrolysed by virtually 
all ß- lactamases. However, these drugs are often first choice therapy for 
streptococcal and pneumococcal infections. 
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1.2.3.2. Anti Staphylococcal Penicillins. 
Anti staphylococcal penicillins are penicillin derivatives that are 
penicillinase resistant. These drugs are first line treatment for 
staphylococcal infections. However, the emergence of methicillin resistant 
Staphylococcus aureus (MRSA) in the early 1980s has eroded their 
usefulness. 
1.2.3.3. Broad Spectrum Penicillins. 
These penicillins were the first compounds with bactericidal activity against 
Escherichia coli and Haemophilus influenzae, and yet retained activity 
against penicillin sensitive Gram positive bacteria. 
1.2.3.4. Penicillins Active Against P. aeruginosa. 
These compounds possess an antibacterial spectrum of activity similar to 
ampicillin with activity against several species of Enterobacter. The 
carboxypenicillins must be given by the intramuscular or intravenous route 
as they are not absorbed after oral administration. 
1.2.4. Penicillin Use In The 1990s. 
Structural modifications of the ß- lactam acyl side chains as discussed 
earlier have gone some way to increasing ß- lactamase stability, but 
bacteria have countered this by producing enzymes with a much broader 
spectrum of activity. The increasing spread of bacterial resistance, 
particularly amongst the Enterobacteriaceae and H. influenzae, has 
curtailed the usefulness of such drugs in these clinical settings. However, 
these drugs are still prescribed today for minor infections, more than 50 
years after their discovery. 
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ß- lactam compounds are generally non -toxic to humans, although 
immunological sensitisation has been observed in a small proportion (<10 %) 
of those treated with these compounds. This sensitisation precludes the use 
of these compounds in those individuals affected because of the risk of 
anaphylaxis, although some cephalosporins cause no reaction in some 
patients sensitive to penicillins [9]. 
1.3. The Cephalosporins. 
1.3.1. The Discovery of the Cephalosporins. 
The first report of a cephalosporin was made by Brotzu who isolated a 
strain of Cephalosporiuin acremonium from a sewage outfall in Sardinia in 
1945. Treatment of bacterial infections and abscesses with a crude extract 
of this mould gave promising results and so, in 1948 he sent a sample of the 
mould to Florey in Oxford. A series of molecules were isolated from this 
mould which exhibited bactericidal activity against Gram positive 
organisms, and these were collectively named cephalosporin P [10]. The 
separation of these molecules led to the discovery of Cephalosporin N [10] 
(which was later renamed Penicillin N) which exhibited activity against both 
Gram positive and Gram negative organisms [11]. Also present was a small 
amount of a compound named Cephalosporin C [12]. This compound was 
found to have a similar spectrum of activity to penicillin N, but was found to 
be resistant to hydrolysis by penicillinase and was later shown to have a 
ß- lactam ring, but a dihydrothiazine (cephem) ring replaced the thiazolidine 
ring of the penams [12] as shown in Figure 1.2 overleaf. 
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1.3.2. 7- Cephalosporanic Acid (7 -ACA). 








After 7 -ACA had become available in quantity, many semi -synthetic 
derivatives were produced, some with similar acyl groups to benzyl- 
penicillin and the semi - synthetic penicillins This led to the production of 
cephalothin and cephaloridine. These early cephalosporins were soon to be 
followed by cephalexin, cefaclor and many others. 
The basic cephalosporin nucleus consists of the essential ß- lactam ring 
fused to a dihydrothiazine ring. Modifications of the cephem nucleus at 
position 7 by the addition of methoxy groups (forming cephamycins) 
increase ß- lactamase stability but decrease activity against Gram positive 
species because of the lower affinity of these compounds for the penicillin 
binding proteins [13]. The more useful acyl side chains have been those that 
contain a 2- aminothiazoyl group, as this increases the affinity of the 
molecule for the penicillin binding proteins of Gram negative bacteria and 
streptococcal species. Iminomethoxy groups provide ß- lactamase stability 
against the common plasmid ß- lactamases from Staph. aureus and the 
TEM, SHV -1, OXA and PSE enzymes found in Enterobacteriaceae and P. 
aeruginosa, as well as the chromosomally mediated P99 -type enzymes of 
Enterobacter spp. The newer cephalosporins have a much wider spectrum of 
activity compared with the first generation cephalosporins, although some 
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clinical bacteria have also become resistant to these newer compounds. 
Replacement of the sulphur atom in the cephalosporin dihydrothiazine ring 
by oxygen produces an increase in intrinsic activity in a number of 
cephalosporins [14]. 
The first cephalosporinase with the ability to hydrolyse cephalosporin C 
was reported in 1956 [15]. 
1.3.3. Classification of The Cephalosporins. 
It was soon discovered that the substitution of the acyl side chains of 
7 -ACA could alter the antibacterial and pharmacokinetic properties of the 
compounds with this core structure. Hence, like the penicillins, many semi - 
synthetic compounds were produced with varying antibacterial spectra of 
activity. 
Table 1.2: Classification System for Cephalosporins. 
Cephalosporin Generation 
























A recent review of the classification of cephalosporins can be found in [16]. 
1.3.3.1. First Generation Cephalosporins. 
The first generation cephalosporins include oral and parenteral compounds 
with moderate antibacterial activity, and are stable to staphylococcal 
13- lactamases. However, these compounds are susceptible to hydrolysis by 
a wide variety of enterobacterial ß- lactamases. 
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1.3.3.2. Second Generation Cephalosporins. 
These compounds are parenteral compounds with moderate antibacterial 
activity, and show resistance to a wide range of 13-lactamases. 
1.3.3.3. Third Generation Cephalosporins. 
The third generation cephalosporins were heralded as the ultimate 
cephalosporins with stability against ß- lactamase hydrolysis coupled with a 
wider spectrum of antibacterial activity. These compounds showed 
increased activity against Gram negative strains, and were designed to 
have increased anti- Pseudornonas activity [14]. These compounds were also 
designed to be resistant to hydrolysis by early TEM- and SHV- derived 
enzymes. However, whilst the TEM -1 and SHV -1 ß- lactamases remained 
sensitive to these compounds, point mutations in the gene encoding these 
enzymes have occurred, resulting in an `opening' of the active site to 
facilitate the binding and hydrolysis of these compounds by extended 
spectrum TEM- and SHV- derived enzymes such as TEM -3, TEM -5, and 
SHV -2. 
1.3.3.4. Fourth Generation Cephalosporins. 
Examples of this class of compounds include cefepime and cefpirome. 
Structurally, these compounds resemble second generation cephalosporins 
in their substituted groups. However, cefpirome is a zwitterionic 
shaped' molecule, engineered for rapid penetration into the cell. These 
compounds are resistant to hydrolysis by extended spectrum ß- lactamases 
such as TEM -3 and TEM -5 but hydrolysed by all known metallo- 
ß-lactamases with the exception of CphA [17]. 
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1.4. Monobactams. 
Naturally occurring compounds of this group also possess a ß- lactam ring, 
but show limited antibacterial activity alone [18]. These compounds bind to 
penicillin binding proteins and it has been reported that sulbactam was 
efficacious in the treatment of both Burkholderria cepacia [19] and 
Acinetobacter baumannii [20]. 
Monobactams are capable of inhibiting several ß- lactamases by binding to 
and hence occupying the active site. Certain enzymes are capable of 
hydrolysing these compounds, although this hydrolysis is slow because the 
acyl - enzyme complex exists for a relatively long period of time before the 
hydrolysis product is released. 
Semi - synthetic monobactams (6- desaminopenicillin sulphones) were 
developed, including aztreonam, sulbactam and tazobactam. Aztreonam 
was the first monobactam marketed, and was followed by sulbactam and 
tazobactam which exhibit a broader spectrum of activity and show greater 
stability than aztreonam. 
1.5. ß- lactamase Inhibitors. 
When the molecular mechanism of drug resistance has been determined, it 
has been possible in some cases to design specific therapeutic combinations 
to overcome particular resistance determinants. If the resistance is 
mediated by an enzyme capable of inactivating the ß- lactam agent, the 
formulation and hence co- administration of a ß- lactamase inhibitor with a 
ß- lactam agent will increase the half life of the antibacterially active 
ß- lactam. 
The mechanisms of ß- lactamase inhibition mediated by these compounds 
can fall into any one of the several categories shown in Figure 1.3 overleaf. 
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Figure 1.3: Mechanisms of ß- lactamase Inhibition. 
Competitive Inhibition. 
E+I - EI ` E + I 
Non -Competitive `Time Dependant" Inhibition. 
E + I (EI)i 




(EI) 4 E + P1 + P2 
E+I 
(EP1) + P2 
E - Enzyme I - Inhibitor 
Px - Product E I - Enzyme Inhibitor acyl intermediate 
Adapted from [21]. 
The strategy of combining a ß- lactam with a ß- lactamase inhibitor [22], for 
example amoxycillin with clavulanic acid, is marketed as Augmenting and 
remains active against many strains which produce a ß- lactamase capable 
of hydrolysing amoxycillin. Clavulanic acid has a high affinity for class A 
ß- lactamases such as PSE -4, SHV -1, and TEM -1 ß- lactamases and is a 
potent inhibitor [23], but has poor antibacterial activity alone [24]. 
Clavulanic acid (an oxapenam) and sulbactam (a penicillin sulphone) have 
novel structures which resemble the nucleus of the penicillin molecule, and 
yet are not hydrolysed by the vast majority of these enzymes. These 
inhibitors work by either irreversibly binding to, and inhibiting the 
ß- lactamase as a suicide inhibitor [25] or by potentiating the effect of the 
1 Trademark of SmithKline Beecham Pharmaceuticals. 
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ß- lactam antibiotic. Sulbactam has been shown to inhibit ß- lactamases in a 
similar way to clavulanic acid, although it is hydrolysed prior to inhibition 
[26]. Tazobactam, another monobactam is a slightly more effective 
inhibitor than sulbactam [21] although hydrolysis has been detected [27], 
and has been formulated with piperacillin and marketed as Tazocin2. 
BRL 42715, an experimental penem, is more effective against both 
chromosomal and plasmid mediated ß- lactamases than sulbactam, 
tazobactam or clavulanic acid. ID60s for this compound are less than 10nM 
for virtually all serine active site ß- lactamases, between 10- and 100 -fold 
less than other ß- lactamase inhibitors [28] [this thesis]. 
1.6. The Carbapenems. 
These compounds possess a ß- lactam ring, as do all ß- lactam compounds. 
However, compounds from this group possess an unsaturated penem ring, 
unlike the saturated penam ring of the penicillins and cephem ring of the 
cephalosporins. The olivanic acids are related to the carbapenems and were 
first isolated from a strain of Strep. olivaceus, but were so unstable that 
they have not been employed clinically [29]. 
The carbapenems have the broadest spectrum of all ß- lactam antibiotics, 
encompassing both Gram positive and Gram negative organisms, aerobes, 
and anaerobes, fermenters and non -fermenters [30]. The carbapenems 
remain active against Gram negative strains that resist broad spectrum 
cephalosporins via stably de- repressed chromosomal Ambler class C 
ß- lactamases, and also those strains which produce extended spectrum 
variants of TEM- and SHV- enzymes [29]. Potent carbapenemase activity 
was thought to be mediated solely by metallo- ß- lactamases, although it has 
recently been reported in some serine active ß- lactamases. Stability to 
common ß- lactamases is not total, as imipenem hydrolysis has been 
detected in several Class 1 enzymes, but is usually very slow; 
2 Trademark of Lederle. 
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Vmax= <0.006% Vmax of cephaloridine. It should be noted that imipenem is 
a strong inducer of ß- lactamases, although the enzyme produced is usually 
unable to hydrolyse this compound [31]. 
1.6.1. Currently Available Carbapenems. 
Imipenem is currently licensed for use in the UK and in many other 
countries around the world. It is marketed as Primaxin3, and is formulated 
with cilastatin, a renal dehydropeptidase 1 inhibitor with no antibacterial 
activity itself [32]. Imipenem (N- formamidoyl -thienamycin) is derived from 
thienamycin, a natural product of the soil organism Streptomyces cattleya 
[33], and it is the N- formamidoyl side chain which increased the chemical 
stability of thienamycin [34]. The stability of this compound in the presence 
of many ß- lactamases is conferred by the trans configuration of the 
hydroxyethyl side chain on the ß- lactam ring, which differs from the usual 
cis conformation of substitutions at this position [30]. 
Meropenem4, another carbapenem, has also been licensed for use in Italy 
and Great Britain. The structure of these compounds are shown in Figure 
1.4 overleaf together with the renal dehydropeptidase 1 inhibitor cilastatin 
which is co- administered with imipenem. 
1.6.2. Mechanism of Action. 
The mechanism of action of the carbapenem antibiotics is fundamentally 
the same as that for all other ß- lactams, and is discussed in Section 1.7. 
Imipenem is one of the smallest ß- lactam antibiotics. Its small size and 
zwitterion state enable it to gain access to the periplasmic space of Gram 
negative bacilli by passing through canals in the cell membrane created by 
porin proteins. 
3 Trademark of Merck Sharp & Dohme. 
4 Trademark of Zeneca Pharmaceuticals. 
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Whilst cilastatin, the renal dehydropeptidase 1 inhibitor, is not a 
carbapenem, it has been included in the above figure because it is co- 
administered with imipenem. Meropenem requires no such inhibitor since it 
is stable in the presence of this mammalian enzyme. 
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1.6.3. Carbapenems and Renal Dehydropeptidase 1 
Renal dehydropeptidase 1 (EC 3.4.13.11) is a mammalian protease of the 
renal brush border which uses a zinc ion co- ordinated in its active site for 
catalysis. The incorporation of an active site divalent cation (usually zinc) is 
a feature common amongst metallo-13-lactamases, although there is very 
little sequence homology between renal dehydropeptidase 1 and any of the 
metallo -ß- lactamases sequenced to date [35]. This enzyme is able to 
hydrolyse imipenem [36 -38], but not meropenem or biapenem, and so 
imipenem has been formulated with cilastatin [Figure 1.4] to inhibit this 
mammalian enzyme. Meropenem and biapenem are stable to mammalian 
renal dehydropeptidase 1 as they are both methylated at position 1. 
Modifications to the C -3 position have been shown to affect the 
antimicrobial activity of PS -5 carbapenem derivatives, but have little effect 
on increasing compound stability in the presence of dehydropeptidase 1 
[39]. This enzyme has no hydrolytic activity against other ß- lactam agents 
[40]. 
1.7. Mechanism of Action of ß- lactam Antibiotics. 
All ß- lactam antibiotics act by inhibiting bacterial cell wall synthesis. 
The structure of Escherichia coli cell wall peptidoglycan, and that of 
virtually all other bacteria consists of alternating B-1,4 linked residues of 
N- acetyl- D- glucosamine (NAG) and of N- acetylmuramic acid (NAM). The 
strict alternation of NAG and NAM in the glycan is ensured by the 
synthesis of disaccharide repeating units prior to polymerisation. These 
disaccharides are themselves linked ß -1,4 so that the glycan becomes a 
modified form of chitin [41]. 
All peptidoglycans initially carry a pentapeptide subunit (L- Ala- D -Glu- 
mDAP -D -Ala -D -Ala) on each D- lactyl group of the NAM moiety. This is 
thought to be common to all Gram negative and some Gram positive 
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organisms. However, this may be further modified by transpeptidation or 
carboxypeptidation. 
The final step of cell wall synthesis is the transpeptidase catalysed cross 
linking of the peptidoglycan chains. Cross linkage involves the elimination of 
a D -Ala residue from the N- terminal peptide unit, thus cleaving the D- 
alanyl-D- alanine linkage, followed by formation of a D- alanyl- acceptor cross 
link. 
The mature peptidoglycan is thus crosslinked into a single polymer which 
forms a sheath around the bacterial cell. This peptidoglycan polymer layer 
is thought to be thinner in some Gram negative organisms than in Grain 
positive organisms, possibly a mono -layer, as Gram negative organisms 
also possess an outer membrane to protect the peptidoglycan from 
degradative attack. As this membrane is not present in Gram positive 
organisms, the peptidoglycan is thought to exist as a multi- layered 
structure to which other polymers are covalently linked. 
Penicillin binding proteins are penicillin sensitive enzymes found in all 
bacteria which catalyse these terminal steps in the assembly of 
peptidoglycan, and can be D- D- carboxypeptidases, transglycosylases or 
transpeptidases. They are quantitatively a minor component of the plasma 
membrane and vary from species to species, with molecular masses 
between 30kDa and 150kDa, and are numbered in order of decreasing size 
[41, 42]. 
ß- lactam antibiotics are structural analogues of acyl D- alanyl-D- alanine 
donor substrates for transpeptidation. This observation was first reported 
in 1965 [43], and is shown in Figure 1.5 overleaf. The ß- lactam antibiotic 
will bind to the PBPs and thus inhibit peptidoglycan cross -linking leading to 
bacterial cell death. 
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Adapted from [43]. 






Substituted D- alanyl -D- alanine 
A recent report examined the relative binding affinities of biapenem, 
imipenem, and meropenem to the various PBPs of E. coli, P. aeruginosa and 
Staph. aureus [44]. The main advantage of this study was that the same 
PBP preparations were used for all assays, and the same methodology was 
employed, allowing the resulting data to be compared directly. This study re- 
inforced the previous report that the affinities of the various PBP for 
ß- lactams vary from species to species [45]. 
All three carbapenems bound tightly Lo PBP -1 of Staph. aureus. In E. coli, 
all three carbapenems had high affinities for PBPs 2 and 4. However, 
meropenem bound to PBPs 2 and 4 from P. aeruginosa with greater affinity 
than biapenem or imipenem. In general, meropenem was reported to have 
the broadest PBP profile in Gram negative organisms, although biapenem 
showed the best PBP profile against Staph. aureus. 
In E. coli, ß- lactams which bind to PBPs in group 1 are the most potent at 
effecting cell lysis. PBPs lA and 1B are involved in cell elongation. PBP -2 is 
thought to mediate a transpeptidase or carboxylase reaction as ß- lactams 
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which preferentially bound to PBP -2 caused ovoid cell morphology. PBP -3 is 
involved in cell division, and ß- lactams which bound to this PBP caused 
filament formation. PBPs 4, 5, and 6 are not inhibited by ß- lactains [41, 46, 
47]. 
Bacteria also produce murein hydrolases, which create nicks in the cell wall 
peptidoglycan to provide sites for new peptidoglycan synthesis during 
bacterial cell enlargement [48]. These enzymes are unaffected by 
ß- lactaras. Thus the continued activity of these enzymes without the 
restorative peptidoglycan cross linking will lead to autolysis of the bacterial 
cell [49]. 
1.8. Resistance to ß- lactam. Antibiotics. 
Resistance to ß- lactam antibiotics is mediated through either a minor or 
major DNA rearrangement. 
An example of a minor rearrangment is a point mutation. Such a mutation 
could alter the level of expression of a gene giving the organism a selective 
advantage over others. A point mutation could alter the sequence of a 
translated protein. If this protein were the target of the antimicrobial, the 
mutation could alter the target protein such that the antibacterial agent 
could no longer bind to its target. If this protein were an enzyme capable of 
destroying the antimicrobial, such a mutation could alter its specificity or 
spectrum of activity [50 -53]. 
There are several examples of major rearrangements, including gene 
duplication, and the acquisition of foreign DNA. The acquisition of foreign 
DNA may include acquisition of resistance determinants, and such 
transfers can be mediated by plasmid conjugation, as in the case of TEM -1 
[54]. Bacteriophages, transposons and integrons have also been shown to 
have the ability to carry resistance determinants [55 -58]. The ability of 
bacteria to acquire and disseminate genetic material is well illustrated by 
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the dramatic increase in the frequency with which resistant organisms 
have been isolated from clinical infections. 
There are several mechanisms by which bacteria may become resistant to 
ß- lactam antibiotics. 
1.8.1. Permeability. 
ß- lactam resistance has been linked to a reduction of membrane 
permeability [59, 60], a resistance mechanism relying on the exclusion of 
the ß- lactam compound from the target site. Imipenem resistance mediated 
by this mechanism was first reported in P. aeruginosa in 1986 [61] and has 
also been observed in several other species. In P. aeruginosa, it has been 
linked to the loss of porin protein D2 [62] and F [59]. Porin D2 has been 
shown to facilitate the penetration of imipenem across the outer membrane 
[63] and maps to between 71 and 75 minutes on the PAO1 chromosome 
[64]. In 1991, Kapotas and co- workers [65] acclimatised a strain of P. 
aeruginosa to imipenem and observed the concomitant loss of 6 membrane 
proteins, namely porins Dl, D2, E, protein H1, lipoprotein H2 and an 
unidentified 85kDa protein, although this strain remained sensitive to 
azlocillin and polymyxin B. Recently the efficacy of the new carbapenem 
BMS- 181139 has been shown to be independent of porin D2 levels, unlike 
imipenem, meropenem and biapenem [66], and is the first report of such 
independence on porin levels. This porin independent penetration is thought 
to be more rapid than the D2 dependent pathway and has been attributed 
to the presence of a basic substituted group on position 1 or 6 of the penem 
nucleus [67]. 
Whilst the loss of outer membrane porins in Gram negative bacteria has 
been shown to lead to decreased susceptibility to a variety of antibiotics, it 
has been possible to modify ß- lactams to take advantage of facilitated 
entry mechanisms into the periplasm by means of solute specific 
scavenging systems [68 -70]. See [71] for a recent review. 
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1.8.2. Change In Target Site - Penicillin Binding Proteins (PBPs). 
Resistance to ß- lactam compounds can also be mediated by alteration of 
the target site. This was characterised in a P. aeruginosa clinical isolate as 
an alteration in PBP -4 which occurred during imipenem therapy, although 
no concomitant loss of membrane porin proteins was observed in this 
strain. This alteration led to a 16 -fold increase in imipenem MIC, but MICs 
of all other antimicrobials remained unchanged [72]. In other Gram 
negative bacilli, penems have been shown to bind to PBP -2 [44,73] whereas 
other ß-lactams bind to primarily to PBP -1A, PBP -1B and PBP -3 [44,74]. 
Organisms may become resistant to ß- lactaras by either altering existing 
PBPs so that they no longer bind penicillins, or the bacteria may acquire 
supplementary resistant PBPs. An example of this is a report of a Staph. 
aureus strain in which PBP -2 and PBP -3 were lost and replaced with PBP -2' 
[75]. PBP -2' functionally complemented PBP -2 and PBP -3, and yet was not 
susceptible to many ß-lactams. 
1.8.3. Permeability and Hyper- production of a ß- lactamase. 
The combination of a reduction in outer membrane permeability and the 
production of a ß- lactamase have been shown to cause resistance to many 
ß- lactam antibiotics, including imipenem [76] even though the ß- lactamase 
produced may be unable to hydrolyse carbapenems at a significant rate. 
The permeability barrier reduces the concentration of the ß- lactam agent in 
the periplasm such that the low level ß- lactam hydrolysis by the enzyme is 
sufficient to protect the organism from this agent. This has been well 
documented in P. aeruginosa isolates, and Enterobacteria which hyper - 
produced a P99 type ß- lactamase. 
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1.8.4. Efflux Mechanism. 
Several membrane associated energy driven efflux mechanisms with broad 
substrate specificity have been described, mainly in P. aeruginosa. These 
efflux systems confer resistance to antimicrobials from many different 
classes, including tetracycline, chloramphenicol and fluoroquinolones [77, 
78]. It has also been shown that such an efflux mechanism can increase the 
resistance of isolates to ß- lactams [79]. 
1.8.5. Enzymatic Degradation of ß- lactam. 
The last, and most important form of resistance is mediated by the 
hydrolysis, and hence inactivation of the ß- lactain ring of the compound. 
This is caused by the action of a ß- lactamase enzyme. ß- lactainases (EC 
3.5.2.6) form a large family of enzymes that can hydrolyse the ß- lactam 
ring of antimicrobial agents which possess this bio- active structure, but do 
not interfere with peptidoglycan metabolism as they lack DD- peptidase 
activity. Ironically, the first report of a ß- lactamase [80] was published in 
the same year that penicillin underwent its first clinical trial in humans. 
Since then, the use of ß- lactams has led to an increase in the prevalence of 
ß- lactam resistance amongst bacteria. In 1940, virtually all strains of 
Staph. aureus world -wide were sensitive to penicillin. However, just over ten 
years after its first clinical use, 73% of Staph. aureus isolates from in- 
patients at the Boston City Hospital were resistant to penicillin, and most 
of these organisms produced a ß- lactamase [81]. By 1975, 84% of the in- 
patient Staph. aureus isolates at the Massachusetts General Hospital were 
resistant to penicillin [82], and by 1986 this figure had increased to more 
than 90% of Staph. aureus being penicillin resistant [83]. 
Resistance to ß- lactam antibiotics can be mediated by the production of a 
ß- lactamase, or by other mechanisms, but these are not mutually exclusive 
[84]. The production of a ß- lactamase is the most common mechanism of 
resistance to this class of antibacterial compounds. These enzymes are 
discussed in greater detail in Section 1.9 overleaf. 
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1.9. ß-lactamases. 
Over the last 30 years, many different 13-lactamases have been described 
from both Gram positive and Gram negative bacteria. There are currently 
196 different ß- lactamases known to exist [85]. The vast majority of these 
enzymes use a serine residue in the active site to hydrolyse the ß- lactam 
ring and these enzymes vary considerably in their ability to hydrolyse many 
different ß- lactam antibiotics. The other type of ß- lactamase contains a 
metal ion within its active site. 
1.9.1. Origin of ß- lactamases. 
Kelly and co- workers [86] have proposed that ß- lactamases evolved from 
penicillin sensitive DD- peptidases by comparing the structure of 
DD- peptidases with the ß- lactamase from B. licheniforinis 749 /C. Whilst 
these proteins lacked primary sequence homology, they shared a similar 
3- dimensional structure, and some residues were conserved around the 
active site [86, 87]. The evolution of Class A ß- lactamases has also been 
examined [88]. Kirby [89] investigated this further by constructing a 
phylogenetic tree and postulated that Class A and Class C ß- lactamases 
evolved from an actinomycete ß- lactamase, which itself had evolved from 
DD- peptidases. See Section 1.9.2 for ß- lactamase classification. 
There have not been any reports suggesting an evolutionary origin for Class 
B ß- lactamases, but since these enzymes share neither sequence homology 
or mechanism of action with serine active site ß- lactamases, it may be 
possible that parallels could be drawn with other enzymes which 
incorporate a zinc ion as part of the active site [90] including cytidine 
deaminases, angiotensin converting enzymes and matrix metallo- 
proteinases. See [91] for a recent review. 
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1.9.2. Classification of ß- lactamases. 
Several schemes have been devised to classify ß- lactamases. The first was 
described by Richmond and Sykes [92] and was based upon substrate 
affinities, iso- electric points and inhibition data. Since this classification 
system was introduced, many more ß- lactamases have been described, and 
other classification systems based upon new criteria have been devised 
which include these newer enzymes. 
The Ambler system [93] was proposed in 1980, and remains the most 
widely used classification system today. It is based on amino acid sequence 
homology around the active sites of the enzymes, and a standard 
numbering system for the amino acids in the sequence has also been 
proposed [94]. Since its publication, other classes have been added to this 
classification scheme, and these classes are discussed later. 
The Bush classification scheme [95, 96] was developed in response to the 
plethora of enzymes that were discovered with different properties. This 
scheme is based upon the Richmond and Sykes classification, but has been 
modified to include both physical and kinetic data. A recent report updated 
the Bush classification scheme [85] with the addition of new groups to 
include novel ß- lactamases which had been characterised since the 
publication of the original scheme. However, the Ambler [93] system is the 



























































































































































































































































































































































































































































































































































































































































































































Chapter 1: Introduction 
It can be seen from Table 1.3 that the Ambler system classified the 
enzymes into a smaller number of classes than the Bush system. The 
Ambler classification system will be used throughout this thesis unless 
otherwise stated. 
The formation of an extra class to accommodate the homo- tetrameric zinc 
metallo -ß- lactamase from Sten. maltophilia, has been proposed by Sanders 
[99], although the need for this additional class remains to be proven as this 
is the only enzyme currently in this class. 
1.9.2.1. Ambler Class A. 
All ß- lactamases within this class catalyse ß- lactam hydrolysis via a serine 
residue usually found at position 70 within the active site. These enzymes 
vary considerably in their ability to hydrolyse many different ß- lactar 
antibiotics, ranging from strict penicillinases to broad spectrum 
ß- lactamases and carbenicillinases. This class of enzymes includes all 
TEM- derived and SHV- derived enzymes which are the most prevalent 
ß- lactamases found in Gram negative isolates. 
Enzymes of this class may be chromosomally or plasmid encoded and are, 
with the exception of TRC -1 [100], generally regarded as sensitive to 
clavulanic acid, tazobactam and other ß- lactamase inhibitors. 
In the last two years, several class A enzymes from this class have been 
characterised which have the ability to hydrolyse carbapenems [101, 102 - 
see Table 1.5], a compound previously thought to be stable to all Class A 
enzymes. However, the carbapenem hydrolysing Class A enzymes do still 
show some sensitivity to ß- lactamase inhibitors, including clavulanic acid 
and tazobactam. 
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1.9.2.2. Ambler Classes B and E. 
Enzymes of these classes require a divalent cation, usually zinc for activity. 
These metallo -ß- lactamases are able to hydrolyse penicillins, 
cephalosporins and carbapenems, although penicillins tend to be their 
preferred substrate. For this reason, they have been referred to as metallo- 
penicillinases in some publications. Metallo -ß- lactamases are not 
susceptible to any ß- lactamase inhibitors in clinical use, such as clavulanic 
acid or sulbactam, which exert their effect by inactivating active site serine 
residues. In fact sulbactam has been shown to be hydrolysed by these 
enzymes [103], as has the experimental penem BRL 42715. Despite being 
a substrate for enzymes of this class, BRL 42715 is the only known 
ß- lactam with the ability to inhibit these enzymes at physiologically 
attainable concentrations [this thesis], most probably by acting as a 
competitive substrate for the metallo-13-lactamase. 
An overview of the kinetic parameters of enzymes from this class can be 
in [103] and [17]. 
These enzymes are generally monomeric proteins with molecular masses of 
25 -35 kDa, similar to the serine active site enzymes. They are readily 
inhibited by chelating agents such as EDTA, dipicolinic acid, and 
o- phenanthroline which are thought to inactivate the enzyme by 
sequestering the metal cation from the active site. The only currently 
known exceptions to this are the L1 enzyme from Sten. maltophilia, which 
is thought to exist as a homo- tetramer with an overall mass of 
approximately 118kDa and, in 1990 an imipenem hydrolysing ß- lactamase 
with an estimated molecular mass of over 60kDa was reported from 
Bacteroides distasonis but this enzyme was insensitive to EDTA, and so 
may not belong to this class of enzymes. 
These enzymes are usually chromosomally encoded. The only transferable 
metallo- ß- lactamases have been reported from P. aeruginosa [104], Bact. 
fragilis [105] and S. mnarcescens [106]. In the P. aeruginosa and Bact. fi°agilis 
isolates, the metallo-ß- lactamase gene was coded on a plasmid. These 
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plasmids were transferable to other strains of the same species with a 
concomitant transfer of imipenem resistance, although attempts to 
transfer imipenem resistance to E. coli were unsuccessful, and no plasmid 
transfer was detected. 
1.9.2.3. Ambler Class C. 
The formation of this class was proposed by Jaurin and Grundstrom who, 
having sequenced the ampC gene encoding a cephalosporinase from 
Escherichia coli K -12, found little sequence homology with Class A 
penicillinases [97]. Class C enzymes also utilise a serine residue within the 
active site like class A enzymes, but overall sequence homology between 
enzymes of these two classes is low. These enzymes are generally 
chromosomally encoded inducible cephalosporinases and are generally 
regarded as resistant to inhibition by clavulanic acid [107] and other 
ß- lactamase inhibitors. Examples of enzymes belonging to this class include 
P99 and AmpC. 
The kinetic parameters of six enzymes from this class have been 
determined and compared [108]. 
1.9.2.4. Ambler Class D. 
Enzymes of this class are serine active site enzymes and have been found 
in both Gram positive and Gram negative organisms. They are sensitive to 
clavulanic acid. This class was proposed by Huovinen and co- workers who 
sequenced PSE -2 [98]. This class also includes all OXA- derived enzymes. 
Ledent and co- workers have studied and compared the kinetic parameters 
of three ß- lactamases from this class [109]. 
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1.9.3. Mechanism of Action of ß- lactamases. 
The basic principle of ß- lactam hydrolysis is similar for both metallo- and 
serine active enzymes, namely the hydrolysis of the ß- lactam ring to form 
an acid product with no antibacterial activity as shown in Figure 1.6 below. 
However, the mechanism of hydrolysis varies between these two types of 
enzymes. 





1.9.3.1. Serine Active ß- lactamases. 
Ì 
ß- lactamases of Ambler classes A and C and D [see Section 1.9.2] all 
possess a serine residue at position 70 (Ambler numbering system as 
proposed in [94]). This residue is essential for catalytic activity and 
mutation of this residue results in almost, if not total, inactivation of the 
enzyme [110]. A Lys -Thr(Ser) -Gly triad is also conserved around the active 
site [111]. Serine -70 is thought to act as a nucleophile, attacking the 
carbonyl group in the ß- lactam ring to which it becomes covalently bound 
forming an acyl -enzyme intermediate. Lysine 73 is thought to act as a 
general base, transferring a proton from serine -70 to the nitrogen atom in 
the ß- lactain ring via serine -130 [112]. 
Site directed mutagenesis of ß- lactamase I from Bacillus cereus 569/H and 
other enzymes have shown that Glu -166 may activate the catalytic water 
(designated water -673) molecule for deacylation of the enzyme intermediate 
by causing fission of the bond between the enzyme and inactive ß- lactam 
[112 -114]. Figure 1.7 overleaf describes this hydrolytic mechanism. 
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Figure 1.7: General Mechanism of Serine- Active ß- lactamases. 




Serine - 70 
Acyl- Enzyme Intermediate 








Serine - 70 
Adapted from [40, 112, 113, 115]. 
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1.9.3.2. Metallo -ß- lactamases. 
Enzymes of this class require a divalent cation, usually zinc for activity. 
This ion is co- ordinated within the active site by a combination of histidine 
and cysteine residues [116 -118]. The zinc ion is thought to be involved in 
binding the water molecule which is then deprotonated and attacks the 
ß- lactam carbonyl group. Glutamate at position 37 was thought to act as a 
general base for water deprotonation as it is required for enzyme activity 
[119], although this has since been shown not to occur [117]. It since been 
suggested that this role is fulfilled by aspartate at position 90 [120, 121]. 
In addition to the zinc ion co- ordinated within the active site, it has been 
proposed that the B. cereus II metallo- ß- lactamase possesses another zinc 
binding site [116, 122] of lower affinity [118]. This second zinc ion may be 
responsible for maintaining conformational stability of the enzyme. It is 
unclear at present whether other metallo -ß- lactamases also possess more 
than one zinc binding site. Figure 1.8 overleaf decribes the proposed 
mechanism for the metallo -ß- lactamase hydrolysis of a ß- lactam. 
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1.9.4. Carbapenemases. 
As described earlier, carbapenemase activity has been reported from 
enzymes belonging to Ambler classes A and B, although the formation of 
class E has been proposed to accommodate the Ll enzyme from Sten. 
maltophilia [99]. To date, several carbapenemases have been 
characterised and sequenced from different organisms of this species. 
1.9.4.1. Class B / E Carbapenemases. 
These enzymes are metallo-ß- lactamases as stated in Section 1.9.2.2. All 
metallo-13-lactamases studied to date have been found to be able to 
hydrolyse carbapenems and a wide variety of ß- lactam antibiotics. The only 
currently known exception to this is the CphA metallo -ß- lactamase from A. 
hydrophila which exhibits a narrow spectrum of activity against non - 
carbapenem ß- lactams [17]. 
The first report of a metallo-ß- lactamase was made by Sabath and co- 
workers in 1966 [123] in a strain of Bacillus cereus, almost 20 years before 
the first carbapenem was licensed for clinical use. Neither imipenem nor 
meropenem had been discovered at the time of this publication, but have 
since been shown to be substrates for this enzyme. This enzyme from B. 
cereus has often been referred to as the `prototype' metallo -ß- lactamase, 
and much work has been conducted on this enzyme to determine its 
mechanism of action [124, 125]. The DNA sequence of the gene encoding 
this protein has been determined [121, 133] and this is the only metallo- 
ß-lactamase for which an X -ray crystallographic structure has been 
determined [117]. Table 1.4 overleaf lists all known or suspected metallo- 
ß-lactamases characterised to date. The enzyme from a strain of 
Alcaligenes faecalis is also listed, but in a greyed box as this enzyme may be 
a metallo -ß- lactamase as it shows a substrate and inhibitor profile 
consistent with known metallo -ß- lactamases, but imipenem hydrolysis was 
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1.9.4.2. Class A Carbapenemases. 
It was originally thought that metallo -ß- lactamases were the only 
13-lactamases with the ability to hydrolyse carbapenems, and that these 
compounds were stable in the presence of serine active site enzymes. The 
first serine active carbapenemase was discovered in an isolate of S. 
marcescens, and was reported by Yang and co- workers [156] although this 
enzyme was originally thought to be a metallo -ß- lactamase until its 
sequence was determined in 1994 [102]. Also in 1990, a report was made 
characterising a ß- lactamase from Bacteroides distasonis with the ability to 
hydrolyse imipenem, but this enzyme appeared resistant to inhibition by 
EDTA and thus may be a class A enzyme [157]. The molecular mass of this 
enzyme ( >60000) was inconsistent with ß- lactamases of this class and also 
with ß- lactamases of class B. In 1993, Nordmann and co- workers correctly 
reported a serine active carbapenemase designated NmcA from an isolate 
of Enterobacter cloacae [101], an enzyme whose sequence has since been 
determined [158]. 
Table 1.5 overleaf compares the properties of all serine active site 






















































































































































































































































































































































































































































































































































Chapter 1: Introduction 
1.9.5. Sequence Homology Between Metallo -ß- lactamases. 
As yet there have been few reports of metallo -ß- lactamases which have included 
sequence determination. As a result, there are limited data currently available on 
the heterogeneity of metallo -ß- lactamase DNA sequences within each species. 
The DNA sequence of metallo -ß- lactamases from several strains of B. cereus have 
been determined, although these strains were related. The only other genus for 
which the sequence of several metallo- ß- lactamases have been determined, is 
Bacteroides. The enzymes of this genus show very high sequence homology and 
only differ in two amino acids [153], however the sequence of the only plasmid 
mediated metallo -ß- lactamase from this species has not yet been determined 
[105]. The total sequence homology between metallo- ß- lactamases of different 
species varies between 21% and 39% when compared with B. cereus II. Five 
distinct regions of homology have been identified in these metallo- enzymes [127], 
with deduced sequence homology of these enzymes increasing up to 80% around 
the active site, with almost all of these enzymes possessing three conserved 
histidines and a cysteine residue for metal ion co- ordination. 
Table 1.6 overleaf describes the relative homology of metallo- ß- lactamases 
sequenced to date. It should be noted however, that regions at the far C- and N- 
terminus were eliminated for normalisation purposes prior to alignment [103]. 
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Table 1.6: To Show % Identity of Metallo -ß- lactamases 









A. hydrophila CphA 34.3 34.9 - 
B. cereus II 5/B/6 41.4 - - 
Sten. maltophilia L1 22.7 21.4 21.0 
S. marcescens IMP-1 35.9 38.9 22.1 
Adapted from [103]. 
No sequence homology has been detected between metallo- ß- lactamases and 
serine active carbapenemases. However, the serine active site carbapenemases 
Nmc -A from Enterobacter cloacae NOR -1 and Sme -1 from Serratia marcescens S6 
share 70% amino acid identity [102]. The most similar non -carbapenem 
hydrolysing enzyme was the extended spectrum ß- lactamase MEN -1 from 
Escherichia coli, which shared 50% amino acid identity with Nmc -A [158], 
although the homology of these carbapenemases with other class A 
was low. 
1.9.6. Clinical Relevance of Carbapenemase Expression. 
Whilst resistance to carbapenem antibiotics is rare, some isolates have been 
shown to be resistant to virtually all ß- lactams and also to antimicrobials of other 
classes. Examples of these organisms include Acinetobacter, Pseudomonas, 
Stenotrophomonas isolates and Burkholderria strains from cystic fibrosis (CF) 
patients. 
The production of a carbapenem hydrolysing ß- lactamase is currently thought to 
represent the main threat to the use of carbapenems for serious nosocomial 
infections, although it should also be noted that neither metallo -ß- lactamases nor 
serine active carbapenemases are the sole mechanism of resistance to 
carbapenems as described earlier in Section 1.8. 
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1.9.6.1. Acinetobacter spp. 
Organisms from the genus Acinetobacter are opportunistic nosocomial pathogens 
which are encountered predominantly in ITUs and have been implicated in 
pneumonia, meningitis, endocarditis and septicaemia. To date, only one 
carbapenem hydrolysing ß- lactamase has been characterised from this species 
[159]. This enzyme appeared to be a serine active site enzyme, and has recently 
been shown to be transferable to another Acinetobacter strain [Scraife, Young, 
Paton and Amyes, Personal Communication]. 
1.9.6.2. Aerojnonas spp. 
These organisms are widely distributed in the environment, and are increasingly 
being recognised as human pathogens. They have been implicated in a wide range 
of enteric diseases including gastro -enteritis, soft tissue infections and 
bacteraemia. These organisms can be found both in marine and fresh water 
environments, and there have been many reports of the presence of these 
bacteria in raw meats and fish, suggesting that this may be a food -borne 
pathogen. Aeromonas hydrophila is the species from this genus most frequently 
isolated in clinical specimens [161]. Clinical infections involving this organism are 
usually polymicrobial. The ß- lactamases produced by this genus found to date 
have been chromosomally encoded and inducible. 
The Aeromonas CphA enzyme has been shown to have a narrow substrate profile, 
with low hydrolysis rates of penicillins and cephalosporins including the 
chromogenic cephalosporin, nitrocephin [162]. It has also been reported that the 
carbapenemase activity of one Aeromonas salmonicida strain was caused by a 
ß- lactamase which was unable to hydrolyse nitrocephin [131]. These reports 
contradict the observation by laconis and Sanders who stated that the A2 
enzyme hydrolysed carbapenems, penicillins and nitrocephin [128]. This substrate 
profile was probably caused by the co- purification of the CphA -type 
carbapenemase with a cephalosporinase which both have a similar pl. This may 
explain the observation by this group that the apparent sensitivity of the A2 
enzyme to the inhibitor clavulanic acid appeared to be substrate dependant [128]. 
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In a recent study of 114 Aeromonas isolates [163], all A. hydrophila and 
Aeromonas veronii strains positively hybridised with a gene probe containing the 
CphA gene and its flanking regions. 42% of all the Aeromonas strains in the study 
hybridised with the probe, and carbapenemase activity was detected in 83% of 
hybridisation positive isolates. These data suggest that all A. hydrophila and. A. 
veronii strains, the two most clinically relevant species of this genus, may encode 
a metallo-13-lactamase. Despite this, the MIC90 of imipenem for all these strains 
was less than the NCCLS breakpoint at an inoculum of 105 per ml, indicating that 
carbapenems are still effective against these organisms. The presence of a 
carbapenemase in this species cannot be ignored as mutations may occur, leading 
to a higher level of expression of these enzymes, resulting in treatment failure. 
1.9.6.3. Bacillus spp. 
Bacillus cereus is often regarded as a contaminant or as a non -pathogenic 
organism when isolated from clinical infections. There are thus relatively little 
data on its pathogenic role or frequency in clinical infections. The B. cereus II 
metallo -ß- lactamase was the first metallo- enzyme reported [164] and the only one 
for which a crystal structure has been determined [117]. This enzyme has become 
the `model' metallo -ß- lactamase, although this may not be entirely justified, as this 
metallo- ß- lactamase has certain biochemical properties which differ from most 
other metallo- enzymes studied to date [103] (this thesis). 
1.9.6.4. Bacteroides spp. 
Most anaerobic infections are polymicrobial and thus require treatment with 
agents active against an array of aerobic and anaerobic bacteria. Organisms from 
the Bacteroides fragilis group are the most frequently isolated gram negative 
anaerobic pathogens from clinical infections. 
There have been several reports in the last six years in which alterations in the 
classification of Bacteroides have been described. Shah and Gharbia have reported 
these changes, and related these species to specific sites of colonisation [165]. 
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The frequency of ß- lactamase production by various Bacteroides species is high. It 
has been reported that between 75% - 100% of strains from the Bacteroides 
f °agilis group are ß- lactamase producers [166, 167]. These enzymes are usually 
serine active chromosomal cephalosporinases, and the species specific 
cephalosporinase from Bacteroides uniformnis has been sequenced [168]. 
There have been many surveys studying the antimicrobial susceptibilities of 
Bacteroides isolates around the world, although there have been few conducted in 
Great Britain [169 -171]. Resistance to carbapenems has been found to vary from 
0.1% to 4% [157, 172] even between surveys in the same country, for example 
France [172, 173] and Japan [174, 175]. This may well be caused by the use of 
different media and different breakpoints in these surveys, with relatively few 
studies adhering to the NCCLS guidelines on susceptibility testing of these 
organisms [176]. This means that many of these surveys cannot be compared 
directly. In an attempt to circumvent this, several groups have published ongoing 
susceptibility surveys which, whilst not necessarily conforming to NCCLS 
guidelines, do at least employ a consistent methodology from year to year [172, 
174, 175, 177]. 
There have been several reports of carbapenemases from isolates of the genus 
Bacteroides, which include metallo -ß- lactamases [see Table 1.4] and a 
carbapenemase whose mechanism of action has not been determined, but is likely 
to be a serine active site enzyme [157] [see Table 1.5]. One of the metallo- 
ß-lactamases was found to be plasmid mediated and could be transferred to other 
Bacteroides isolates but not to Escherichia coli [105] leading to the possible 
dissemination of this gene into other strains. A report has also been made 
indicating that many ß- lactam sensitive organisms of the Bacteroides fiagilis 
group may harbour silent carbapenemase genes which can be activated after 
exposure to carbapenems [178] or introduction of an insertion sequence [179] 
resulting in a 100 -fold increase in MIC to these compounds. These observations 
may indicate a potential threat to the use of carbapenems for anaerobic 
infections. It can be concluded from these reports that resistance to carbapenems 
may be higher than actually found in many surveys. 
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1.9.6.4.1. Other Antimicrobials Active Against Bacteroides spp. 
Tetracyclines were once the drug of choice for Bact. fragilis but up to 50% of 
strains are now resistant, possibly due in part to the presence of an active class F 
efflux mechanism determinant [180]. Fluoroquinolones show very limited activity 
against Bacteroides and other anaerobes which are regarded as resistant to all but 
the newest fluoroquinolones [181]. Only Clostridium perfringens and some 
eubacteria show some sensitivity to these compounds. Typical MIC values for 
Bact. fragilis and other members of the Bact. fragilis group range from 4- 32mg/1 
[182, 183]. 
Metronidazole and its hydroxy metabolite [184] are effective against virtually all 
anaerobes including some anaerobic cocci. However, it has virtually no effect on 
aerobic bacteria although some bactericidal activity on dormant cells of 
Mycobacterium tuberculosis has been demonstrated recently [185]. 
The exact mechanism of action of metronidazole in vivo is not known, but it has 
been proposed that this compound and its hydroxy metabolite interact with DNA, 
preferentially with adenine or thymidine [186], and cause oxidative damage to 
pyrimidines of metronidazole complexes based on the induction of exonucleases 
[187]. In vitro work involving metronidazole has shown that it interacts with DNA 
causing single and double strand breaks [188]. 
It was originally postulated that resistance to 5- nitromidazole antibiotics (such as 
metronidazole, ornidazole and tinidazole) was not possible, but several Bact. 
fragilis isolates have been described which are resistant to metronidazole [188- 
190]. 5- nitromidazole resistance has been found to be both plasmid mediated and 
chromosomally encoded, but was found to be transferable in all isolates tested. 
Transferability was not tested in one of these strains [189]. One metronidazole 
resistant Bact. fragilis isolate has been found to produce MetA, an extra cellular 
protein which is able to protect cells against the action of metronidazole by 
reducing the degree of DNA damage, but has been shown not to inactivate the 
compound itself [188]. It is unlikely that MetA interacts with DNA since it 
contains no DNA binding motif, and its mechanism of protection is tmknown. 
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1.9.6.5. Enterobacter cloacae. 
To date, two similar serine active site (Ambler class A) carbapenemases have 
been reported [101, 160], but no transfer of resistance was observed. Whilst these 
enzymes are capable of hydrolysing carbapenem antibiotics, ß- lactamase 
inhibitors such as clavulanic acid still retained some inhibitory activity against 
these enzymes. This allowed ß- lactam / ß- lactamase inhibitor combinations to still 
show some antibacterial activity against organisms producing these 
ß- lactamases. 
1.9.6.6. Flavobacterium spp. 
Bacteria from the genus Flavobacterium are widely distributed in natural 
ecosystems as well as clinical specimens, most notably in neonatal meningitis, 
and are also recognised as nosocomial pathogens. These organisms show optimal 
growth at 30 °C, but several clinical isolates have been shown to be able to grow at 
37 °C. As a result of this, their clinical relevance as pathogens is often 
underestimated. 
The first metallo -ß- lactamase from this species was identified in 1985 [144]. 
Recently, two successive Flavobacterium meningosepticum isolates from the same 
patient have been shown to produce an enzyme with carbapenem hydrolysing 
activity [191], although it is possible that both isolates are in fact the same strain 
since these strains had identical properties and antibiograms. This report 
proposed that these enzymes were metallo-ß- lactamases solely on the basis of 
partial inhibition in the presence of EDTA, but this evidence is not conclusive as 
serine active carbapenemases have been described which are sensitive to EDTA 
[102, 156]. No other biochemical data on the carbapenemases were given. It is, for 
these reasons, that this report is not included in Table 1.4. The only other report of 
a ß- lactamase from this species described an extended spectrum ß- lactamase 
from an isolate of F. meningosepticurn which was unable to hydrolyse imipenem 
[192]. 
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1.9.6.7. Pseudomonas spp. 
Pseudomonas aeruginosa has become an important human pathogen because of 
its innate resistance to many antibiotics. It has been implicated in many 
nosocomial infections including burns and septicaemia, and is frequently isolated 
from neutropoenic patients. 
In a recent survey, the antimicrobial susceptibility of 1991 P. aeruginosa isolates 
were examined. 1.2% of these organisms were found to be resistant to imipenem 
by NCCLS recommended breakpoint, as opposed to the low breakpoint adopted by 
that study [193]. A similar study was conducted in 1982, but direct comparison of 
these is not possible since neither imipenem or meropenem were used in the earlier 
study [194], and so it has not been possible to determine any trend in the 
resistance of these organisms to carbapenem antibiotics. One P. aeruginosa 
clinical isolate which produced a plasmid mediated metallo -ß- lactamase has been 
reported [104] but this plasmid was not transferable to E. coli. 
Burkholderria cepacia, and to a lesser extent P. aeruginosa are important 
pathogens in cystic fibrosis patients. It has been suggested that all Burk. cepacia 
organisms may have the ability to produce carbapenemases [195], and if this 
holds true, has serious implications for patients with this condition. The metallo- 
ß-lactamase of one such strain has already been characterised [146]. 
1.9.6.8. Serratia marcescens. 
Serratia marcescens is becoming more frequently isolated from 
immunocompromised or Intensive Therapy Unit (ITU) patients. Serratia 
marcescens is one of the few species from which both serine active site 
carbapenemases [102, 156] and metallo-ß-lactamases [106, 147] have been 
reported. This has serious ramifications for the treatment of this species with 
carbapenems, as plasmid mediated metallo-ß- lactamases have been successfully 
transferrred from this species [106]. 
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1.9.6.9. Stenotrophomonas maltophilia. 
Recently, this organism has undergone several taxonomic changes, from 
Pseudoinonas maltophilia to Xanthomonas maltophilia, and most recently to 
Stenotrophomonas maltophilia [196]. The name Stenotrophomonas will be used 
throughout this thesis. 
This organism is responsible for septicaemia, meningitis, peritonitis and 
endocarditis, especially in immuno- compromised patients. 
The L1 type metallo -ß- lactamase from Sten. maltophilia has been shown to be 
able to hydrolyse imipenem and several penicillins [151]. In addition to L1, Sten. 
maltophilia isolates also produce a cephalosporinase, designated L2 [197]. Both of 
these enzymes are chromosomally encoded and inducible [151, 197] although the 
level of induction varies considerably between isolates. The metallo -ß- lactamase 
(which preferentially hydrolyses penicillins and carbapenems) and the 
cephalosporinase (which hydrolyses cephalosporins) exhibit complementary 
spectra of activity which together are able to confer resistance to virtually all 
ß- lactam antibiotics. It has been suggested that there is some heterogeneity 
between the ß- lactamases produced by this species [154, 155]. This was 
supported by the surprising observation that 1mM EDTA did not affect 
carbapenem hydrolysis in certain Sten. maltophilia clinical isolates [154], and 
more work would be necessary to determine the type of enzyme responsible for the 
carbapenem hydrolysis in that study. 
The observation that many Sten. maltophilia isolates show poor membrane 
permeability to antimicrobials [198], coupled with the production of ß- lactamases 
capable of hydrolysing every class of ß- lactam, only reinforces this organism's 
resistance profile. One study found that Sten. maltophilia represented 
approximately 2% of all nosocomial respiratory tract infections in the laboratory 
[198], confirming that this organism is emerging as an important nosocomial 
pathogen. 
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1.10. Concluding Remarks. 
It must be noted that any infection may be polymicrobial and ß- lactam treatment 
failure may be caused by the presence of a metallo -ß- lactamase producing 
organism as part of the mixed clinical infection conferring protection to a more 
pathogenic organism by hydrolysing the ß- lactam agent administered for its 
treatment. 
Metallo -ß- lactamases represent a significant threat to the use of ß- lactam 
antibiotics as they have a very broad spectrum of activity, hydrolysing penicillins 
and cephalosporins as well as carbapenems, and are resistant to classic 
ß- lactamase inhibitors. Their role in the clinical environment is unclear as the vast 
majority of metallo -ß- lactamases studied to date are chromosomally encoded, and 
not transferable. It is interesting to note that metallo -ß- lactamase production has 
been found predominantly in organisms which until recently have not been 
considered serious pathogens, for example Acinetobacter, Bacillus cereus, 
Flavobacterium, Legionella, Serratia and Stenotrophomonas. It is possible that the 
use of newer and more powerful antimicrobials like the carbapenems have 
selected these organisms as pathogens as they are able to colonise sites which 
have been de -nuded of other micro -organisms by the intense antimicrobial activity 
of these compounds. Many of these patients in ITUs are immuno- compromised, 
and hence less able to fight these infections themselves. 
The rate of dissemination of these carbapenemases into the bacterial population 
currently appears to be slow, and this is because all but four of these enzymes 
examined to date have been chromosomally encoded and non -transferable. 
Carbapenem therapy in Britain is currently restricted to ITU patients, although 
their use in Europe and South America is less restricted. 
The controlled use of carbapenems as `last line' treatments will slow the spread of 
these resistance determinants, although such spread is likely to occur in the 
future as the use of these compounds becomes more widespread. 
46 
Chapter 1: Introduction 
Aims of This Thesis. 
1. To determine the efficacy of the carbapenems and fourth 
generation cephalosporins amongst random clinical isolates of both 
aerobic and anaerobic bacteria from clinically important species, 
and conduct the in vitro susceptibilities of these isolates on NCCLS 
[176] and BSAC [199] recommended agars. 
2. To examine the mechanism of resistance in any imipenem 
resistant strains encountered, with special emphasis on those 
isolates in which the resistance was mediated by the production of 
a carbapenem hydrolysing ß- lactamase. 
3. To examine the assay conditions employed to study metallo- 
ß-lactamases. 
4. To determine the incidence of carbapenemase production amongst 
isolates from the genus Flavobacterium, from which only a single 
metallo-B-lactamase has been previously reported. 
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CHAPTER TWO 
Materials & Methods. 
2.1. Chemical Reagents. 
All chemical reagents were obtained from Sigma Chemical Co. (Poole, 
Dorset, UK) unless otherwise stated. 
Antibiotics were obtained from the companies listed in Table 2.1 below, and 
were stored as sterile powders in the absence of light at 4 °C until required. 
Table 2.1: Source Companies for Antibacterial Compounds. 
Compound Source 
Ampicillin Sigma Chemical Co. 
Aztreonam E.R. Squibb & Sons 
Benzylpenicillin Sigma Chemical Co. 
BRL 42715 SmithKline Beecham 
Carbenicillin SmithKline Beecham 
Cefotaxime Roussell Lab. Ltd 
Cefoxitin Merck Sharp and Dohme 
Ceftazidime Glaxo Group Research 
Cefuroxime Sigma Chemical Co. 
Cephaloridine Glaxo Group Research 
Ciprofloxacin Bayer (UK) Ltd 
Clavulanic Acid SmithKline Beecham 
Gentamicin Nicholas Laboratories 
Imipenem Merck Sharp and Dohme 
Meropenem Zeneca Pharmaceuticals 
Nitrocephin SmithKline Beecham 
Rifampicin Ciba Laboratories 
Sulbactam Pfizer pharmaceuticals 
Lederle Laboratories Tazobactam 
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All antibiotic solutions were prepared immediately prior to use, and were 
prepared in sterile distilled water for MIC determinations, or prepared in the 
appropriate assay buffer and maintained at 0 °C on ice for 
spectrophotometric assays. 
2.2. Bacterial Strains. 
Table 2.2 below describes the source of standard ß- lactamases and 
standard strains which feature in this thesis. 
Table 2.2: Bacterial Strains Producing Known ß- lactamases. 
Species ß- lactamase (pI) Plasmid Reference 
Bact. fragilis ED- 
262 




CfiA (4.6 -5.0) Chrom [142] 
Ent. cloacae 
NOR -1 
Nmc -A (6.9) + 
AmpC ( -9.0) 
Chrom [101] 
E. coli K12 J62 -2 TEM -1 (5.4) R1 S.G.B. Amyes 
E. coli J53 -2 SHV -1 (7.6) R1010 -6 S.G.B. Amyes 
Sten. maltophilia 
ULA -511 
L1 (6.9) + L2 (8.4) Chrom D.J. Payne 
Chrom - Chromosomal ß- lactamase. 
Pure preparations of the B. cereus II and Sten. inaltophilia L1 metallo- 
ß-lactamases featured in Chapter 7 were received from Dr. D. J. Payne, and 
had been purified previously. 
In addition to the strains in Table 2.2 which produce known ß- lactamases, 
the standard strains listed in Table 2.3 overleaf were also used for 
comparative and control purposes. 
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Table 2.3: Control Organisms. 
Species Reference ß- lactamase Source 
Bact. fragilis NCTC 9343 bla - NCTC, London 
P. aeruginosa NCTC 10662 bla - NCTC, London 
The clinical isolates examined in this thesis were received from a variety of 
sources. Certain isolates were received because they exhibited reduced 
sensitivity or resistance to imipenem. Other isolates were random, and no 
prior data on their sensitivity to imipenem had been determined. Table 2.4 
below details these isolates, and their source, together with the reason for 
isolation. 
Table 2.4: Clinical Isolates Examined in This Thesis. 
Species Number 
of Isolates 
Source Reason for 
Selection 
Acinetobacter spp. 9 CBL, Edinburgh Random 






Bacteroides group 166 CBL, Edinburgh Random 
Burk. cepacia 3 WGH, Edinburgh Imp' 
Ent. aerogenes 1 GRI Imp' 
Ent. cloacae 1 WGH, Edinburgh Imp' 
Enterobacter spp. 9 CBL, Edinburgh Random 
Flavobacteriuin spp. 10 NCTC, London Unknown' 
Klebsiella spp. 11 CBL, Edinburgh Random 






Sten maltophilia 18 WGH, Edinburgh Imp' 
CBL, Edinburgh - Clinical Bacteriology Laboratories, Edinburgh. 
GRI - Glasgow Royal Infirmary. 
SARL, Edinburgh - Scottish Anaerobe Reference Laboratory, Edinburgh. 
WGH, Edinburgh - Western General Hospital, Edinburgh. 
Imp" - Resistant to Imipenem. 
Random - Random Isolate. 
Unknown - Reason for submission to NCTC unknown. NCTC catalogue showed no data 
on imipenem sensitivity. 
¶ Strain received was designated JMS -121 [see Chapter 6]. The imipenem resistance of 
this strain had been previously reported [189]. 
§ Strains received were designated JMS -219 and JMS -221 [see Chapter 6]. 
G Each of these strains were distinct clinical isolates, although the reason for submission 
to the NCTC is not known. 
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All other strains originate in this thesis unless otherwise stated. The 
identity of the clinical isolates were confirmed with the identification strips 
detailed in Table 2.5 below irrespective of their source with the exception of 
the isolates received from the Clinical Bacteriology Laboratories, Edinburgh 
which were identified by the staff at the Clinical Bacteriology Laboratories. 
Table 2.5: Bacterial Identification Strips. 
Suspected Species Strip type Manufacturer 




API20NE Bio Merieux, France 
Enterobacter API20E Bio Merieux, France 
Flavobacterium ATB32GN Bio Merieux, France 
All identification strips were used in accordance with the manufacturers 
instructions with the appropriate reagents supplied. 
2.3. Growth and Storage Media. 
All growth media were sterilised by autoclaving at 121 °C for 15 minutes at 
15 pounds per square inch. Stock solutions of 10mis 50% v/v glycerol were 
autoclaved twice and stored at room temperature until required. All 
anaerobic liquid media were pre- reduced overnight in an anaerobic cabinet 
or anaerobic jar after autoclaving. 
All strains were stored in duplicate 1.6ml aliquots at -70 °C in equal volumes 
of growth broth and sterile 50% glycerol. 
All media were obtained from Oxoid (Basingstoke, Hants) as dry powders, 
and prepared as single strength solutions as recommended by the 
manufacturer unless otherwise stated. 
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2.3.1. Preparation of Gentamicin Blood Agar (GBA) Plates. 
GBA plates consisted of single strength sterile Columbia agar to which was 
added defibrinated horse blood together with gentamicin to give final 
concentrations of 5% and 10mg/1 respectively, once the molten agar had 
cooled to below 55 °C. 
2.3.2. Other Complex Media. 
In addition to gentamicin blood agar plates, Isosensitest (IST), MacConkey 
agars were also used, an prepared according to the manufacturers 
instructions. 
Brain Heart Infusion (BHI) broth, Nutrient broth No.2, thioglycollate broth 
and Wilkins- Chalgren broth were used, and were obtained as dry powders 
from Oxoid (Basingstoke, Hants) and prepared as single strength broths. 
Robertson's cooked meat medium (RCM) was prepared as BHI broth with 
the addition of 5% v/v dried cooked meat [200]. 
2.4. In vitro Sensitivity Testing (MIC Determinations). 
In each case, a small scale overnight culture [see Section 2.5] of the strains 
to be tested were diluted in single strength Davis and Mingioli salts (DM) 
[201]. Single strength DM was prepared as a double strength solution and 
diluted with an equal volume of sterile distilled water. 
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Table 2.6: Davis and Mingioli Salts Solution. 




di Potassium hydrogen phosphate 14 7 
Potassium hydrogen phosphate 6 3 
tri -Sodium citrate 0.94 0.47 
Magnesium sulphate 0.2 0.1 
Ammonium sulphate 2 1 
2.4.1. Aerobes. 
Sensitivity testing of all aerobic isolates was performed according to the 
NCCLS guidelines [176] where applicable on Oxoid Isosensitest (IST) agar 
(Oxoid, Basingstoke, Hants.) containing doubling dilutions of the 
antimicrobial agent. A 2µl inoculation was achieved with a Denley 
multipoint inoculator (Denley, Sussex) at 104 cfu per spot, except 
Flavobacterium strains which were inoculated at 106 cfu per spot unless 
otherwise stated. Plates were incubated for 16 hours at 37 °C for all isolates 
except those belonging to the genus Flavobacteriurn which were incubated 
for 16 hours at 30 °C. 
2.4.2. Anaerobes. 
Sensitivity testing of Bacteroides isolates was performed according to the 
NCCLS guidelines [176] on Wilkins- Chalgren agar (Oxoid) supplemented 
with haemin [202] and 5% defibrinated horse blood [203] containing doubling 
dilutions of the antimicrobial agent. Inoculation was achieved with a Denley 
multipoint inoculator at 104 cfu per spot. Plates were incubated for 48 hours 
at 37 °C in either an anaerobic cabinet or an anaerobic jar with an Oxoid 
BR38 Gas Generating Kit. A single plate inoculated as above but without 
antibiotic was also incubated aerobically at 37 °C for 16 hours to ensure 
that no aerobic contaminants were present. 
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In all cases, the MIC was taken as the lowest concentration of the selected 
antimicrobial which effected significant inhibition of growth. Where the 
MICs of ß- lactam / ß- lactamase inhibitors were determined, for example 
amoxycillin and clavulanic acid, the concentration stated is that of the 
ß- lactam, and all combinations were tested in a 2:1 ratio unless otherwise 
stated. 
Antibiotic sensitivity discs were supplied by Mast Laboratories Ltd 
(Merseyside). 
2.5. Culture of Clinical Isolates. 
2.5.1. Aerobes. 
Small scale cultures were grown in 10mis Oxoid Nutrient Broth No. 2 in 
Universal bottles and incubated for 16 hours at 37 °C with agitation at 200 
rpm. Flavobacterium isolates were cultured in the same broth, but 
incubated at 28 -30 °C with agitation wherever possible. Strains were tested 
for ß- lactamase induction by the addition of imipenem after 2 hours growth 
to a final concentration of1,1 the MIC of the cultured strain [204]. 
Large scale cultures of aerobic bacteria were initially grown as small 
scale cultures, and a 1ml inoculum was added to 1 litre of pre -warmed 
Nutrient Broth No. 2 in 2 litre conical flasks, or multiples thereof. Imipenem 
was always added to a final concentration of 3 the MIC of the cultured 
strain, whether inducible or not, to ensure ß- lactamase production. 
2.5.2. Anaerobes. 
Small scale cultures were set up by taking single colonies from a GBA 
plate and inoculating 20mis Robertson's Cooked Meat medium in 
McCartney bottles. 
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Large scale cultures were initially set up as small scale cultures as 
described above. 10mis of this small scale culture was added to 1 litre of 
Robertson's Cooked Meat Broth in a 1 litre Duran bottle which had been 
pre -reduced and pre -warmed to 37 °C. Imipenem was added to a final 
concentration of 1,1 the MIC of the strain on Wilkins Chalgren agar or 16mg/1, 
whichever was lower. The culture was allowed to grow overnight at 37 °C. 
2.6. ß- lactamase Preparation. 
The stationary phase culture was harvested at 6000 x g at 4 °C for 20 
minutes in a Sorvall RC -5B refrigerated centrifuge or a Beckman J2 -21 
Refrigerated Superspeed centrifuge. This force was increased to 7000 x g for 
Flavobacterium isolates. The pellets were resuspended in 25mM PIPES 
buffer pH 7.0 supplemented with 1mM ZnSO4 (unless otherwise stated) as a 
washing step, and re -spun. 
Pellets were resuspended in the minimum volume of 25mM PIPES pH 7.0 
supplemented with 1mM ZnSO4 (unless otherwise stated) and soriicated 
(MSE SoniPrep 150) on ice at an amplitude of 8µM for 3 x 30 seconds with 
30 second intervals for aerobes and 5 x 30 seconds with 30 second intervals 
for anaerobes. 
The resulting lysate was centrifuged at 40,000 x g for 60 minutes for all 
strains with the exception of Flavobacterium isolates which were 
centrifuged at 60,000 x g in an MSE Europa or a Beckman refrigerated 
ultracentrifuge. 
The increased g force for all Flavobacterium centrifugation was required to 
obtain satisfactory separation of the pellet and supernatant. 
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2.7. Analytical Iso- electric Focusing. 
ß- lactamases were separated and identified by analytical iso- electric 
focusing (IEF) on a thin layer polyacrylamide gel film as described by 
Matthew [205] containing broad range carrier ampholytes. 
Two methodologies were employed for this procedure; one involving the 
making of the gel pH 3.5 -10 followed by polymerisation, and the other 
involving pre -cast Pharmacia Ampholine PAGplate gels pH 3.5 to 9.5. 
These methods are described separately below: 
2.7.1. Preparation of IEF gel pH 3.5 -10. 
The poly -acrylamide gel was made as described in Table 2.7 below. 
Table 2.7: Composition of Analytical IEF Gels. 




Sterile distilled water 25 - 
5% v/v N,N,N',N' -tetramethyl- 
ethylenediamine (TEMED) 
0.2 0.05% v/v 
40% w/v carrier ampholytes: 
pH3.5 -10 
2.0 2% w/v 
33.9 %T, 2.7 %C acrylamide/ 
N,N'methylene bis - acrylamide 
9.0 7.6 %T 
2.7 %C 
0.002% w/v Riboflavin 4.0 0.0002% w/v 
The gel solution was poured between two glass plates of differing sizes, the 
smaller of which was coated to promote the adhesion of the gel. The plate 
coating solution consisted of 0.5% w/v gelatin and 0.5% w/v chromium 
potassium sulphate in sterile distilled water, and was allowed to dry on the 
plate. When poured, the acrylamide was polymerised by the riboflavin in the 
presence of ultraviolet light for 6 hours, forming a gel measuring 200mm x 
150mm x 1mm. 
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When the glass plates were prised apart, the gel (which had adhered to the 
smaller plate) was allowed to dry in air for up to 60 minutes before loading 
with samples of ß- lactamase preparations on to the gel surface close to the 
anode. The nitrocephin spot test time determined the volume of the 
ß- lactamase preparation loaded onto the gel, the volume being calculated as 
the nitrocephin spot test time (in seconds) [Section 2.10.1] up to a 
maximum of 300. for crude cell extracts and l00111 for partially purified 
ß- lactamases. 
The IEF gels were focused overnight at 4 °C with the following limiting 
parameters; voltage = 500V, current = 20mA, power = 1.0W. The gels were 
calibrated by focusing ß- lactamases of known pI. 
2.7.2. Pre -cast IEF Gels. 
Pre -cast gels had a range of pH 3.5 to 9.5 (T =5 %, C =3 %) (PAGplate, 
Pharmacia, Sweden) and up to 70111 of the sample to be focused was loaded 
onto applicator strips placed near the anode, the exact volume being 
determined by the nitrocephin spot test time as described in Section 2.10.1. 
The only modification to the manufacturers instructions was that the filter 
paper electrode strips between the electrodes and the gel were soaked in 
distilled water as opposed to the 11,130, and NaOH recommended. The gel 
was laid on a ceramic plate which was water cooled and maintained at 9 °C. 
The gel was focused for 3 hours with the following limiting parameters; 
voltage = 1500V, current 50mA, power = 30W. The gels were calibrated by 
loading 51.1l IEF markers pI 4.7 -10.6 (BDH, Poole, Dorset). 
The focused ß- lactamases on both gel types were visualised firstly by 
overlaying the gel with a sheet of Whatman No. 1 filter paper soaked in 
1mM ZnSO4 for five minutes, followed by overlaying the gel with filter paper 
soaked in 500mg/1 nitrocephin. The iso- electric points of unknown or novel 
enzymes were estimated from the focused bands of ß- lactamases of known 
pI or iso -electric focusing makers. 
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2.8. Partial Purification of B-lactamases. 
2.8.1. Gel filtration. 
Sephadex (Pharmacia, Sweden) was used for molecular mass estimations 
and partial ß- lactamase purification as described by Andrews [206]. 
Sephadex consists of beads of controlled diameter, the bead size determining 
the range of molecular masses of peptides and globular proteins which can 
be fractionated by the column. Both G75 (useful range 10- 50kDa) and G150 
(useful range 20- 150kDa) were used. 
2.8.1.1. Column Preparation. 
Dry Sephadex, either G75 or G150 was taken and swollen in 25mM PIPES 
buffer pH 7.0 supplemented with 1mM ZnSO4, a volume 15 times that of 
the dry mass of the Sephadex, and steamed for 3 hours. Once steamed, the 
slurry was cooled to 4 °C and slowly poured into a vertical glass column 2cm2 
x 90cm (Amicon Ltd, Glos, UK.), allowing the slurry to pack together. The 
packed column was washed for 48 hours with the same buffer at a flow rate 
of 12m1s/hour. The buffer was pumped up the column against gravity by a 
P -1 peristaltic pump (Pharmacia). The column was maintained at 4 °C with 
continuous recycling of the column buffer in a reservoir containing at least 
500mis of the same buffer. 
2.8.1.2. Calibration. 
The column was calibrated by the addition of a lml solution of column buffer 
containing 10mg of each of three proteins of known molecular mass which, 
in the case of a G75 column, were ovalbmnin (47kDa), chymotrypsinogen A 
(25.5kDa) and cytochrome C (12384Da). These proteins were separated as 
they passed through the column, and were collected by an LKB- BROMMA 
2070 fraction collector (Pharmacia, Sweden) in 2ml aliquots. The relative 
elution volumes of these proteins were determined by measuring the A280 of 
the fractions on a Perkin Elmer Lambda 2 UV/Vis Spectrophotometer 
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(Bucks, UK). The void volume of the column was determined by the addition 
of 1ml of 0.1% w/v Blue Dextran (Mr. -2MDa) as described above for 
calibration. A plot of molecular mass against elution volume could be 
generated, forming a standard graph from which the molecular mass of a 
ß- lactamase could be determined as outlined in Figure 2.1 below and Figure 
2.2 overleaf. 
Figure 2.1: Typical Elution Profile of Known Proteins from a 
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Figure 2.2: Typical Semi -Log Calibration Plot of Known Proteins 
from a Sephadex G75 Column. 
10 ...III ...III ...1...1.. 





The molecular mass standards for Sephadex G150 columns were alcohol 
dehydrogenase, (150kDa), Bovine Serum Albumin (66kDa), and 
chymotrypsinogen A (25.5kDa). The calibration graph was generated as 
described above. 
2.8.1.3. Sample Loading and Running. 
Crude cell free lysates were added to the column at a flow rate of 12m1s/hour 
in a volume no greater than 2m1s, and eluted with the column buffer, 
ensuring that 2m1 fractions from least one column volume were collected. 
Fractions containing ß- lactamase activity were initially determined by 
nitrocephin spot test, and then assayed on a Perkin Elmer Lambda 2 
spectrophotometer for both nitrocephin hydrolysing activity (AAbs @ 
384nm) and imipenemase activity (AAbs @ 299nm). 
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2.8.2. Preparative Iso- electric Focusing of ß- lactamases. 
Preparative IEF of partially purified ß- lactamases was employed to 
separate the ß- lactamases produced by a single strain. The gel was made 
and poured as described in Section 2.7.1. However, instead of adding 12 
different samples to the gel, lane 1 contained the standard ß- lactamase 
TEM -1, and the remainder of the gel was covered with lud of the partially 
purified ß- lactamase extract, and the gel was run as normal. Once rim, only 
lanes 1, 2 and 12 were overlaid with nitrocephin to confirm that the gel had 
run properly and to determine where the ß- lactamases had focused. Slices of 
acrylamide containing each enzyme were cut out of the gel with a scalpel, 
and placed into a dialysis sac with 5m1 PIPES buffer in a gel tank containing 
the same buffer. A potential difference of 150 volts was applied to the tank 
for two minutes to allow the ß- lactamase to elute from the gel, followed by 
20 seconds with the polarity reversed to ensure that the enzyme did not 
remain bound to the side of the sac. The buffer within the sac was collected 
and assayed for ß- lactamase activity. 
2.8.3. ß- lactamase Purification by Fast Protein Liquid 
Chromatography (FPLC). 
2.8.3.1. Optimum Matrix determination. 
A screening system involving 46 different ion exchange matrices from all 
major matrix groups was used to determine the most effective matrix for 
ß- lactamase purification. Table 2.8 overleaf lists the matrices tested. 
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Table 2.8: Matrices Tested for Optimum ß- lactamase Binding. 
Number Matrix Number Matrix 
1_ Sepharose CL4B (control) 24 Green 1 Agarose 
2 Gelatin Sepharose 25 Blue 1 Agarose 
3 Heparin Sepharose 26 Blue 2 Agarose 
4 Fibronectin Sepharose 27 DEAE Sepharose 
5 Bacitracin Sepharose 28 CM Sepharose 
6 cc -Amino Hexyl Sepharose 29 Q- Sepharose FF 
7 p -ABA Sepharose 30 MacroPrep High Q 
8 Lysine Sepharose 31 S- Sepharose 
9 Benzamidine Sepharose 32 MacroPrep High S 
10 Protein A Sepharose 33 HW 650S (control) 
11 Aprotonin Agarose 34 Toyopearl Butyl 650S 
12 Zinc Chelate 35 Toyopearl Butyl 650M 
13 Prosep A (high capacity) 36 MacroPrep Butyl 
14 D- Alanine Agarose 37 Butyl Sepharose FF 
15 Blue Sepharose 38 MacroPrep Methyl 
16 Green Agarose 39 Phenyl Sepharose (HP) 
17 Red 1 Agarose 40 Phenyl Sepharose 6FF (LS) 
18 Red 2 Agarose 41 Phenyl Sepharose 6FF (HS) 
19 Orange 1 Agarose 42 Octyl Sepharose 4FF 
20 Orange 2 Agarose 43 Fractogel EMD SO,- 
21 Orange 3 Agarose 44 Fractogel 
22 Yellow 1 Agarose 45 Fractogel TSK DEAE 650S 
23 Yellow 2 Agarose 46 Hydroxyapatite 
HP - High Performance. 
LS - Low sub. 
HS - High sub. 
All matrices were stored in de- ionised water / 0.02% Kathon CG. 
1000 of each matrix suspension was added into a separate well of a 
V- bottomed microtitre plate. 50µ1 of the crude cell lysate was added to each 
well and mixed with the suspension, and then left for 30 minutes at room 
temperature to facilitate protein binding to the matrix. After this time, the 
plate was centrifuged at 1000 rpm for 1 minute to pellet the matrix together 
with bound proteins. 5011l of the supernatant from each well was removed to 
a clean flat -bottomed microtitre plate, and 100µmoles nitrocephin was 
added to the supernatant aliquots. The supernatants of matrices which 
bound the ß- lactamase would remain yellow, whilst those which did not bind 
the ß- lactamase turned red as the ß- lactamase still present in the 
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supernatant hydrolysed the nitrocephin. `Hits' were defined at those 
matrices whose supernatants remained yellow after the addition of 
nitrocephin. 
Where this matrix screen did not yield any `hits', small scale columns 
(bed volume ''20m1s) were set up and equilibrated with an appropriate 
buffer at 2m1/minute. A sample of the crude cell -free ß- lactamase extract 
was applied to the column and allowed to adsorb onto the matrix. Once the 
A280 of the eluent had fallen below 0.05, the proteins were eluted in NaC1 
step gradients of 0.25M, 0.5M, 0.75M, and 1.0M at 2m1/minute. Each step 
was continued until the A280 of the eluent no longer increased. Step eluted 
fractions were assayed for ß- lactamase activity and subjected to IEF to 
determine if the column had bound the ß- lactamase successfully before a 
large scale column was prepared. 
2.8.3.2. Column Preparation and Running. 
Once the matrix had been chosen, a column was poured and mounted onto a 
Pharmacia FPLC system as detailed in Table 6.2. The column was 
equilibrated with running buffer which had been degassed. 
The pH of the sample which was to be loaded onto the column was altered to 
that of the running buffer by a 1:4 dilution with running buffer followed by 
pH adjustment with an acid or base appropriate to the running buffer if 
necessary. The sample was loaded onto the column at a rate of 2m1/minute. 
Once loaded, the column was flushed with running buffer until the A280 of the 
column eluent fell below 0.05. 
Proteins bound to the column were selectively eluted by an increasing 
concentration of NaCl in the running buffer, with column eluent collected in 
5m1 fractions. The concentration of NaC1 in the running buffer varied from 0 
to 1M, although the gradient was not always linear as detailed in Figures 
6.4 -6.7. However, in all cases, the run started with no NaCl and finished 
with 1M NaCl in the buffer, and ran for at least 4 column volumes. 
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Fractions containing ß- lactamase activity were detected by 
spectrophotometric assays with both nitrocephin and imipenem as reporter 
substrates. Active fractions were pooled, divided into 1ín1 aliquots and 
rapidly frozen on solid CO2 to -20 °C and assayed within one week. 
2.8.4. Ion Exchange Chromatography. 
This section details the protocol for running a Whatman DE52 anion 
exchange column. This section refers solely to Chapter 3, and was used to 
separate NmcA (pI 6.9) and AmpC (pl -9.0) from Enterobacter cloacae 
NOR -1. 
150g (dry mass) of Whatman DE52 DEAE (diethylaminoethyl -) cellulose 
was prepared according to the manufacturers instructions and equilibrated 
with 10mM Tris IICI pH 8.5° in a Wright jacketed column (4cm2 x 60 cm) at 
4 °C in a cold cabinet. 
The crude dialysed ß- lactamase preparation was added to the top of the 
column. Once the sample had adsorbed to the top of the matrix, the column 
was flushed with running buffer until the A280 of the eluent fell below 0.08. 
The ß- lactamase was eluted by a linear NaCl gradient, increasing from OM 
to 1M NaC1 in the running buffer. 5ml samples were collected in a LKB 
BROMMA 2070 fraction Collector (Pharmacia, Sweden). 
2.8.5. Ammonium Sul s hate Selective Preci s itation. 
Crude cell -free lysates containing ß- lactamase activity were placed in a 
beaker and cooled to 4 °C. Ammonium sulphate was added slowly, over a 
course of 30 minutes to a final saturation of 30% with gentle stirring, the 
6 The change in pKa per degree celcius for Tris buffer is very high (ApKa/C° = -0.031). For 
this reason, This buffer was made up and pH altered to 8.5 at 4 °C. Otherwise a buffer 
pH 8.5 made at 25 °C and chilled to 4 °C will drop by 0.65 pH units to 7.85. 
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exact mass of ammonium sulphate was determined as described by [207]. 
After each increase in ammonium sulphate saturation, the solution was left 
for 30 minutes with gentle stirring. The precipitate was harvested by 
centrifugation at 15,000 x g in a Sorvall RC -5B refrigerated centrifuge or a 
Beckman J2 -21 Refrigerated Superspeed centrifuge for 10 minutes. The 
pellet was resuspended in a minimum volume of 25mM PIPES pH 7.0 with 
1mM ZnSO4 and assayed together with the supernatant for ß- lactamase 
activity by nitrocephin spot test to determine whether the ß- lactamase had 
been precipitated. If not, the saturation of the supernatant was increased to 
50% as described above and the precipitated protein was re- assayed. This 
was increased to a final saturation of 80% ammonium sulphate if 
necessary. The fractions were dialysed against 25mM PIPES pH 7.0 with 
1mM ZnSO4 to remove all ammonium sulphate, and assayed for 
ß- lactamase activity spectrophotometrically. 
2.8.6. Free flow IEF. 
Free flow IEF is a technique in which proteins can be separated in a similar 
manner to conventional IEF, but the pH gradient is set up across a moving 
liquid containing carrier ampholytes. This allows a larger amount of protein 
to be loaded, and facilitates the collection of focused proteins of narrow pH 
ranges (approximately 0.5 pH units). 
Crude ß- lactamase extracts were purified on the MinipHor system (Rainin, 
California) which was used according to the manufacturers instructions. 
Additional solutions are listed in Table 2.9 below. 





Pharmalyte pH 3.5 -10 (40% v /v) 0.8 1% v/v 
Glycerol 3.5 10% v/v 
Glycine (100% w /v) 0.35 1% w/v 
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The solution was made up to a final volume of 30m1 with deionised water, 
and loaded onto the MinipHor apparatus and pre- focused for 30 minutes at 
4 °C. 
Once prefocused, a 5ml crude cell -free extract was injected and allowed to 
focus at 1000V and 40W limiting for 30 minutes, followed by 500V 20W 
limiting for a further 10 minutes prior to sample collection. A total of 20 
samples of approximately 1.25m1 were collected, representing the pH 
spectrum of the pharmalytes. The exact pH of each sample was determined 
by pH indicator paper strips (BDH Laboratories). Samples were dialysed 
against a 100 fold excess of 25mM PIPES pH 7.0 in 1mM zinc sulphate to 
remove the pharmalytes and then assayed against nitrocephin and 
imipenem for ß- lactainase activity. 
2.9. Protein Determination. 
The protein concentration of a given sample was determined in one of two 
ways. 
2.9.1. Spectrophotometric. 
This method was first described by Waddell [208]. A dilution (1 in 1000) of 
the sample was placed in a quartz cuvette with a path length of 1cm. The 
protein concentration was calculated according to the equation 
A215 -A226x 165 
2.9.2. Chemical. 
This method was first described by Bradford [209]. l0µ1 of the sample was 
added to 1000 BioRad Coomassie brilliant blue G250 reagent in a microtitre 
plate, and the A600 was compared with a standard graph. The standard 
graphs were prepared with bovine serum albumin by Dr. P. J. E. Rowling, 
SmithKline Beecham Pharmaceuticals. 
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2.10. Assays for ß- lactamase Activity. 
2.10.1. Nitrocephin Spot Test. 
30µ1 of the sample was placed in a well of a microtitre plate, and mixed with 
100111 of 50mg /1 nitrocephin. The time taken for the nitrocephin to be 
hydrolysed, characterised by a colour change from yellow to red was noted. 
Where this time was greater that five minutes, the plate was incubated at 
37 °C. 
2.10.2. Kinetic Analysis. 
Assays of ß- lactamase activity were conducted on a Perkin Elmer Lambda 
2 dual beam spectrophotometer or a Beckman DU -7400 diode -array 
spectrophotometer as described by [210, 211]. Both spectrophotometers 
had thermostatically controlled cuvettes, and assays were conducted at 
37 °C in 25mM PIPES pH 7.0 unless otherwise stated. In all cases, the 
buffer present in the `blank' cuvette was identical to that present in the test 
cuvette, including any zinc supplement for the experiments in Chapter 5. 
All ß- lactamase assays were conducted in the absence of a ZnSO4 
supplement with the exception of those detailed in Chapter 5. 
The rates of hydrolysis of nitrocephin were measured at 10-4M. Both 
carbapenems and cephalosporins were measured at 10-3M, and penicillins 
were measured at 10-2M. The hydroysis of ß- lactam antibiotics were 
measured at the wavelengths detailed in Table 2.10 overleaf. 
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Table 2.10: Wavelengths for Measurement of ß- lactam Antibiotics. 
. Compound Molecular Mass X,max (nm) 
P.E. Lambda 2 Beckman DU7400 
Ampicillin 371.4 238 235 
Cefuroxime 446.4 260 260 
Cefotaxiine 477.4 265 260 
Ceftazidime 636.6 260 260 
Imipenem 321.4 299 299 
Meropenem 437.5 300 300 
Nitrocephin 516 384 482 
BRL 42715 300 - 285 
Cefoxitin 449 - 268 
Cefpirome 462 260 260 
Cephaloridine 415.5 255 264 
Ceftriaxone 509.2 - 258 
Cefepime 480.6 260 260 
P.E. Lambda 2 - Perkin Elmer Lambda 2 spectrophotometer. 
The activity of the ß- lactamase was determined by the equation: 
AAbs xnx1000 
R= 
AAbstotat x time x enz 
Where: 
R = µmoles of substrate hydrolysed per minute per ml enzyme. 
AAbs = `corrected' change in absorbance measured. 
n = µmoles substrate in the cuvette. 
AAbstotai = Total change in absorbance after complete substrate hydrolysis. 
time = time in minutes. 
enz = volume of enzyme present (µl). 
The corrected change in absorbance describes a subtraction of the change 
in absorbance in the presence of enzyme and substrate from the change in 
absorbance in the presence of substrate, but in the absence of enzyme. 
Enzyme inhibition experiments were conducted with nitrocephin as reporter 
substrate unless otherwise stated. IDbos (the concentration of inhibitor 
required to inhibit hydrolytic activity by 50 %) were determined by a five 
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minute pre -incubation of increasing concentrations of inhibitor (10'M - 
10-3M) with the enzyme at 37 °C prior to the addition of substrate unless 
otherwise stated. 
The enzymes were assayed in decreasing substrate concentrations and 
decreasing rates of hydrolysis plotted on a double reciprocal plot to 
determine Vmax and Km as described by Lineweaver and Burk [212]. 
2.11. Molecular Mass Determinations. 
The molecular masses of ß- lactamases were estimated in two ways. 
2.11.1. Sephadex Gel Filtration. 
The eluted fractions of a calibrated sephadex column showing peak 
ß- lactamase activity could be compared to the standard graph as described 
in Section 2.8.1.2. 
2.11.2. SDS PAGE. 
2.11.2.1. Sample Preparation. 
Samples contained up to 30µg protein in up to 3O0. (which was increased to 
40111 after the addition of loading reagents). Samples of less than 30111 were 
made up to 3O0 with sterile distilled water. The reagents described in Table 
2.11 were added to the sample before loading. 
Table 2.11: Additional Rea ' ents for SDS -PAGE Sam les. 
Stock solution Volume Final 
(µl) Concentration 
10% SDS 4 1% (v /v) 
Phenol Red 4 10% (v /v) 
ß -2 Mercaptoethanol 2 5% (v /v) 
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This mixture was heated to 70 °C for 20 minutes immediately prior to 
loading onto the gel. 
2.11.2.2. Gel Preparation and Running. 
Samples were run on precast Novex 10 -well polyacrylamide minigels (10- 
27% acrylamide; 2.6 -5% Bis- acrylamide) of the Tris- Glycine type, pH 8.6 
which separate proteins between 5- 100kDa. Gels were stored at 4 °C. The 
gel and gel wells were rinsed thoroughly in deionised water prior to use to 
remove any unpolymerised acrylamide and storage solution. 
Samples were loaded with a Hamilton Syringe and run in lx Laemmli buffer 
at 80mA (constant current) for 80 minutes or until the Phenol Red dye front 
was just visible at the bottom of the gel. 
Once run, the plastic cassette enclosing the gel was opened and the bottom 
3mm of the gel and the stacking gel at the top were removed and discarded. 
2.11.2.3. Stain / Destain. 
The gel was stained in Coomassie Blue R -250 for 20 minutes with gentle 
shaking, and washed in deionised water. 
The gel was destained twice in destain solution (5% methanol, 10% acetic 
acid, 85% deionised water) for 1 hour with gentle shaking together with foam 
bungs cut into small pieces to help absorb excess stain. 
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2.12. Passage Experiments. 
2.12.1. Selection of Imipenem Resistant Mutants. 
The strains to be passaged were set up in Robertson's Cooked Meat Broth 
without imipenem. 
Broth cultures of the selected strains were set up in 20 ml broth Wilkins 
Chalgren broth (unless otherwise stated) in McCartney bottles with 
increasing concentrations of imipenem. A total of six broths were set up for 
each strain, one bottle a single dilution below the MIC, one bottle equal to 
the MIC, and three bottles with increasing concentrations of imipenem. One 
bottle contained no imipenem to act as a control. 
The bottles were inoculated with a 1% inoculum of the strain to be passaged 
unless otherwise stated and incubated for 24 hours at 37 °C. 
Each day for five days, the bottle with the highest imipenem concentration 
which still showed significant bacterial growth was used to inoculate 6 fresh 
bottles with imipenem as before. 
2.12.2. Selection of Imipenem Sensitive Mutants. 
A culture of the strain was set up in 4.5 ml Nutrient Broth No. 2 with no 
selective pressure in a universal bottle, and incubated for 24 hours at 37 °C. 
Each day, 50µ1 was taken and used to inoculate a fresh pre -warmed 
universal containing 4.5ml broth. This procedure was repeated for 26 days. 
The antibiograms of the strain and the passaged mutant were compared to 
determine any change in the level of ß- lactam resistance. 
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2.13. Conjugation Studies. 
2.13.1. Formation of Rifampicin Resistant Mutant. 
Since no suitable recipient for Bacteroides conjugation studies was available, 
a mutant strain of the ß- lactamase negative Bact. fragilis NCTC 9343 was 
selected for the formation of a rifampicin mutant. 
This strain was cultured in 100m1 Robertson's Cooked Meat medium at 
37 °C overnight. The culture was decanted into a sterile centrifuge bottle and 
centrifuged at 6000 x g for 20 minutes at 4 °C in a Beckman J2 -21 
Refrigerated Superspeed centrifuge. The pellet was resuspended in 4m1 
fresh BHI broth, and 1m1 was plated onto each of four GBA plates 
containing 20mg/1 rifampicin and incubated in an anerobic jar for 60 hours. 
Of the three colonies that grew, all were plated onto fresh GBA plates 
containing 20mg/1 rifampicin for a further 60 hours. 
Each of these colonies were identified by API32A, but only was identified as 
Bact. fragilis. This strain was designated JMS -431. 
2.13.2. Mating Experiments. 
Donor and recipient strains were incubated in 20m1 Robertson's Cooked 
Meat medium in a sealed McCartney bottle overnight at 37 °C. 
5m1 fresh pre -warmed Robertson's Cooked Meat medium was inoculated 
with 0.1m1 donor and 1m1 recipient and incubated for 8 hours at 37 °C. After 
this time, the culture was harvested by centrifugation at 6000 x g in a 
Beckman J2 -21 Refrigerated Superspeed centrifuge, resuspended in 2ml 
sterile 0.85% saline and inoculated onto Columbia blood agar plates with 
20mg/1 rifampicin and 4mg/1 imipenem. The plates were incubated 
anaerobically for 48 hours at 37 °C. 
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CHAPTER THREE 
Purification of Known Carbapenemases. 
3.1. Prologue. 
To ensure the accuracy of results obtained in this thesis during experiments 
on carbapenem hydrolysing enzymes, several previously described 
carbapenemases were included in these experiments for control and 
comparative purposes. 
Since the experiments involving the effects of divalent cations on 
carbapenemase activity [see Chapter 5] required a serine active 
carbapenemase, ß- lactamase NmcA was purified from Enterobacter cloacae 
NOR -1. 
3.2. Purification of NmcA from Enterobacter cloacae 
NOR -1. 
Enterobacter cloacae NOR -1 is known to produce two ß- lactamases; a serine 
active site carbapenemase designated NmcA and an AmpC type 
chromosomal cephalosporinase. Since these ß- lactamases have different 
iso- electric points, 6.9 and -9.3 respectively, they were separated on a 
DEAE cellulose column (Whatman DE52) equilibrated in 10mM Tris pH 8.5 
as described in Materials and Methods. The AmpC cephalosporinase failed 
to bind to the column, and was eluted in the void volume. However, NmcA 
bound to the column matrix, and was eluted by an linear NaC1 gradient. A 
nitrocephin microtitre plate assay of the eluted fractions was conducted to 
locate those with ß- lactamase activity. This plate can be seen in Figure 3.1 
overleafand Figure 3.2. 
73 
Chapter 3: Results 
Figure 3.1: Diagrammatic View of Microtitre Plate Assay To 
Determine Fractions with ß- lactamase Activity After Ion Exchange 
Chromatography. 
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I3 11 13 ® 17 19 
C 21 127 29 
D 31 33 35 37 39 
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The above diagram denotes the loading sequence for the microtitre plate 
assay. The numbers represent the fraction numbers. The salt gradient was 
started at fraction 41. 
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Figure 3.2: Microtitre Plate Assay To Determine Fractions with 
ß- lactamase Activity After Ion Exchange Chromatography. 
Figure 3.3 overleaf shows the elution profiles of these ß- lactamases. 
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Figure 3.3: Elution Profiles of NOR -1 ß- lactamases by Ion Exchange. 
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Figure 3.4 overleaf shows an IEF gel with the separated ß- lactamases, 
together with the crude preparation of Enterobacter cloacae NOR -l. 
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Figure 3.4: IEF Showing Separation of Enterobacter cloacae NOR -1 





A B C D 
Lane A Crude Extract of Enterobacter cloacae NOR -1. 
Lane B AmpC. 
Lane C Nmc -A. 
Lane D TEM -1. 
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CHAPTER FOUR 
Determination of ß- lactam Resistance in 
Clinical Bacteria. 
4.1. Prologue. 
Resistance to carbapenem antibiotics is rare, as stated in Chapter 1. Of 
those strains which exhibit resistance to carbapenems, such resistance can 
be mediated by a variety of mechanisms, including the production of a 
ß- lactamase which may be capable of hydrolysing these compounds. 
Carbapenemases have been found which employ a metal ion as part of 
their active site and more recently, serine active site carbapenemases have 
also been reported. 
4.2. Clinical Isolates Received for Examination. 
As part of this thesis, clinical isolates from several clinically relevant 
species have been collected as described in Section 2.2. This collection has 
been examined both for carbapenem resistance and for the production of a 
carbapenem hydrolysing ß- lactamase. 
These isolates are discussed in the following sections, and classified by 
source. 
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4.2.1. Isolates from Glasgow Royal Infirmary. 
Five clinical isolates had been identified by Glasgow Royal Infirmary as 
resistant to imipenem by modified Stokes test. Four of these strains were 
confirmed as P. aeruginosa by API2ONE. All isolates were grown with and 
without 3,1 MIC of imipenem to act as an inducer. Crude cell -free lysates of 
these isolates showed potent ß- lactainase activity with nitrocephin as 
reporter substrate, but no imipenem hydrolysis was detected 
spectrophotometrically. The B-lactamases of these strains failed to focus 
by IEF, but smeared along the gel from pI 7 to 9, and may be caused by the 
production of a stably de- repressed chromosomal ß- lactamase. Since no 
imipenem hydrolysis could be detected spectrophotometrically, no further 
work was conducted on these strains other than the determination of their 
antibiograms. The antibiograms of these strains are shown in Table 4.2 
overleaf. 
The remaining strain received from the Glasgow Royal Infirmary was 
identified as Enterobacter aerogenes by API20E. This isolate was resistant 
to imipenem with an MIC of 32mg /1, above the breakpoint of 16mg/1. 
A sonicated cell free lysate of this isolate showed potent nitrocephin 
hydrolysis, which was resistant to cavulanic acid as shown in Table 4.1. 
However, no imipenem hydrolysis could be detected spectrophotometrically. 
Analysis by IEF showed a single smeared band between pI 8 and 9. These 
data suggest that this strain hyper- produced a ß- lactamase possibly as a 
de- repressed mutant. The biochemical analysis of this enzyme suggested 
that it may be an Ambler Class C enzyme, possibly similar to the p99 
ß- lactamase which is common amongst members of the Enterobacteriaceae. 
The antibiograms of these strains are shown in Table 4.2 overleaf. 
Table 4.1: Effect of Clavulanic Acid on Ent. aerogenes ß- lactamase. 
Strain NCFN Hydrolysis 
( mol/min/ml) 
NCFN Hydrolysis 
+ Clay ( I ol/inin/m1) 
% Activity 
Ent. aerogenes 1270 1130 89 












































































































































































































































































































































































































































































































































































































































Chapter 4: Results 
4.2.1.1. Investigation of the Stability of ß- lactamase Production by 
the Enterobacter aerogenes Isolate. 
Experiments were conducted to determine the stability of the ß- lactamase 
production by this isolate. To this end, this strain (designated JMS -335) was 
inoculated into 4.5 ml fresh Nutrient Broth No.2 without any selective 
pressure every day for 26 days. After this time, the MIC's of both the 
passaged isolate (designated JMS - 335,), and the original strain (JMS -335) 
were determined and compared. The MIC's of imipenem of JMS -335 and 
JMS -335, were 32mg/1 and 8mg/1 respectively. This suggested that the 
hyper- production of the ß- lactamase by this isolate was very stable. This 
reduction in imipenem MIC does result in the strain showing only 
intermediate resistance to imipenem as defined by NCCLS breakpoint 
(intermediate - 8mg/1), but this strain remained resistant as defined by 
BSAC standards (resistant - 8mg/1). 
4.2.2. Isolates from Western General Hospital, Edinburgh. 
A total of 33 clinical isolates were received from the Western General 
Hospital of Edinburgh, which all showed reduced sensitivity to imipenem by 
modified Stokes test. The identities of all these isolates were confirmed by 
API20E or API20NE as appropriate. 
All isolates were grown with and without 11 MIC of imipenem to act as an 
inducer. Sonicated crude cell -free lysates of all these isolates were examined 
for B-lactamase activity. With the exception of a single Sten. maltophilia, 
all isolates appeared to produce a ß- lactamase, since these preparations 
hydrolysed nitrocephin by spot test. However, of the single Enterobacter 
cloacae, 11 P. aeruginosa, 3 Burk. cepacia, and 18 Sten. maltophilia, only 
the Sten. maltophilia isolates were able to hydrolyse imipenem 
spectrophotometrically. Only the Sten. maltophilia isolates appeared to 
produce inducible ß- lactamase activity. The antibiograms of these strains 
























































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 4: Results 
Since several workers have already examined the L1 -type imipenem 
hydrolysing ß- lactamases from Sten. maltophilia, and no other strains were 
able to hydrolyse imipenem, no further work was conducted on these 
isolates apart from their antibiograms. 
The three Burk. cepacia isolates showed resistance to all antimicrobials 
tested, with MICs significantly above the breakpoint for all compounds. It 
should be noted that these strains were also resistant to both 
carbapenems, despite the fact that no imipenem hydrolysis was detected 
spectrophotometrically. Not only were these strains resistant to the 
carbapenems, but ciprofloxacin resistance was also observed. Of the 
compounds tested, only ceftazidime and ciprofloxacin showed any activity 
in vitro, although it is unlikely that these compounds would be effective in 
vivo since the concentrations of these compounds required for antibacterial 
activity are generally greater than those physiologically attainable by 
infusion. 
The P. aeruginosa isolates showed extensive resistance to all penicillins and 
ß- lactam/ß- lactamase inhibitor combinations, with MIC90 values above the 
breakpoints of 32mg/l. 
Of the cephalosporins tested, cefotaxime and ceftazidime MICb0 values were 
below their breakpoints. Ceftazidime MIC90s were only 1 dilution above the 
breakpoint of 32mg/l. This also applied to the carbapenems. Ciprofloxacin 
showed greatest activity; MIC90 values for the compound were below the 
breakpoint of 4mg/1. 
The strains of Sten. maltophilia examined here were found to be resistant to 
all penicillins; MIC90 values significantly above the breakpoint of 32mg/l. 
Ceftazidime and ciprofloxacin were the only compounds which showed an 
MIC60 below the breakpoints of 32mg/1 and 4mg/1 respectively. The 
carbapenems imipenem and meropenem showed little activity, both having 
MIC60 values of 64mg/1, which were well above the breakpoint of 16mg/l. 
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4.2.3. Isolates Received From Clinical Laboratories, Edinburgh 
Royal Infirmary. 
4.2.3.1. Aerobes. 
Nine Acinetobacter, 9 Enterobacter and 11 Klebsiella isolates were received 
from the Clinical Bacteriology laboratories, Edinburgh Royal Infirmary. 
These strains were random consecutive isolates, and were examined for the 
production of an imipenem hydrolysing ß- lactamase. Crude cell -free lysates 
of these isolates showed nitrocephin hydrolysing activity, suggesting the 
presence of a ß- lactamase. However, none of these extracts were able to 
hydrolyse imipenem spectrophotometrically, despite some of these isolates 
having imipenem and meropenem MIC's above the breakpoint of 16mg/1. 
Several Acinetobacter isolates showed resistance to ciprofloxacin and to the 
carbapenems. The `fourth' generation cephalosporin cefepime showed very 
good activity against both Enterobacter and Klebsiella isolates, with MIC's 
comparable to the carbapenems and ciprofloxacin. However, this compound 
did not show such good activity against Acinetobacter isolates. 
The third generation cephalosporins cefotaxime and ceftazidime showed 
good activity against the Klebsiella isolates; the MIC90 values being lower 
than the breakpoints of 64mg/1 and 32mg/1 respectively. These compounds 
were not as effective against Enterobacter, but MIC60 values were still below 
their breakpoints. Klebsiella and Enterobacter MIC90 values for both the 
carbapenems and also ciprofloxacin were below the breakpoints for these 
agents, demonstrating the efficacy of these agents. 
Of the compounds tested, the only compounds to have significant 
antibacterial activity against all the species examined were the 
carbapenems, imipenem and meropenem, and the quinolone, ciprofloxacin. 
Each of these compounds showed MIC60s below their breakpoints, although 
individual resistant isolates were found. 
























































































































































































































































































































































































































































































































































































































































































































Chapter 4: Results 
4.2.3.2. Anaerobes. 
In addition to the aerobes which were received from the clinical laboratories 
of the Edinburgh Royal Infirmary, a survey examining the antimicrobial 
resistance of clinical isolates from of the Bacteroides group of obligate 
anaerobes was undertaken. Isolates from the clinical laboratories included 
strains originally isolated from the Edinburgh Royal Infirmary, and Genito- 
Urinary Medicine clinic. This survey was conducted over three years from 
1993 to 1995. A total of 166 isolates were received and examined. 
Sonicated cell -free extracts of each of these isolates were prepared and 
examined for ß- lactamase activity by nitrocephin spot test. All but 7 
isolates were able to hydrolyse nitrocephin within 60 minutes, indicating 
that 95.8% of these isolates produced measurable ß- lactamase activity. All 
isolates were tested spectrophotometrically for imipenem hydrolysing 
activity. However, no imipenem hydrolysis could be detected in any of these 
preparations. 
The MICs of these isolates were determined against a variety of 
antimicrobial agents. Table 4.5 overleaf shows the MIC ranges of these 
isolates against the compounds tested. 
In addition to the above strains, several Bacteroides isolates were received 
because they exhibited resistance to imipenem. These isolates cannot be 
considered as random isolates, and have not been included in this section. 




































































































































































































































































































































































































































































































































































































































































































































































Chapter 4: Results 
The penici sins ampiciliin and amoxycillin showed very limited activity 
against these isolates, with MICb0 values for these compounds above the 
breakpoint of 4mg/l. Penicillin was not tested since members of the 
Bacteroides fragilis group are generally regarded as resistant to this 
compound, as described in Chapter 1. The addition of the ß- lactamase 
inhibitor clavulanic acid to the ß- lactam amoxycillin potentiated the 
bactericidal activity of this ß- lactam compound. MIC90 values for this 
ß- lactam / ß- lactamase inhibitor combination were 4mg/1 and were below 
the breakpoint of 8mg/l. 
Cefotaxime proved to be the most effective of the cephalosporins tested, 
with MICb0 values of 8mg/1, well below the breakpoint of 32mg/1. However, 
none of the other cephalosporin compounds proved particularly effective 
with MICs comparable to or greater than the breakpoint. 
Both carbapenems, imipenem and meropenem showed good activity 
against the anaerobes, with MIC90 values of lmg/1, well below the NCCLS 
breakpoint of 16mg/I. Interestingly, these MIC90 values were also below the 
BSAC `low' breakpoint of 4mg/l. 
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4.3. Passage Experiments on Two Bact. fragilis Isolates. 
It was decided to attempt to increase the resistance to imipenem of two 
Bact. fragilis isolates by passage experiments in increasing concentrations 
of imipenem over 5 consecutive days. 
The strains chosen were JMS -63 and JMS -71. Both were received from Dr. 
D.J. Payne, SmithKline Beecham, Betchworth, Surrey (SB designations 
ED72 and R416 respectively). When originally sent to Dr. Payne, these 
strains were found to have MICs of imipenem of 1mg/1 and 4mg/1 
respectively. However, the MICs were found to have dropped to 0.125mg/1 
and 0.25mg/1. The ß- lactamase negative Bact. fragilis strain NCTC 9343 
was also included in these passage experiments. 
The imipenem broth MICs of these strains were found to be higher than 
their respective plate MIC's. To ensure growth, cultures were set up in 
20mis Wilkins - Chalgren broth in McCartney bottles with the following 
imipenem concentrations. 










NCTC 9343 - 0.06 0.03 -0.5 
JMS -63 1 0.125 0.125 -2 
JMS -71 4 0.25 0.5 -8 
The passage experiments were conducted as described in Materials and 
Methods. The broth with the highest imipenem concentration showing 
bacterial growth was used to inoculate fresh broth with the same range of 
imipenem concentrations on the following day. However, the culture failed 
to grow when inoculated into fresh media on the third day. These 
experiments were repeated with larger inocula, namely 1 %, 2% and 5 %, but 
in each case, the 5 day passage could not be completed. The ODom of a 
stationary phase culture in this broth varied between 0.8 and 1.2 
absorbance units, suggesting only limited growth. 
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As an alternative, these experiments were repeated in a similar volume of 
BHI broth in McCartney bottles. The broth MIC's of these strains were 
found to be lower than their corresponding plate MIC's, but once the 
imipenem concentrations in the McCartneys had been altered accordingly, 
the culture failed to grow after day 2 in a similar way to that observed with 
Wilkins - Chalgren broth. An increase in the inocula did not improve this 
outcome. 
Since neither of these broths are nutritionally rich, the passage 
experiments were repeated in Robertsons Cooked Meat (RCM) medium in 
McCartney bottles. However, the broth MIC's of all three strains increased 
by over an order of magnitude in this medium, and bacterial growth was not 
consistent from tube to tube. This may have been caused by a variation in 
the mass of cooked meat granules in each bottle affecting the available 
imipenem concentration in each bottle. 
Finally, these experiments were repeated with thioglycollate medium pH 
7.1. The broth MIC's of these strains were comparable with those 
conducted in Wilkins- Chalgren broth, but again, the cultures would fail to 
grow before the end of the passage. This outcome was not improved by 
inoculating a fresh broth with a culture from a lower imipenem 
concentration. 
4.4. Flavobacterium Isolates from Culture Collections. 
Ten clinical isolates from 9 different species of the genus Flavobacterium 
were received from the National Collection of Type Cultures (NCTC) in 
London. These strains are discussed in greater detail in Chapter 7. The 








































































































































































































































































































































































































































































































































Chapter 4: Results 
These isolates were resistant to the penicillins with MIC60s above the 
breakpoint of 32mg/l. The presence of clavulanic acid in co- amoxyclav 
resulted in a drop in MIC90 to 32mg/1 making it equal to the breakpoint. The 
cephalosporins showed limited activity, cefotaxime being the only compound 
of this group with MIC90 comparable to its breakpoint. The carbapenems 
showed good activity against these organisms. MIC90s of both of these 
compounds were 16mg/1, comparable to the breakpoint. The lowest MIC90s 
were observed for ciprofloxacin, which equalled the breakpoint of 4mg/1 for 
this compound. 
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CHAPTER FIVE 
Optimisation of Divalent Cation Concentration 
in Assays Involving Metallo -ß- lactamases. 
5.1. Prologue. 
Since the first observation by Sabath and Abraham that metallo- 
ß- lactamases require a divalent transition metal cation, usually zinc for 
activity [164], many workers have simply included a 1mM zinc sulphate 
supplement to their assay buffers. Little work has been done on the effect 
of zinc on catalytic activity apart from the observation that the 
sequestration of this ion from the metallo- ß- lactamase by EDTA and other 
chelators results in enzyme inactivation. This inhibition can be partially 
restored by the addition of excess zinc sulphate at a later time, although the 
degree to which activity is restored varies from enzyme to enzyme. 
The only work which suggests any investigation into the effects of zinc on 
these enzymes was made in 1974 by Davies and Abraham who observed 
that zinc increased the hydrolytic activity of B. cereus II against 
cephalosporin C [122]. In 1993, Felici and co- workers studied several known 
metallo -ß- lactamases. This group assayed B. cereus II in buffer containing 
0.3mM ZnCl2, whereas all other metallo-ß- lactamases were assayed in 
buffer containing 0.1mM ZnC12 [103]. No explanations were given for the 
choice of these supplement concentrations. 
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5.2. Effects of Zinc on the Carbapenemase Activity of a 
Metallo -ß- lactamase. 
For the assay of these enzymes, an investigation of the effects of zinc on 
the catalytic activity of these enzymes was undertaken. Experiments were 
conducted on crude cell free lysates of Bact. fragilis JMS -221, which 
produces a single imipenem hydrolysing ß- lactamase, probably a metallo- 
ß-lactamase [see Chapter 6]. Disposable glassware was used wherever 
possible, and any re- usable glassware was firstly washed in O.1M EDTA 
and rinsed in MilliQ water, followed by a wash in 0.1M NaOH and rinsed in 
MilliQ water until the pH returned to neutral, to ensure that the glass was 
free of any detergent or excess ions respectively. All bottles had plastic 
caps, and no rubber inserts were used since it has been reported that such 
inserts can act as a significant reservoir of metal ions, including zinc [214]. 
All buffers were prepared in MilliQ water. 
A crude sonicated cell -free extract of a 1 litre stationary phase culture was 
prepared in 25mM PIPES pH 7.0 supplemented with 1mM ZnSO4. Prior to 
any assays, the extract was dialysed four times in a greater than 100 -fold 
excess of 25mM PIPES pH 7.0 in MilliQ water to remove any excess zinc 
ions. This preparation was then assayed against several substrates in the 
presence of increasing concentrations of ZnSO4. Enzyme activity was 
plotted as a percentage of basal activity. For the purposes of this thesis, 
basal activity was taken as the rate of hydrolysis of the tested substrate 
by the crude preparation in the presence of no ZnSO4 supplement. Each 
assay was blanked against substrate with the same zinc concentration as 
that of the assay mixture. 
A graph showing ß- lactam hydrolysis against zinc concentration is shown in 









































































































































































































Chapter 5: Results 
It can be seen from Figure 5.1 that the concentration of zinc in the assay 
buffer had little effect on the rate of hydrolysis of cephaloridine, cefuroxime 
or cefotaxime. However, the hydrolysis by this preparation of both 
imipenem and meropenem was increasingly inhibited as the concentration 
of ZnSO4 in the assay buffer was raised. Additional experiments were 
conducted to further characterise this inhibition, and to determine whether 
the method of ß- lactamase preparation affected the rate of carbapenem 
hydrolysis by this preparation. 
5.3. Effects of Zinc Concentration During Metallo- 
ß-lactamase Preparation on ß- lactamase Activity. 
A 1 litre culture of JMS -121 was grown in the presence of 4mg/1 imipenem, 
and the stationary phase culture was harvested by centrifugation. The 
pellet was washed in 25mM PIPES pH 7.0 in MilliQ water and divided into 
three aliquots of identical wet cell mass. These three aliquots were treated 
identically, except that the concentration of the zinc sulphate supplement 
in the preparation buffer was kept at three different concentrations; no 
ZnSO4, 1µM ZnSO4, and 1mM ZnSO4 throughout the preparation procedure. 
These enzyme preparations were designated BFR0, BFRI and BFR1000 
respectively, to distinguish between the different ZnSO4 concentrations 
present during their preparation. 
Prior to spectrophotometric assays, each aliquot was dialysed separately 
four times against a greater than 100 -fold excess of 25mM PIPES buffer 
pH 7.0 in MilliQ water to remove any excess zinc ions. The assays were 
conducted with a variety of reporter substrates known to be hydrolysed by 
this enzyme. Each enzyme was pre -incubated with varying zinc sulphate 
concentrations for 5 minutes and then assayed for hydrolytic activity. The 
basal activity of each aliquot was taken as the rate of ß- lactam hydrolysis 
with no ZnSO4 in the assay buffer. These data are shown in Figures 5.2, 5.3 
and 5.4 overleaf, which are all shown to the same scale to facilitate direct 
comparisons of these graphs. 
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Figure 5.2: Effect of Zinc on Metallo -ß- lactamase Prepared with no 













Figure 5.3: Effect of Zinc on Metallo -ß- lactamase Prepared with 



















Figure 5.4: Effect of Zinc on Metallo -ß- lactamase Prepared with 




















Chapter 5: Results 
Assays were conducted at half log dilutions of zinc sulphate i.e. (1x10-3, 
3.16x10 -4, 1x10-4, 3.16x105, 1x10-5, 3.16x10 -6 and 1x106 molar). The value of 
3.16 was chosen as it falls half way between 1 and 10 on a logro plot. 
The effect of preparing the ß- lactamase in a buffer with no zinc sulphate or 
with 1µM zinc sulphate was minimal since the basal hydrolytic activity of 
the BFR0 and BFR1 preparations did not vary to any significant degree for 
any of the substrates tested. However, as the zinc concentration in the 
assay buffer was increased, a slow, but steady increase in the hydrolytic 
activity of cephaloridine was observed in both the BFR0 and BFR1 
preparations. 
With imipenem as substrate however, BFRo and BFR1 both showed an 
enzyme activation of up to 150% as the ZnSO4 concentration increased, 
reaching a peak at 10011M ZnSO4 for both preparations. The imipenem 
hydrolysis of BFR1000 showed no such activation as the ZnSO4 concentration 
was increased. Conversely, BFR,000 appeared to be inhibited as this ZnSO4 
supplement was increased, such that an ID60 of this compound could be 
calculated as 1mM ZnSO4. This inhibition was found to be reversible, since 
dialysis of BFR1000 which had been incubated with 1mM ZnSO4 restored 
hydrolytic activity to basal, once a correction for protein concentration had 
been made. 
Whilst the imipenem hydrolysis of BFRl000 showed no activation on the 
addition of ZnSO4 to the assay mixture, its basal activity was significantly 
greater than the maximum rate reached by BFRo or BFR1, even at 
maximum activation. 
It is interesting to note that the rate of hydrolysis of cephaloridine by 
BFR1000 was nearly twice that of BFRo and BFR1. Cephaloridine hydrolysis 
by BFR0, BFR1 or BFR1000 was unaffected by the ZnSO4 concentration in 
the assay buffer. Nitrocephin hydrolysis was also unaffected in this 
manner, as described in Figure 5.5 overleaf. The nitrocephin hydrolysis of 
these preparations are shown on a separate graph from Figures 5.2, 5.3 and 
5.4 because this substrate is hydrolysed at 3.5 - 4.5 times the rate of 
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imipenem and cephaloridine [see Chapter 6] and if plotted on the saine axes, 
these effects would not appear as marked. 
Figure 5.5: Effects of Zinc During Preparation and Assays on 
Metallo -ß- lactamase Mediated Nitrocephin Hydrolysis. 
1500 
1250 
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The rate of nitrocephin hydrolysis by BFRo, BFRI or BFR1000 at any zinc 
sulphate concentration showed no significant difference from basal activity. 
5.4. Effects of Cobalt Concentration on Metallo- 
ß-lactamase Activity. 
Similar experiments to those conducted with ZnSO4 were conducted with 
cobalt, in the form of CoC12 in the assay solution to determine whether this 
inhibition could have been caused by heavy metal poisoning of the 
ß- lactamase. Metallo -ß- lactamases are known to be able to function with 
cobalt instead of zinc as part of their active site, as described in Chapter 1. 
BFR1000 was assayed in the presence of increasing concentrations of CoC12. 
These data can be seen in Figure 5.6. Only a slight inhibition of 
imipenemase activity could be detected at 1mM CoC12. As found with 
ZnSO4, no inhibition of cephaloridine, nitrocephin or cefuroxime hydrolysis 
was detected. For clarity, only cephaloridine and imipenem are shown in the 
graph. 
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Figure 5.6: Effect of Cobalt on Metallo -ß- lactamase Prepared with a 
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This figure shows that cobalt had little effect on the imipenem hydrolysis of 
BFR1000. Hydrolysis of cephaloridine by this preparation was completely 
unaffected, and hence implies that that the inhibition of imipenem 
hydrolysis by 1mM ZnSO4 did not result from heavy metal poisoning. 
5.5. Effect of Zinc and Cobalt on Other Metallo- 
ß-lactamases. 
5.5.1. Bact. fragilis Metallo -ß- lactamases. 
These experiments were repeated with the metallo -ß- lactamases described 
in Chapter 6 and the known CfiA -type metallo-ß-lactamase from Bact. 
fragilis ED -262. 
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Figure 5.7: Effects of Zinc on Imipenem Hydrolysis of Bact. fi-a,ilis 
Metallo -ß- lactamases Prepared with no Zinc Sulphate Supplement. 
10 100 
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Figure 5.8: Effects of Zinc on Imipenem Hydrolysis of Bact. fragilis 
Metallo -ß- lactamases Prepared with a 1mM Zinc Sulphate 
Supplement. 
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Figure 5.9: Effects of Zinc on Nitrocephin Hydrolysis of Bact. 
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Chapter 5: Results 
Figures 5.7, 5.8 and 5.9 indicate that each of the metallo -ß- lactamases 
produced by the Bact. fragilis isolates JMS -121, JMS -219, JMS -221 and 
ED -262 showed similar zinc sensitivity profiles, whether prepared in the 
presence of 1mM zinc sulphate, or without this buffer supplement. 
Experiments were also conducted with cobalt in the assay buffer to 
determine whether this similar profile extended to this buffer supplement. 
The metallo -ß- lactamases in Figures 5.10 and 5.11 were prepared in a 
similar manner to BFR1000. 
Figure 5.10: Effect of Cobalt on Bact. fragilis Metallo-ß- lactamases 
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Figure 5.11: Effect of Cobalt on Bact. fragilis Metallo -ß- lactamases 
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In a similar manner to the zinc data from these enzymes, each of these 
metallo -ß- lactamases demonstrated a similar cobalt sensitivity profile. 
5.5.2. B. cereus II Metallo -ß- lactamase. 
These effects appeared to extend to all of the Bact. fragilis metallo- 
ß -lactamases examined. Since several other species also produce metallo- 
ß -lactamases, the effects of these ions on the B. cereus II metallo- 
ß-lactamase were also investigated. 
This enzyme was prepared by selective ammonium sulphate precipitation, 
followed by Sephadex G75 gel filtration with 25mM PIPES pH 7.0 as the 
elution buffer. The different zinc sulphate concentrations during enzyme 
preparation refer to the zinc sulphate concentration in the buffer employed 
to resuspend the ammonium sulphate precipitate and also the 
concentration present as a supplement to the G75 gel filtration buffer. Only 
imipenem was tested as a reporter substrate, since this purification 
protocol did not completely resolve the B. cereus II metallo- ß- lactamase 
from B. cereus I. B. cereus I does not hydrolyse imipenem. 
Figure 5.12: Effect of Zinc on the B. cereus II Metallo -ß- lactamase 
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It can be seen from Figure 5.12 that the B. cereus II metallo-13-lactamase 
showed a zinc sensitivity profile similar to that of BFR,000 when prepared in 
the presence of 1mM ZnSO4, but when prepared in the absence of a zinc 
sulphate supplement, this ß- lactamase showed greater activation than the 
Bact. fragilis enzymes, and less inhibition at 1mM zinc sulphate. 
5.5.3. Sten. maltophilia L1. 
Crude extracts of the Sten. maltophilia L1 metallo -ß- lactamase were 
prepared in a similar manner to BFRo, BFR, and BFR,000. These 
preparations were designated L10, L1, and L1,00o Imipenem was the only 
reporter substrate examined, since this preparation was a crude extract, 
and the L2 cephalosporinase was still present in the preparation. This 
latter enzyme does not hydrolyse imipenem. 
Figure 5.13: Effect of Zinc on the Sten. maltophilia L1 Metallo- 
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The Sten. maltophilia L1 metallo -ß- lactamase exhibited a very different 
zinc sensitivity profile to B. cereus II or the Bact. fragilis metallo- 
ß-lactamases. The concentration of the zinc sulphate supplements in the 
preparation buffer did not affect the zinc sensitivity profile of this enzyme 
since Llo, L1, and L1,000 each showed a similar sigmoidal activation curve, 
although the degree of activation is slightly less marked in Li,000. 
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5.6. Effect of Divalent Cations on Serine Active 
Carbapenemases. 
5.6.1. Prologue. 
It was postulated that this zinc mediated inhibition of carbapenem 
hydrolysis may have been caused by the binding of several zinc ions to the 
active site of a metallo -ß- lactamase, since B. cereus II has been shown to 
possess more than one zinc binding site [see Chapter 1]. 
To test this hypothesis, a ß- lactamase with a different mechanism of action 
was required. Since this phenomenon was restricted to carbapenem 
hydrolysis, Nmc -A, the only serine active carbapenemase known at that 
time was examined under similar conditions to see whether this 
phenomenon was restricted to metallo- ß- lactamases, or applied to 
carbapenem hydrolysis by all carbapenemases. Enterobacter cloacae 
NOR -1 produces two ß- lactamases, the serine active site carbapenemase 
NmcA, and a chromosomal AmpC type cephalosporinase. The separation 
of these ß- lactamases was conducted as described in Chapter 3. 
5.6.2. Effect of Zinc on the Hydrolytic Activity of NincA. 
Figure 5.14 overleaf shows the effect of zinc on ß- lactam hydrolysis by 
Nmc -A. 
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It can be seen from Figure 5.14 that the hydrolysis of both imipenem and 
cephaloridine were inhibited as the ZnSO4 concentration was increased. In a 
similar way to BFR1000, this inhibition was reversed after dialysis. 
Nitrocephin however, showed no significant inhibition, even at 1mM zinc 
sulphate. 
5.6.3. Effect of Cobalt on the Hydrolytic Activity of NmcA. 
Since zinc inhibited the hydrolysis of both imipenem and cephaloridine by 
Nmc -A, the effect of cobalt on this serine active carbapenemase was also 
determined. These data are shown in Figure 5.15 overleaf. 
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Figure 5.15: Effect of Cobalt on the ß- lactamase Activity of Nmc -A. 
10 100 1000 




It can be clearly seen from this figure that the addition of cobalt chloride to 
the assay buffer had no significant effect on the ability of NmcA to 
hydrolyse cephaloridine or nitrocephin. Interestingly, as the concentration 
of this ion approached 1mM, significant inhibition of imipenem hydrolysis 
could be detected. Dialysis of this sample demonstrated that this inhibition 
was reversible. 
5.7. Effect of Zinc on Metallo -ß- lactamase Inhibitor 
Studies. 
The above sections state that the presence of zinc during ß- lactamase 
preparation and assays has an effect on hydrolytic activity. The 
concentration of these supplements also affect IDb0 values for a diagnostic 
metallo -ß- lactamase inhibitor. The ID60 of EDTA is partially dependent 
upon zinc concentration during ß- lactamase preparation, as described in 
Table 5.1 overleaf. 
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Table 5.1: Effect of Zinc on Metallo -ß- lactamase Inhibition by EDTA. 




JMS -121 0 200 
1000 1000 
JMS -219 0 250 
1000 1000 
JMS -221 0 300 
1000 1000 
ED -262 0 150 
1000 1000 
It can be seen from Table 5.1 above that the presence of a 1mM zinc 
sulphate supplement during ß- lactamase preparation caused a 3 to 5 fold 
increase in the apparent ID60 for this compound. This is despite dialysis 
against buffer without a zinc sulphate supplement prior to ID50 
determination. 
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CHAPTER SIX 
Characterisation of the Metallo -ß- lactamases 
from 3 Bacteroides fragilis Clinical Isolates. 
6.1. Prologue. 
In addition to the survey of Bacteroides group isolates, several other Bact. 
fragilis clinical isolates were also received for examination. These isolates 
have not been included in the survey conducted in Chapter 4, since these 
isolates were received from various sources, and were sent because they 
exhibited reduced sensitivity to imipenem. It should be noted that all strains 
examined in this section were originally isolated from geographically distinct 
regions within Great Britain. 
6.2. Case Histories. 
Bact. fragilis JMS -121 was received from the Scottish 
Anaerobe Reference Laboratory, and was originally 
isolated from a 50 year old man with a duodenal ulcer. This 
isolate had previously been shown to be resistant to 
metronidazole [189] but no information about its 
sensitivity to imipenem was known. 
Bact. fragilis JMS -219 was received from the Public 
Health Service Laboratory (PHLS), Cardiff. This isolate 
was discovered in 1992 at Ealing Hospital, and was 
originally isolated from an 82 year old woman with leg and 
heel blisters. This strain was also reported to be resistant 
to metronidazole (Dr. J. Brazier, Pers. Comm.). 
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Bact. fragilis JMS -221 was also received from the 
PHLS, Cardiff. This clinical isolate was discovered at 
Ninewells Hospital, Dundee, and was originally isolated 
from the abdominal wounds of a patient with myelofibrosis 
(Dr. J. Brazier, Pers. Comm.). 
6.3. Initial Studies. 
1. Bact. fragilis strains JMS -121, JMS -219 and JMS -221 were all 
clinical isolates, and were found to be resistant to imipenem and 
meropenem by breakpoint. 
2. Sonicated crude cell -free lysates of each of these isolates were 
found to be able to hydrolyse imipenem spectrophotometrically. 
3. Incubation of these extracts with 10mM EDTA overnight caused 
a greater than 99% reduction in both imipenem and nitrocephin 
hydrolysis for all three isolates. This incubation had no effect on 
the nitrocephin hydrolysis of the TEM -1 ß- lactamase. 
4. A five minute incubation of the EDTA dialysed samples with 
1mM zinc sulphate resulted in restoration of -25% of the 
nitrocephin hydrolysing activity and 20 -26% of imipenem 
hydrolysing activity. These data are described in Table 6.7. 
For these reasons, all three isolates were chosen for further study. All three 
isolates were confirmed as Bact. fragilis by API32A. 
MIC data were determined for these isolates, against a variety of 




























































































































































































































































































































































































































































































































































































Chapter 6: Results 
JMS -121 and JMS -221 both produced a doublet band of ß- lactamase 
activity at pI 4.6 -5.0 by IEF. JMS -219, however failed to focus by this 
method. Gel filtration and iso- electric focusing suggested that these strains 
each produced a single ß- lactamase since column fractions showed a single 
peak of ß- lactamase activity, with a constant ratio of nitrocephin:imipenem 
hydrolysis, and active fractions co- focused at pI 4.6 -5.0 with crude cell -free 
lysates. 
This was supported by the observation that tazobactam had little 
inhibitory effect on the rate of substrate hydrolysis. This indicated that no 
significant hydrolysis was mediated by another ß- lactamase as the 
previously described [215] Bact. fragilis chromosomal ß- lactamase (Bush 
classification group 2e) was found to be sensitive to tazobactam [see also 
Section 1.9.6.4]. 
6.4. Purification of Imipenemases from Bact. fragilis 
Clinical Isolates by FPLC. 
To determine the best ion exchange matrix to purify these enzymes, crude 
cell -free extracts of the isolates were tested against 46 different matrices as 
described in Materials and Methods. A diagrammatic view of the microtitre 
plate layout is shown in Figure 6.1 overleaf. A photograph of the actual 
microtitre plates showing matrix binding is shown in Figure 6.2 and Figure 
6.3. 
The binding of a ß- lactamase to a specific matrix was detected by the 
addition of the chromogenic cephalosporin nitrocephin to the matrix 
supernatant. Matrices which bound ß- lactamase activity remained yellow, 
whilst unbound ß- lactamase remained in the supernatant and hydrolysed 
the yellow nitrocephin to a red product. 
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Figure 6.1: Diagrammatic View of Microtitre Assay Plate. 
A 10 O O O 5O O6 7O 8O 0 10 11 12 
B g 14 ® 
C 25 26 27 
D 37 10 39 
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H 37 CI CI 40 
17 18 19 20 21 CI 10 10 
29 30 31 32 33 34 35 36 
41 42 43 44 45 46 O O 
The number within the microtitre well denotes the matrix in that particular 
well. Since each set of 46 matrices only filled four rows of the plate, it was 
possible to assay up to two samples per microtitre plate. Where applicable, 
Rows E -H were loaded with matrix in a similar manner to rows A -D, to 
facilitate the assay of another enzyme. 
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Figure 6.2: Microtitre Plate Showing the Relative Binding of 
JMS -121 and JMS -219 ß- lactamase to 46 Ion Exchange Matrices. 
Figure 6.3: Microtitre Plate Showing the Relative Binding of the 
ß- lactamase from JMS -221 to 46 Ion Exchange Matrices. 
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From Figures 6.2 and 6.3, it was clear that matrix 30 (MacroPrep High Q) 
showed greatest ß- lactamase binding. It should also be noted that matrix 6 
(to -Amino Hexyl Sepharose) and matrix 29 (Q- Sepharose) also showed some 
binding. This binding profile was similar for all three enzymes, and so a 
MacroPrep High Q column in 20mM Bis Tris buffer pH 6.0 with 0.1mM 
ZnSO4 was used to purify these enzymes. Bact. fragilis ED -262, a strain 
known to be a CfiA metallo-ß- lactamase producer was also purified on this 
column under similar buffer conditions. Table 6.2 below shows the FPLC 
parameters for each strain. 











0 -0.5M 0.5 -1M 
JMS -121 58 2.0 175 85 260 
JMS -219 58 2.0 175 85 260 
JMS -221 58 2.0 175 85 260 
ED -262 48 2.0 100 100 200 
The parameters for the separation of the unknown JMS- isolates were 
identical. The protocol employed a linear salt gradient between no NaCl and 
0.5M NaCl for 67% of the run time, and the salt gradient was altered such 
that the remaining 0.5 -1M NaCl gradient would be completed in the 
remaining 33% of the run -time. 
However, the parameters were altered for the purification of the ED -262 
(known CfiA -type) ß- lactamase purely to reduce the column run -time, and 
hence run volume. The column was run at the same rate, but since the total 
run volume had been reduced, a linear NaC1 gradient between OM and 1M 
was employed. 
Figures 6.4 -6.7 overleaf shows the purification chart of these four strains 
by FPLC. 
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Figure 6.6: FPLC Purification Trace from Bact. fragilis JMS -221. 
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Figure 6.7: FPLC Purification Trace from Bact. fragilis ED -262. 
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Chapter 6: Results 
It can be seen from Figures 6.4, 6.5, 6.6 and 6.7 that each of these enzymes 
exhibited similar elution profiles from the MacroPrep High Q column; each 
enzyme eluting between fractions 10 and 16. Fractions containing 
significant ß- lactamase activity were pooled, as described in Table 6.3. 
Table 6.3: Fractions Pooled after FPLC Purification. 
Strain Fractions Pooled 
JMS -121 12 -16 
JMS -219 12 -16 
JMS -221 12 -16 
ED -262 10 -13 
Pooled fractions were dispensed into 1ml aliquots and maintained at -20 °C 
until required. Biochemical analysis of FPLC purified enzymes was 
conducted within one week of purification wherever possible. 
Whilst crude extracts of JMS -219 failed to focus by IEF, once purified by 
FPLC, sufficient ß- lactamase activity could be loaded onto the IEF gel to 
allow the visualisation of all four ß- lactamases by this method. This gel is 
shown in Figure 6.8 overleaf, and it can be seen that all three JMS- strains 
produced a doublet at pI 4.6 -5.0 which is characteristic of the CfiA 
ß- lactamase from both the original TAL 2480 Bact. fragilis isolate, and 
Bact. fragilis ED -262 which is known to produce a CfiA -type ß- lactamase. 
This adds further credence to the suggestion that all three of these JMS - 
strains produced a CfiA related ß- lactamase. 
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Figure 6.8: Iso- electric Focusing Gel of ß- lactamases from Bact. 









A B C D E F 
ß- lactamase from JMS -121. 
ß- lactamase from JMS -219. 
TEM -1. 
ß- lactamase from JMS -221. 
ß- lactamase from ED -262. 
TEM -1. 
119 
Chapter 6: Results 
SDS -PAGE of the FPLC fractions of the JMS- enzymes indicate that all 
these proteins were of approximately 31kDa which correlated with 
previously published values [see Table 1.4] Table 6.4 below compares the 
apparent molecular weights of these enzymes. 
Table 6.4: Molecular Weights of Bact. fragilis ß- lactamases. 
Strain 
Molecular weight (kDa) 
SDS -PAGE Gel Filtration 
JMS -121 31 24 
JMS -219 31 21 
JMS -221 31 25 
ED -262 31 ND 
Published Range' 26 -44 - 
_ 
ND - Not Determined 
a See Chapter 8 for sources of published range. 
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Figure 6.9: SDS -PAGE of Bacteroides Isolates. 
A B C D E F G H 
Lane A JMS -121 FPLC fraction 11. 
Lane B JMS -121 FPLC fraction 12. 
Lane C JMS -121 FPLC fraction 13. 
Lane D JMS -121 FPLC fraction 14. 
Lane E JMS -121 FPLC fraction 15. 
Lane F JMS -121 FPLC fraction 16. 
Lane G JMS -121 FPLC fraction 17. 
Lane I Protein molecular weight markers. 
Lane J Crude JMS -121. 
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Figure 6.10: SDS -PAGE of Bacteroides Isolates. 
Lane A JMS 219 FPLC fraction 12. 
Lane B JMS -219 FPLC fraction 15. 
Lane C JMS -219 FPLC fraction 18. 
Lane D JMS -221 FPLC fraction 12. 
Lane E JMS -221 FPLC fraction 15. 
Lane F JMS -221 FPLC fraction 18. 
Lane G JMS -221 crude cell -free lysate. 
Lane H Molecular weight markers. 
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6.5. Biochemical Analysis of Bact. fragilis ß- lactamases. 
6.5.1. Substrate Profiles. 
The substrate profiles of these enzymes for 12 different antimicrobials were 
then determined. Each of these compounds are known substrates for all 
metallo- ß- lactamase known to date with the single exception of the CphA 
enzyme from A. hydrophila. The relative rates of hydrolysis of these 
ß- lactams can be seen in Figure 6.11 overleaf. 
All rates of substrate hydrolysis are plotted relative to cephaloridine, which 















































































































































































Chapter 6: Results 
The substrate profiles of the ß- lactamases from JMS -121, JMS -219 and 
JMS -221 were very similar to that of Bact. fragilis ED -262, a known CfiA. 
producer. This suggested that the enzymes may all be CfiA -type metallo- 
ß-lactamases. JMS -219 exhibited a slightly lower rate of hydrolysis of 
imipenem compared with the other enzymes, but this difference in rate 
(which is shown relative to cephaloridine) was not sufficient to suggest that 
this enzyme is unrelated to the others. It is possible that this difference 
may have been caused by a point mutation in the CfiA gene since several 
mutations have been reported between the enzymes sequenced to date, 
although these seem to have little effect on hydrolytic activity or substrate 
specificity. A list of the strains for which the CfiA type metallo- ß- lactamase 
sequences have been reported, is shown in Table 1.4. 
All these B-lactamases were able to hydrolyse the carbapenem meropenem 
as well as imipenem, although this data could not be compared directly to 
the other substrates, and hence are not shown in Figure 6.11. 
6.5.2. Inhibitor Profiles. 
Table 6.5 on the next page clearly shows that none of the clinically available 
ß- lactamase inhibitors had any significant effect on these ß- lactamases. 
These mechanism based inactivators have been designed and utilised to 
fight serine active site ß- lactamases, and as such, show little or no effect on 


































































































































































































































































































































































































































































































Chapter 6: Results 
The experimental penem BRL 42715 was the only compound with the 
ability to inhibit any of these ß- lactamases at a physiologically attainable 
concentration. However, it should be noted that this compound has been 
shown to be a substrate for metallo- ß- lactamases [28]. This is confirmed by 
the data shown in Figure 6.11. It is thus possible that this compound may 
be acting as a competitive substrate for these metallo -ß- lactamases, and 
this manifests itself as an inhibition of hydrolytic activity. 
Metal ion chelators, which sequester the divalent cation from the metallo- 
ß-lactamase have been shown to be effective inhibitors of these enzymes in 
vitro but their indiscriminate ion chelation leads to toxicity, and hence 
precludes their use outside diagnostic experiments in the laboratory. 
Dipicolinic acid, o- phenanthroline and EDTA are all examples of such 
chelators, each of which show similar ID60 values for all the Bact. fragilis 
ß- lactamases tested. 
Table 6.6. Effects of Chelators on Bact fragilis ß- lactamases. 
Strain IDfi0 Values for Various Chelators (µM) 
Dipicolinic Acid o- Phenanthroline EDTA 
JMS -121 30 30 1000 
JMS -219 40 40 1000 
JMS -221 60 50 1000 
ED -262 40 30 1000 
Bc II 70 110 990 
NmcA 1000 >1000 >1000 
Bc II denotes the Bacillus cereus II metallo -ß- lactamase. 
NmcA denotes the serine active site carbapenemase from Enterobacter cloacae strain 
NOR -1. 
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Table 6.7. Ability of Zinc to Restore ß- lactamase Activity. 
Strain % Activity after 
10mM EDTA o /nt 
% Activity after 1mM 
Zinc (10mins)¢ 
JMS -121 0.8 22 
JMS -219 0.2 20 
JMS -221 0.3 21 
ED -262 0.6 26 
BcII ND 78 
TEM -1 98 97 
t Activity after overnight dialysis against a 100 -fold excess of 25mM PIPES pH 7.0 with 
10mM EDTA at 4 °C. 
Activity after a 10 minute preincubation of the EDTA dialysed sample in a 100 -fold 
excess of 25mM PIPES pH 7.0 with 1mM zinc sulphate at 37 °C. 
BcII - B. cereus II metallo -ß- lactamase. 
Since these enzymes exhibited substrate and inhibitor profiles consistent 
with metallo- ß- lactamases, more specifically, the CfiA type metallo- 
ß-lactamase, and metallo -ß- lactamases have been compared with other 
metal ion proteases, the ID50 of captopril, an angiotensin converting enzyme 
inhibitor [217] was also determined. Angiotensin converting enzymes also 
employ a metal ion, in this case zinc as part of their active site. 
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Table 6.8: Effects of Other Compounds on Bact fragilis 
B- lactamases. 
Strain Substrate 
ID60 Values for Other Compounds (µM) 
Captopril pCMB ZnSO4 
































Bc II Nitrocephin 200 ND No Effect * 
NmcA Nitrocephin >1000 ND No Effect * 
ND - Not Determined 
Bc II denotes the Bacillus cereus II metallo -ß- lactamase. 
NmcA denotes the serine active site carbapenemase from Enterobacter cloacae strain 
NOR -1. 
* No effect with nitrocephin as reporter substrate. ID60 can be determined with imipenem 
as reporter substrate. See Chapter 5. 
pCMB is an amino acid modifier which binds to cysteine residues in 
proteins. Since metallo -ß- lactamases can employ histidine or cysteine 
residues for metal ion co- ordination, and CfiA employs three histidines and a 
cysteine residue for co- ordination, the inhibition by this compound further 
suggests that these enzymes are metallo -ß- lactamases. 
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6.5.3. Kinetic Constants of Bact. fragilis ß- lactamases. 
A comparison of the enzyme kinetics of these ß- lactamase was undertaken 
with imipenem as reporter substrate. These data are shown in Table 6.9 
below. 
Table 6.9: Activity Constants from Bact. fragilis ß- lactamases. 
Strain Km (µM) a Vmax ' 
(µmoUmin/mg) 
JMS-121 350 0.31 
JMS-219 380 0.41 
JMS-221 385 0.38 
ED-262 360 0.36 
Imipenem as reporter substrate. 
Together, the substrate, inhibitor, and kinetic profiles of these ß- lactamases 
strongly suggest that the ß- lactamase produced by the JMS- strains are 
CfiA related metallo- ß- lactamases. 
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CHAPTER SEVEN 
Carbapenemase Production by Clinical 
Isolates of the Genus Flavobacterium. 
7.1. Prologue. 
To date there has only been a single report describing the production of a 
metallo- ß- lactainase from an isolate of the genus Flavobacterium. In this 
thesis it was postulated that other organisms from this genus may also 
produce metallo -ß- lactamases. To investigate this, other clinical isolates of 
the genus Flavobacterium were examined for the production of a 
carbapenem hydrolysing ß- lactamase, possibly a metallo -ß- lactamase. 
Organisms of the genus Flavobacterium have been found both in natural 
ecosystems and in clinical specimens. A total of 10 Flavobacterium clinical 
isolates were received from the National Collection of Type Cultures 
(NCTC) in London, and examined for metallo -ß- lactamase production. The 
NCTC catalogue numbers and sites of original isolation are listed in Table 
7.1 below. The identities of all strains were confirmed by ATB32GN. 
Table 7.1: Flavobacterium Isolates received from NCTC. 
Species NCTC 
Cat. No. 
Site of Isolation 
F. breve 11099 bronchial secretion 
F. gleum (indologenes) 10795 sputum 
F. indologenes 10796 trachea 
F. meningosepticuin 10016 spinal fluid 
F. multivorum 11343 spleen 
F. odoratum 11180 wound 
F. spiritivorum 11388 blood 
F. thalpophilum 11429 wound 
F. thalpophilum 11430 abscess 
F. yabuuchiae 12114 peritoneal fluid 
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7.2. Determination of Carbapenem Hydrolysis. 
Initially, these strains were grown up in 10mis Nutrient Broth No. 2, with 
and without 0.5mg/I imipenem to act as inducer. Spectrophotometric 
analysis of these sonicated crude cell -free lysates with nitrocephin and 
imipenem as reporter substrates showed that the ß- lactainase activities of 
these strains were expressed constitutively, since no significant increase in 
specific activity of any of these strains could be detected after induction. All 
but one of the preparations were able to cause significant imipenem 
hydrolysis. Additional experiments were conducted to further characterise 
this imipenem hydrolysis. 
The rate of hydrolysis of imipenem by each crude preparation was 
determined. An aliquot of each sample was then assayed after a five minute 
pre -incubation with 1mM EDTA. This procedure was repeated with 
nitrocephin as reporter substrate. Table 7.2 below shows the rate of 
hydrolysis of imipenem by each sample, and the effect of 1mM EDTA on 
this hydrolysis. 






Rate of Imipenem 
Hydrolysis ([iM/min) 
% Activity with 
1mM EDTA 
F. indologenes 10796 8 56.5 67 
F. meningosepticum 10016 4 31.8 56 
F. breve 11099 0.25 16.3 48 
F. gleum ( indologenes) 10795 4 10.2 16 
F. spiritivorum 11388 4 7.6 36 
F. odoratum 11180 1 6.7 68 
F. thalj2ophilum 11429 1 4.7 100 
F. multivorum 11343 2 2.9 63 
F. yabuuchiae 12114 2 2.1 64 
F. thalpophilum 11430 2 0.81 - 
§ Minimum inhibitory concentration of imipenem. 
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In all but two of the isolates imipenem hydrolysis was partially inhibited by 
the pre- incubation of the enzymes with 1mM EDTA suggesting that these 
isolates may produce a metallo -ß- lactamase, in some cases in addition to a 
serine active enzyme. This EDTA inhibition was measured after a 5 minute 
pre -incubation with this chelator. When repeated. after a 10 minute pre - 
incubation with EDTA prior to the assays, similar data were obtained, 
suggesting that all inhibition of enzyme activity had occurred within the 
first 5 minutes of pre -incubation. 
7.3. Separation of Flavobacteriufn ß-lactamases by IEF. 
The ß- lactamases of these strains were separated by IEF, to determine 
whether this imipenem hydrolysis was mediated by the production of an 
enzyme similar to that found in the imipenem resistant F. odoratum strain 
previously reported. To indicate this, the enzymes were separated by IEF, 
and the gel was overlaid with 1mM ZnSO4 for 5 minutes. Duplicate loadings 
were overlaid with 100µM BRL 42715, since this is known to be a potent 
inhibitor of all serine active site ß- lactamases. It was postulated that if 
present, a metallo -ß- lactamase would retain ß- lactamase activity in the 
presence of this compound, and hence still hydrolyse the nitrocephin 
present in the gel overlay. Possible metallo-ß- lactamases could thus be 
identified separately from serine active site ß- lactamases. 
Iso- electric focusing of these extracts revealed between 1 and 3 bands when 
stained with nitrocephin. Two strains (F. indologenes and F. gleurn 
(indologenes)) both appeared to produce one ß- lactamase with pI >9.0. The 
F. spiritivoruin and F. meningosepticum strains both appeared to produce 3 
bands by IEF at pI 5.4, 7.6 and 8.6. 
Figure 7.1 overleaf shows the nitrocephin stained IEF gel of these isolates, 
with and without the 100µM BRL42715 overlay. 
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Figure 7.1: IEF ShowingFlavobacteriuna ß-lactamases. 
pI 8.3 7.3 6.5 5.9 4.8 
I I I 
pI Markers. 
- F. gleurn (10795). 
- F. spiritivorum (11388). 
F. thalpophilum (11429). 
F. yabuuchiae (12114). 
_ TEM-1. 
- pI Markers. 
_F. gleum (10795). 
F. spiritivorum (11388). 
F. thalpophilum (11429). 
F. yabuuchiae (12114). 
TEM-1. 
pI 8.3 7.3 6.5 5.9 4.8 
F. spiritivorum (11388). 
F. meningosepticum (10016). 
- F. breve (11099). 
F. odoraturn (11180). 
F. multivorum (11343). 
F. thalophilum (11430). 
-F. indologenes (10796). 
- TEM-1. 
- pI Markers. 
-F. spiritivorum (11388). 
-F. meningosepticum (10016). 
- F. breve (11099). 
F. odoraturn (11180). 
F. multivorum (11343). 
_F. thalophilum (11430). 
F. indologenes (10796). 
TEM-1. 
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Of the strains examined, only F. spiritivorum NCTC 11388 and F. 
multivorum NCTC 11343 retained any ß- lactamase activity after the BRL 
42715 overlay. F. spiritivorum appeared to produce a nitrocephin 
hydrolysing doublet band at pI 5.4, whereas F. multivorum produced a 
diffuse band of high pI (pI -'9.0). Since F. multivorum also produced another 
band of ß- lactamase activity in the absence of the overlay (pI 8.0) very 
close to the BRL 42715 resistant band, work continued on the F. 
spiritivorum isolate. 
7.4. Flavobacterium spiritivorum NCTC 11388. 
Of these isolates, one strain; F. spiritivorum NCTC 11388 was chosen for 
further study. This strain showed significant imipenem hydrolysis, and an 
MIC of imipenem of 4mg/1. In addition to this, this isolate appeared to 
produce 3 ß- lactamases of pI 8.6, 7.6 and 5.4. These bands were designated 
FSP -1, FSP -2 and FSP -3 respectively. After iso- electric focusing, and 
overlay of the gel with 1mM ZnSO4 and 10011M BRL 42715, only the band 
at pI 5.4 retained nitrocephin hydrolysing activity. From these data, it was 
postulated that the pI 5.4 band was most likely to be responsible for 
imipenem hydrolysis. 
7.4.1. Separation of F. spiritivorum ß-lactamases by FPLC. 
Since this strain produced 3 ß- lactamases with provisional allocation of the 
pI 5.4 enzyme as the metallo -ß- lactamase, it was decided to separate these 
enzymes by FPLC. To this end, a separation methodology was developed to 
separate this enzyme from the other two ß- lactamases. 
Initially, a crude cell free extract of this strain was tested against the 46 ion 
exchange matrices as described in Materials and Methods. However, no hits 
were observed by this method. This may have been caused by the fact that 
this isolate appeared to produce 3 ß- lactamases by nitrocephin stained IEF, 
and no single matrix bound all three enzymes simultaneously as shown in 
Figure 7.2 overleaf. 
135 
Chapter 7: Results 
Figure 7.2: Ion Exchange Matrix Screen of F. spiritivorum 
NCTC 11388. 
Rows E to II were not loaded. 
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Since the ion exchange matrix screen did not yield any `hits', several small 
scale matrices were set up in an attempt to resolve these enzymes. 
Figure 7.3 overleaf shows a summary of the purification methodology, and 
the steps involved in its development. Attempts to bind FSP -3 were 
unsuccessful, at any of the pH values tested. As a result of this, the anion 
matrix had to be substituted with a cation exchange matrix. 
Each of these matrices were set up as a small scale column with a bed 
volume of 20m1s and equilibrated at the appropriate pH with elution buffer. 
Fractions were eluted in a NaC1 step gradient OM, 0.25M, 0.5M 0.75M and 
1M with respect to sodium chloride as described in Materials and Methods. 
Eluted fractions were assayed for nitrocephin hydrolysis, and sensitivity to 
inhibition by clavulanic acid and EDTA in an attempt to determine the 
class of ß- lactamase eluted. Active fractions were also separated by IEF. 
A MacroPrep High S column was set up in Bis Tris pH 6.0 in an attempt to 
bind FSP -1 and FSP -2. These enzymes were separated first, since this 
column would bind proteins of high pI, and bacteria produce fewer proteins 
of high pl, than low pI. The pI 8.6 ß- lactamase partially bound to this 
column, when assayed, was found to hydrolyse iinipenem. 
This purification protocol was altered, such that the crude extract would be 
passed through a cation exchange column to bind the high pI enzymes, 
followed by an anion exchange column to bind the other enzymes. This 
purification system did resolve FSP -2 which bound to the Q- Sepharose 
column, and the FSP -3 which failed to bind to either matrix. However, 
insufficient ß- lactamase activity was purified to complete the biochemical 












































































































































































































































































































































































































































































































































































































































































































































Chapter 7: Results 
FSP -2 was found to be resistant to EDTA dialysis, but extremely sensitive 
to inhibition with BRL 42715. However, FSP -3 was not inhibited by either 
of these compounds. These data are shown in Figure 7.5 on page 142. 
When repeated, FSP -2 only partially bound to the Q- Sepharose column, 
which whilst allowing the FSP -1 and FSP -3 to be separated, FSP -3 activity 
was contaminated with the FSP -2 ß- lactamase. 
7.4.2. Separation of F. spiritivorum ß- lactamases by Other Methods. 
Since this FPLC procedure led to significant, but not total separation of 
FSP -3 and FSP -2, other biochemical methods of separation were examined. 
7.4.2.1. Gel Filtration. 
Attempts to separate these enzymes by Sephadex G150 gel filtration were 
unsuccessful, because there was insufficient resolution of these enzymes. 
However, eluted fractions containing predominantly FSP -3 activity were 
pooled and, since a large proportion of the lipid, DNA and membrane 
fragments of the crude cell -free extracts were eluted from the column in the 
void volume, these fractions could be concentrated on Amicon protein 
concentrators from 25ml to 2ml without protein precipitation. 
7.4.2.2. Free -Flow and Preparative IEF. 
Attempts to separate these ß- lactamases by free -flow IEF were 
unsucessful, since only insubstantial ß- lactamase activity could be detected 
in any fractions after separation. Figure 7.4 shows the activity of the 20 
fractions eluted after MinipHor free -flow IEF. After separation, a very low 
level of nitrocephin hydrolysis was detected in the fractions containing 
proteins of high pI. No imipenem hydrolysis was detected in any of the 
eluted fractions. 
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Figure 7.4: ß- lactamase Activity of Fractions Eluted from 













One mililitre of the concentrated sample from Section 7.4.2.1 was loaded 
onto lanes 2 -11 of a 12 lane analytical poly -acrylamide IEF gel pH 3.5 -9.5. 
Lanes 1 and 12 contained TEM -1 (pI 5.4) to act as a pl marker and control. 
Once run, only lanes 1, 2 and 12 were visualised with 500mg/1 nitrocephin. 
The regions of the gel in lanes 3 -11 which corresponded to FSP -3 (pI 5.4) 
were excised, and eluted from the gel slice by electrodialysis. However, no 
ß- lactamase activity could be detected from the sample eluted from the gel. 
Staining of the remainder of the IEF gel and gel slice failed to locate FSP -3, 
suggesting that it had been lost during electroelution. 
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7.4.2.3. Combination of Gel Filtration and Selective Inactivation. 
FSP -1 and FSP -2 could be separated by FPLC. However, FSP -3 could not 
be eluted separately, and failed to bind to any of the ion exchange matrices. 
Since FSP -3 could not be separated from the other ß- lactamases 
biochemically, an alternative purification method was employed for assays 
on this enzyme involving gel filtration. Previous experiments determined 
that FSP -1 (the pl 8.6 metallo- ß- lactamase) could be totally inhibited by 
overnight dialysis against 10mM EDTA, and FSP -2 could be totally 
inhibited by BRL 42715. Neither of these compounds had any effect on the 
nitrocephin hydrolysing activity of FSP -3. Experiments were conducted to 
determine the minimum concentration of BRL 42715 required to totally 
inactivate the FSP -2 ß- lactamase. An IEF gel was prepared, and five lanes 
were loaded with the concentrated fractions from Sephadex G150 gel 
filtration. Once run, the gel was overlaid for 5 minutes with concentrations 
of BRL 42715 varying from 1µM to 100µM prior to visualisation with 
nitrocephin. 
Figure 7.5 overleaf shows this gel. It can be clearly seen from this gel that 
10µM BRL 42715 effects total enzyme inhibition. This concentration was 
sufficiently low that this inhibitor could be present in the assay solution 
without adversely affecting the measurement of substrate hydrolysis. 
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Figure 7.5: IEF Gel Showing Minimum Concentration of BRL 42715 





A B C D E F GHI 
Lane A G150 eluent of F. spiritivorum overlaid with 100µM BRL 42715. 
Lane B As lane A pre- incubated with 10mM EDTA overnight at 4 °C. 
Lane C G150 eluent of F. spiritivorum overlaid with 10µM BRL 42715. 
Lane D As lane C pre- incubated with 10mM EDTA overnight at 4 °C. 
Lane E G150 eluent of F. spiritivorum overlaid with 1µM BRL 42715. 
Lane F As lane E pre- incubated with 10mM EDTA overnight at 4 °C. 
Lane G G150 eluent of F. spiritivorum (no BRL 42715 overlay). 
Lane H As lane G pre- incubated with 10mM EDTA overnight at 4 °C. 
Lane I TEM -1. 
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Thus, dialysis of the sample against 10mM EDTA followed by the addition 
of 1011,M BRL 42715 to the assay mixture totally inhibited both the FSP -1 
and FSP -2 enzymes respectively. This allowed the analysis of FSP -3 
without contamination from the other enzymes even though the sample 
contained the other (inactivated) ß- lactamases. Figure 7.6 overleaf shows 
an iso- electric focusing gel of a crude preparation of F. spiritivorum NCTC 
11388 together with the enzymes which had been separated by the 
procedures described previously. 
7.4.3. Substrate and Inhibitor Profiles of FSP -1, FSP -2 and FSP -3. 
Once these enzymes had been resolved biochemically, each enzyme was 
examined and characterised separately. Table 7.3 describes the substrate 
profiles of each of these enzymes. 
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A B C D E 
TEM -1 (pI 5.4). 
Crude F. spiritivoruni NCTC 11388. 
FSP -1 (pI 8.6). 
FSP -2 (7.6). 
FSP -3 (5.4) with 101IM BRL 42715 overlay. 
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Table 7.3: Substrate Profiles of ß- lactamases Produced by 












CTX CZD NCFN AMP 
FSP -1 100 425 18 6 6 ND ND 
FSP -2 100 270 ND ND ND ND ND 
FSP -3 100 ND ND ND ND ND ND 
NCFN - nitrocephin CFX - cefuroxime 
AMP - ampicillin CTX - cefotaxime 
IMP - imipenem CZD - ceftazidime 
CLD - cephaloridine 
ND - None Detected. 
The substrate profiles in the above table were expressed relative to 
nitrocephin, since all enzymes were able to hydrolyse this substrate. 
The substrate [Table 7.3 above] and inhibitor profiles [see Figure 7.7 
overleaf] for the FSP -1 enzyme were indicative of a metallo -ß- lactamase. 
This enzyme was able to hydrolyse imipenem, ampicillin, and a range of 
cephalosporins. Metallo -ß- lactamases are generally regarded as resistant to 
all clinical ß- lactamase inhibitors including clavulanic acid. FSP -1 shows 
this type of inhibitor profile, and only BRL 42715 was able to inhibit this 
enzyme at a measurable concentration. The ID50 of this compound is in the 
micro -molar range, which is consistent with that of other metallo- 
ß-lactamases. Serine active ß- lactamases are generally inhibited by nano - 
molar concentrations of this compound as stated in Chapter 1, and Figure 
7.7. This is borne out by the ID50 values for the TEM -1 ß- lactamase which 



















































































































Chapter 7: Results 
The inhibition data for the FSP -2 enzyme suggested that this was a serine 
active site ß- lactamase and by virtue of is pI and its substrate / inhibitor 
profiles [Table 7.3 and Figure 7.7] may be SIIv or OXA derived. Once 
purified by FPLC, the specific activity of this enzyme was very low, and no 
hydrolysis of any substrates other than nitrocephin and ampicillin could be 
detected spectrophotometrically. 
FSP -3 was very unusual. This enzyme did not bind to any of the ion 
exchange matrices, at any of the pH values tested. This is uncommon, and 
more work would be needed to improve the separation protocol to yield a 
greater specific activity to facilitate the completion of the biochemical 
analysis of this protein. This protein was found to be able to hydrolyse 
nitrocephin at a low rate, but no hydrolysis of any other substrate could be 
detected, even after several hours incubation. In addition to this, none of the 
ß- lactam antibiotics or inhibitors tested including BRL 42715 were able to 
inhibit the nitrocephin hydrolysis by this enzyme. The possible reasons for 
this are discussed in a later section. 
7.4.4. Molecular Mass Estimations. 
Sephadex G150 gel filtration of a crude cell -free extract of F. spiritivorum 
NCTC 11388 suggested that the molecular weights of FSP -1, FSP -2 and 
FSP -3 were 33kDa, 27kDa and 21kDa respectively, but did not lead to 
sufficient enzyme separation to allow further analysis. 
7.4.5. Comparison of FSP -1 with Known Carbapenemases. 
Since FSP -1 showed a substrate and inhibitor profile which was indicative 
of a metallo -ß- lactamase, the relative rates of hydrolysis of various 
substrates by this enzyme were compared with several other known 
metallo -ß- lactamases including a Bact. fragilis CfiA -type enzyme, Sten. 
maltophilia Ll, and B. cereus II. The serine active site carbapenemase 
NmcA from Enterobacter cloacae was also included in this comparison. This 
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comparison is shown in Figure 7.8. These carbapenemases each showed 
broad substrate profiles, hydrolysing penicillins, cephalosporins as well as 
carbapenems. Despite this, each of these enzymes show a very distinct 
hydrolytic pattern for the various substrates. By virtue of its pI, inhibitor 
profile, and the observation that its substrate profile is distinct from other 
carbapenemases, I propose that this enzyme is a novel carbapenemase, 
















































































































































































































Chapter 7: Results 
7.4.6. Epilogue. 
The separation of these three enzymes demonstrated the objectivity 
required in the analysis of strains producing several ß- lactamases. Initial 
overlays of the IEF gels with BRL 42715 suggested that the pI 5.4 enzyme 
was the metallo- ß- lactamase. 
Small clues starting with the imipenem hydrolysing activity of the pI 8.6 
enzyme [Section 7.4.1] suggested that the initial observations and 
subsequent hypotheses might be inaccurate. Full separation and analysis 
of the ß- lactamases revealed the imipenem hydrolysing metallo- 
ß-lactamase with a pI 8.6. 
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CHAPTER, EIGHT 
Discussion. 
8.1. Carbapenemases and Divalent Cations. 
8.1.1. Purification Methodology. 
Many different techniques have been tried in the process of metallo- 
ß-lactamase purification to separate these enzymes from other 
ß- lactamases or cell debris. These methods include gel filtration [139], free - 
flow IEF [128], ion exchange chromatography [146, 151], FPLC [140], 
affinity chromatography [103], selective precipitation [164] or 
combinations of these [152] [this thesis]. Whilst many of these techniques 
can be applied to the partial purification of a single protein, there are few 
reports comparing these techniques for a given system. There is no 
evidence to suggest that any particular system has been optimised. An 
example of this can be seen in [134] where Tris buffer was prepared and the 
pH determined at room temperature, yet this buffer was used at 
temperatures between 0 °C and 30 °C. The change in pKa per degree Celsius 
for Tris buffer is very high (ApKa/C° = -0.031). For this reason Tris buffer 
pH 7.0 made at 25 °C and chilled to 4 °C will drop by 0.65 pH units to 6.35. 
Arstila and co- workers examined five different methods for preparing crude 
cell -free lysates [218], but this report did not extend to methods of 
ß- lactamase purification. The screening of 46 different ion exchange 
matrices undertaken in this thesis does go some way toward this 
optimisation. This screen encompassed matrices from all major groups, 
including anion, cation, affinity and agarose matrices. In the case of the 
Bact. fragilis metallo -ß- lactamase purification screens, the MacroPrep 
High -Q, a high capacity anion exchange matrix showed greatest 
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ß- lactamase binding. The co -amino hexyl sepharose matrix, also showed 
good ß- lactamase binding. This latter matrix had been used by Felici and co- 
workers during their purification of the A. hydrophila A2 metallo- 
ß- lactamase [103]. However this system has two potential disadvantages: 
1. Such a matrix relies on the fact that the metallo -ß- lactamase 
will adsorb onto the zinc which was bound to the matrix 
support. This binding will depend on the kd of zinc in the active 
site of such an enzyme. If the metallo -ß- lactamase binds this 
zinc poorly, then total adsorption to the matrix is unlikely. 
2. Once adsorbed onto the column, elution of the metallo- 
ß- lactamase with an increasing sodium chloride gradient will 
leave the metallo -ß- lactamase temporarily without a zinc ion in 
the active site. It is possible that once removed, the protein 
could undergo a conformational change or become denatured in 
such a way that could not be totally renatured by the later 
addition of zinc (if eluted with NaC1), or presence of zinc (if 
eluted with NaC1 and zinc). It is possible that once the divalent 
cation has been removed from the active site, the ensuing 
conformational change could prevent another ion from 
associating with the enzyme. The resulting `zinc -less' metallo- 
ß- lactamase would show negligible ß- lactamase activity. This 
dissociation constant will vary between metallo -ß- lactamases, 
and so certain enzymes, where the recoverability of hydrolytic 
activity after EDTA dialysis is low (e.g. Bact. fragilis CfiA -type 
enzymes), would be more prone to such inactivation than those 
with high recovery after this treatment (e.g. B. cereus II) [see 
Table 6.7]. 
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8.1.2. Assay Conditions. 
For the study of serine active site ß- lactamases, many workers have 
prepared these enzymes and conducted spectrophotometric assays in 
phosphate buffer (usually 25mM or 50mM) at pH 7.0, a well known and 
established general purpose buffer. This buffer is frequently used for assays 
involving ß- lactamases as well as other enzyme systems. The pH of this 
buffer is defined by the ratio of PO42- and HPO4 ions [219]. Once defined, the 
pH is maintained by an equilibrium between these two ions. 
However, when metallo- ß- lactamases were discovered, rather than re- 
evaluate the best buffer for these enzymes, the already established dogma 
of phosphate buffer was simply applied to these enzymes, and many 
workers have conducted their studies in phosphate buffer, but 
supplemented this buffer with 1mM zinc, usually in the form of ZnSO4 [134] 
or ZnCl2 [216] to accommodate the divalent metal ion requirements of 
metallo -ß- lactamases. This assumption is invalid. 
Zinc, in the form of Zn2+ is a small ion with an overall 2+ charge, making it a 
closed - shell 'hard' metal ion. As such, this ion acts as a strong Lewis acid, 
and will co- ordinate and bind to `hard' donors, such as negatively charged 
forms of oxygen. Hard donors can, for this reason be regarded as chelators. 
Hard donors will include HPO4- and PO42- ions. In a solution of phosphate 
buffer to which zinc sulphate has been added, the Lewis acid will become co- 
ordinated with hard donor ions. Zn2+ and phosphate ions both form 
tetrahedral `diamond- shaped' complexes, and will co- ordinate in this fashion. 
However, all zinc phosphate compounds including zinc orthophosphate 
namely Zn3(PO4)2 and zinc hydrogen orthophosphate namely Zn(H2PO4)2 are 
insoluble (S - 10-8 M), even in their octahydrate or tetrahydrate forms 
[220]. These complexes will associate together and grow into a polymeric 
crystal structure as a direct result of their low solubility. This will result not 
only in an overall drop in the Zn2+ concentration in the buffer but the growth 
of these crystals will manifest itself as a fine white flaky precipitate. This 
will have several implications on preparation steps and assays which 
include phosphate buffer with a zinc sulphate supplement: 
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1. Such a precipitate will cause significant light scattering in any 
spectrophotometric cell, and will lead to inaccurate and 
inconsistent readings of A- absorbance. This will affect the 
calculation of rates of substrate hydrolysis. 
2. Since phosphate ions can be regarded as chelators, the 
effective concentration of zinc in the buffer will fall to the 
nanomolar range. Such chelation will mislead workers who 
have employed a specific zinc concentration in their buffer to 
gain maximal metallo- ß- lactamase activity. 
3. The loss of phosphate ions from the buffer will result in a small 
change in buffer pH as the ratio of HPO4 and PO42" ions (which 
defines the pH) changes and hence the ionic strength of the 
buffer will also change. In addition to this, the concentration of 
the buffer will drop from its original concentration (e.g. 25mM 
or 50mM) with respect to phosphate ions. Since zinc and 
phosphate ions will precipitate, an excess of negatively charged 
anions will form; for example 5042- and 2 Cl (if the zinc was 
added to the buffer as zinc sulphate or zinc chloride 
respectively). The presence of these ions will affect not only the 
ionic strength of the buffer, but also the pH. The degree to 
which the buffer will be affected is unknown, but in the vast 
majority of cases the buffer concentration (usually 25mM or 
50mM) will be significantly greater than the concentration of 
the zinc supplement. Nevertheless, these effects cannot be 
discounted. 
4. The zinc ions co- ordinated as part of the active site of a 
metallo- ß- lactamase are in dynamic equilibrium with the zinc 
ions in the surrounding buffer. Hence, the chelating effect of the 
phosphate ions will not only extend to the zinc present as a 
buffer supplement, but will also have a leaching effect on the 
zinc co- ordinated to the active site possibly causing enzyme 
inactivation after prolonged exposure. 
154 
Chapter 8: Discussion 
Metallo -ß- lactamases from different species vary considerably in their 
ability to bind zinc ions. The activity of B. cereus II can be almost totally 
inhibited by dialysis of the enzyme in a buffer without a zinc supplement or 
external chelating agent, for example EDTA. This inhibition can be partially 
restored by the addition of excess zinc sulphate at a later time, although the 
degree to which activity could be restored varied from enzyme to enzyme. In 
the case of B. cereus II [164] and Stew. maltophilia Ll [151], greater than 
90% of enzyme activity can be restored by the introduction of a zinc 
supplement into the assay buffer [see Table 6.7]. Conversely, metallo- 
ß- lactamases from other species, e.g. CfiA -type enzymes from Bact. fiagilis 
were unaffected by dialysis unless an external chelating agent was present 
to sequester the zinc ion from the active site. In these cases, the restoration 
of activity after the re- introduction of zinc was found to be between 22% 
and 25% [Table 6.7] although figures from 45% [216] to 112% [138] have 
been reported. This observation could be explained by a dissociation 
constant kd, describing the binding strength of the metallo -ß- lactamase for 
zinc. If this were true, then B. cereus II would have a low kd for zinc, 
suggesting a dynamic equilibrium between the ion in the active site and 
those in the surrounding buffer. The kd for the Bact. fragilis metallo- 
ß- lactamase would be significantly greater, since dialysis in buffers without 
zinc or chelators had a negligible effect on enzyme activity. 
Whilst the `hydrolysis' of ß- lactam antibiotics by zinc ions in several buffer 
systems [118, 221 -225] and bacteriological media [226] is widely known, 
little work has been conducted on the effects of zinc on the catalytic activity 
of ß- lactamases, apart from the observation that the sequestration of this 
ion from the metallo -ß- lactamase by EDTA and other chelators results in 
partially reversible enzyme inactivation. 
Since it was first shown in 1966 that B. cereus II required zinc for activity 
[164], several other metallo -ß- lactamases have been characterised [see 
Table 1.4]. In every case where the co- ordinated divalent cation has been 
identified, Zn2+ has been found to be the co- ordinated ion. Several workers 
have substituted this ion in different metallo -ß- lactamases with other 
divalent cations including other transition metal ions and Group II ions. 
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These ions include Co', Mg2 +, Mn2+ and Hg2+ [116, 151, 227]. Of these, 
cobalt has been shown to maintain greatest metallo -ß- lactamase activity 
(after zinc) [122]. 
Davies and Abraham [122] also found that the addition of zinc increased the 
hydrolytic activity of B. cereus II against cephalosporin C, the only 
substrate tested, but did not observe enzyme inhibition. The only work 
which suggested any investigation into the determination of the optimum 
zinc concentration present in the buffer for metallo-ß- lactamase activity 
was made in 1993 by Felici and co- workers who conducted assays on 
B. cereus II in buffer supplemented with 0.3mM ZnC12, whereas all other 
metallo -ß- lactamases were assayed in buffer with 0.1mM ZnC12 [103]. 
However, no explanations were given for the choice of these zinc 
concentrations. 
One report by Hawkey and co- workers [214] investigated the effects of 
various divalent cations including zinc naturally present in the 
bacteriological media on the susceptibility to imipenem of several Stew. 
maltophilia isolates. This study concentrated on the microbiological effects 
of these ions, and described a correlation (P= 0.003) between increased 
imipenem MICs and increased zinc ion concentration in the bacteriological 
media. This was attributed to the increased zinc concentration causing 
increased activity of L1 -type metallo -ß- lactamases in the isolates tested. 
This group also found that glassware which included metal caps and rubber 
inserts led to an increase in zinc concentration, especially where the rubber 
was in poor condition. For this reason, all work on the effects of cations on 
carbapenemase activity was conducted in disposable glassware with plastic 
caps wherever possible. Where there was no alternative, re- usable 
glassware was washed in 0.1M EDTA to remove any free ions which may 
be present after washing. A 0.4M NaOH rinse was also used to remove any 
detergent from the glassware which may sequester such ions. The 
glassware was then rinsed in MilliQ water until the pH returned to neutral 
to ensure removal of all compounds involved in these wash steps. No other 
work in the current literature describes these considerations, or has 
reported to have taken such extensive precautions. 
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All ß- lactamase assays in this thesis, whether on suspected metallo- 
ß- lactamases or serine active enzymes were conducted in 25mM PIPES 
buffer pH 7.0. Zinc supplements were added where applicable. This buffer 
was chosen for a variety of reasons: 
1. PIPES is zwitterionic, and hence the ionic strength will not 
change with varying pH. The pKh of PIPES is 6.8 at 20 °C. 
2. PIPES buffer has been shown to be stable in the presence of 
zinc ions, both moieties remaining in solution. PIPES shows low 
zinc binding when compared with other buffers including Tris, 
Ada and Bis Tris [224]. However, since PIPES is zwitterionic, 
there will be a small amount of zinc co- ordination, but since this 
complex remains in solution and forms a dynamic equilibrium, 
the effect on free zinc ion concentration will be minimal 25mM 
PIPES buffer with a 10mM zinc sulphate supplement is stable 
for short periods [this thesis]. PIPES buffer with lower zinc 
sulphate concentrations was stable for prolonged periods. 
For these reasons, PIPES buffer is ideal for the study of ß- lactamases 
including metallo -ß- lactamases, without the problems associated with 
phosphate buffer, outlined above. 
An investigation into the effects of these zinc supplements on 
carbapenemase activity was undertaken in this thesis. By preparing a 
single culture of a metallo -ß- lactamase producer, it was possible to compare 
directly the effects of this ion during preparation and activity 
determinations. It appeared that there was little difference in preparing 
metallo -ß- lactamases in the absence of zinc sulphate, or in the presence of 
1µM zinc sulphate (BFR° and BFRI) as shown in Figures 5.2 and 5.3. Both 
preparations demonstrated similar specific activities for all substrates 
tested. Both preparations showed an activation as the zinc supplement in 
the assay buffer increased. With cephaloridine and nitrocephin as reporter 
substrates, the activation appeared to be linear as the log of zinc 
concentration increased to 1mM. However, with imipenem as substrate, 
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this activation was more marked, and peaked at 100µM ZnSO4. Intriguingly 
carbapenemase activity fell back as the zinc concentration increased 
towards 1mM. 
The interesting observation made during these experiments, was the 
greater specific activity of BFRl000 compared with BFR0 and BFR1 for all 
substrates tested. This increased specific activity in BFRl000 was greater 
than the activation observed with either BFRo or BFR1. No activation was 
observed with BFRl000 for any of the substrates tested, and the rates of 
hydrolysis of any substrates except imipenem was not affected to any 
significant degree by an increase in zinc concentration in the assay buffer. 
However, the presence of zinc in the assay buffer led to reversible inhibition 
of the carbapenemase activity by this enzyme. The initial experiments 
shown in Figure 5.1 were conducted on a separate preparation, prepared in 
a similar manner to BFRl000 and hence showed a similar activity profile. 
This phenomenon extended to all Bact. fragilis CfiA -type metallo- 
ß-lactamases examined in this thesis and to B. cereus II, but not to Stew. 
maltophilia Ll. Only imipenem hydrolysis could be assayed in these 
two preparations, because both isolates also produced a cephalosporinase 
which was unable to hydrolyse imipenem [134, 197] but was present during 
the assays. The L1 metallo -ß- lactamase showed slightly greater basal 
activity when prepared in 1mM ZnSO4, and slightly less activation than the 
same culture prepared in lower zinc concentrations. Nevertheless, all Sten. 
maltophilia Ll preparations, (L10, L11, and L11000) displayed a similar 
sigmoidal activation curve as the zinc concentration in the assay buffer 
was increased. The activation curve was very different from that observed 
with any of the other metallo -ß- lactamases, and of greater amplitude. No 
significant inhibition of imipenemase activity could be detected at high zinc 
concentrations, unlike the other metallo -ß- lactamases or the serine active 
site carbapenemase, Nmc -A. These data suggested that the L1 metallo- 
ß-lactamase was not affected by zinc in the same manner as the other 
carbapenemases. More experiments would be required to determine 
whether this activation curve is substrate specific, although the complete 
separation of the L1 metallo-13-lactamase and L2 cephalosporinase in the 
presence of these three different zinc supplements will be problematic. 
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A direct mechanistic explanation for this imipenemase inhibition at high 
zinc concentration is unclear, since the mechanism of ß- lactamase 
hydrolysis by all but the Ll metallo-ß- lactamase is not substrate specific. 
Cobalt has been successfully substituted for zinc in several metallo- 
ß-lactamases [122, 151], and so the preparations were re- assayed in the 
presence of increasing cobalt concentrations since Co' shares a similar 
ionic radius and charge to zinc [220]. These experiments suggested that the 
decrease in imipenemase activity of BFR1000 at high ZnSO4 concentrations 
was not caused by heavy metal poisoning, since no enzyme activation or 
inhibition could be detected as the cobalt concentration increased [Figure 
5.6]. 
Since this inhibition of hydrolytic activity by increased divalent cation 
concentration was only noticeable with carbapenems as reporter 
substrates, the serine active carbapenemase Nmc -A was also tested in a 
similar manner, but the observation that increasing zinc concentration 
affected the hydrolysis of nitrocephin and cephaloridine as well imipenem 
was consistent with heavy metal poisoning, but inconsistent with that 
found with the metallo- ß- lactamases. Cobalt also affected the imipenem 
hydrolysis of this ß- lactamase reversibly, but no explanation could be found 
for this. 
Heavy metal poisoning would manifest itself as a overall reduction on 
hydrolytic activity, and it is extremely unlikely that such inhibition would be 
substrate specific. 
It has been proposed that the B. cereus II metallo-ß- lactamase possesses 
more than one zinc binding site [116, 122], and it is possible that metallo- 
ß-lactamases from other species may also possess this extra site. The 
purpose of this additional site is unclear, but the possibility of some form of 
allosteric enzyme control cannot be discounted. 
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The implications of these effects on the analysis of suspected metallo- 
ß-lactamases are widespread. It is likely that the presence of zinc ions 
during preparation has a preserving effect on metallo -ß- lactamase activity. 
This would be consistent with the observations of greater basal activity 
from BFRl000 when compared with BFR0 and BFR, against all substrates, 
and also the fact that after loss of the co- ordinated metal ion from the 
active site (for example by ion chelation with EDTA), the addition of zinc 
cannot fully restore hydrolytic activity. A similar observation was also 
made for B. cereus II by Davies and Abraham [122], and also Benitez et al. 
[118]. It is possible that once the zinc ion has been lost from the active site, 
the protein becomes denatured in a manner which cannot be totally 
reversed by the later re- introduction of this ion. 
Most workers prepared their suspected metallo -ß- lactamases in the 
absence of a zinc supplement [132, 151] and some have added this ion to 
the assay buffer [124]. It is thus possible that when assayed, the different 
metallo -ß- lactamases will have been activated to different degrees by this 
supplement, since not all metallo -ß- lactamases showed maximal activation 
at 10011M zinc sulphate [Figure 5.2]. 
Work in this thesis also demonstrated that the relative hydrolysis rates of 
various substrates by BFRo, BFRI and BFR,000 are different, suggesting 
that the substrate profiles of these enzymes will depend partly upon the 
zinc concentration present during preparation and assaying, as well as the 
Vmax and Km for the substrates in question. This is best shown in Figure 
5.1. Assuming a CfiA -type metallo- ß- lactamase was prepared with a 1mM 
ZnSO4 supplement, the rate of imipenem hydrolysis with a 1mM zinc 
sulphate supplement in the assay buffer would be approximately 50% of 
the rate obtained if no zinc sulphate was present during the assay. This 
would give a misleading result, suggesting that this enzyme could hydrolyse 
this substrate at only half the rate of cephaloridine, as opposed to a similar 
rate if the assay was repeated without a zinc supplement in the assay 
buffer. Whilst this effect is most pronounced with the carbapenems 
imipenem and meropenem, it also applied to the third generation 
cephalosporins in a similar manner, but to a lesser degree [Figure 5.1]. 
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Not only are the relative rates of substrate hydrolysis affected by the 
presence of this ion, but the ID60s of EDTA obtained with enzymes prepared 
in this manner will vary, by up to a factor of five [Table 5.1]. 
8.1.3. Recommendations From These Observations. 
These observations have widespread ramifications on the purification and 
assay methodology for these enzymes. Thus I propose that all suspected 
metallo -ß- lactamases be prepared in a suitable zwitterionic buffer with a 
1mM zinc (in the form of ZnSO4 or ZnC12) supplement wherever possible to 
ensure maximal activity and avoid the problems of metallo -ß- lactamase 
activation. It will not matter whether a metallo- ß- lactamase is inhibited by 
this zinc concentration since this inhibition is reversible, and the 
supplement could be removed by dialysis at a later stage with no deleterious 
effects on hydrolytic activity. Initially, such enzymes should be assayed in 
the absence of any zinc supplement. 
Whilst this protocol will suffice for many metallo -ß- lactamases including B. 
cereus II, Sten maltophilia L1 and CfiA -type enzymes, a detailed study of 
the effects of zinc on metallo -ß- lactamase activity should be undertaken 
with each enzyme assayed to avoid any of the potentially misleading results 
described above. 
One of the problems associated with fixing the zinc concentration at 1mM 
during metallo- ß- lactamase preparation is that this concentration may not 
be compatible with certain purification protocols including ion 
exchange/FPLC, IEF or SDS -PAGE based methods. In such cases, an 
alternative zinc concentration will have to be added. 
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8.2. Carbapenems and Clinical Isolates. 
8.2.1. Bacteroides Group Strains. 
Resistance to carbapenem antibiotics amongst members of the Bact. 
fragilis group can be mediated by a variety of mechanisms, as described in 
Section 1.8. However, the resistance which is mediated by the production of 
a carbapenem hydrolysing ß- lactamase has been shown to result from the 
expression of a CfiA -type metallo -ß- lactamase. The single exception 
reported to date has been the carbapenemase from a Bact. distasonis 
isolate which appeared not to be a metallo -ß- lactamase [157]. The isolates 
JMS -121, JMS -219 and JMS -221 all produce a single ß- lactamase of 
pI 4.6 -5.0. These enzymes have virtually identical substrate and inhibitor 
profiles to the known CfiA -type metallo -ß- lactamase from Bact. fragilis 
ED -262. Kinetic and physical data for these enzymes are also comparable, 
although there is a discrepancy between the molecular weights determined 
in this thesis and published values. Several different molecular weights of 
the CfiA, metallo -ß- lactamase have been reported by biochemical assays, 
ranging from 26kDa [216] to 44kDa [152], whereas the molecular weight by 
DNA analysis and deduced amino acid sequence was found to be 25,249Da 
[142]. However, all four ß- lactamases were purified by FPLC under similar 
conditions and showed similar elution profiles. For these reasons it can be 
concluded that these enzymes, characterised from these three isolates, are 
all CfiA -type metallo -ß- lactamases. These strains were originally isolated 
from geographically distinct regions within Great Britain and from patients 
who had not received prior imipenem therapy. Since these metallo- 
ß- lactamases could not be transferred to a rifampicin resistant Bact. 
fragilis recipient, it is likely that these enzymes are chromosomally 
encoded. Transfer to E. coli was not attempted since previous work has 
shown that a known Bacteroides plasmid could not be transferred directly to 
this species. The construction of a specific Bacteroides / E. coli shuttle 
vector with an additional origin of replication was required to facilitate 
plasmid transfer between these two organisms [228]. The antibiograms of 
these strains [Table 6.1] illustrated that these isolates were found to be 
resistant to all the antimicrobials tested, including the carbapenems. The 
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addition of BRL 42715 to imipenem both in a 2:1 ratio and at a fixed 
concentration of 2mg/1 [28, 229] potentiated the antibacterial activity of 
this carbapenem. When imipenem was tested in a 2:1 ratio with 
BRL 42715, the MIC of all four strains was lowered by at least two 
dilutions. However, this combination restored the sensitivity of only JMS- 
219 by breakpoint. The potential threat from these organisms is great, 
especially in the case of JMS -121 which was found to be resistant to 
metronidazole and clindamycin [189] as well as the carbapenems. 
It is of concern that strains producing these metallo -ß- lactamases are being 
isolated clinically, and from patients with no prior imipenem therapy. Since 
these enzymes are capable of hydrolysing virtually every class of ß- lactam 
agent, conferring resistance on the host strain, it is likely that prior 
treatment with ß- lactam compounds other than carbapenems will select for 
strains producing these enzymes. An increase in the frequency of isolation 
of these enzymes is inevitable as ß- lactam and carbapenem therapy 
becomes more widespread. The dissemination of these resistance 
determinants is currently slow, since to date, only one of the Bacteroides 
metallo -ß- lactamases has been shown to be plasmid encoded [105]. 
The sequence of the ß- lactamase from Bact. fragilis ED -262 has been 
determined and found to differ from the published CfiA sequence [142] in 
only 2 amino acids. (A. Fosberry Pers. Comm.). These mutations are not 
unique, and have also been reported in other CfiA -type metallo- 
ß-lactamases [141, 143]. To date, the sequence of four CfiA -type metallo- 
ß- lactamases have been published, in each case from an isolate identified as 
Bact. fragilis. This number of metallo-ß- lactamases have never been 
identified and sequenced from any other species. These mutations do not 
appear to affect the catalytic activity of these enzymes, since their 
substrate and inhibitor profiles are indistinguishable, nor do they alter the 
physical characteristics including pI or molecular mass by a measurable 
degree. The sequence identity of all these CfiA -type genes is greater than 
98 %. 
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Several mutations have been described in the B. cereus II metallo- 
ß-lactamase from B. cereus 569, 569H and 5/B/6. These genes show greater 
heterogeneity, differing by 25 amino acids [121]. These mutations have 
been shown to affect the hydrolytic properties of this metallo -ß- lactamase 
[135]. 
8.2.2. Aerobes. 
Several of the species examined in this thesis do not frequently cause 
infections in immunocompetent individuals. Subjects who are at risk from 
these organisms include immunocompromised or immunosuppressed 
patients, especially those in ITUs. The most commonly isolated organisms 
from these patients include Acinetobacter, Klebsiella and Stenotrophomonas. 
Certain clinical Acinetobacter and Sten. maltophilia strains are becoming 
recognised as resistant to a wide range of antimicrobials including the 
carbapenems, irrespective of whether or not the strains produce an 
imipenem hydrolysing ß- lactamase such as ARI -1 [159] or L1 [151] (this 
thesis) proving that metallo -ß- lactamase production is not a pre -requisite 
for carbapenem resistance. Klebsiella are becoming more difficult to treat in 
this situation as a result of the rapid dissemination of resistant strains 
[230 -233] and the rapid spread of resistance determinants amongst these 
organisms, as occurred with the extended spectrum ß- lactamases 
[234 -236]. Of the isolates from these species examined in this thesis, only 
the Sten. maltophilia (n =18) demonstrated any hydrolytic activity against 
imipenem. This is consistent with several other reports suggesting that the 
production of an L1 -type metallo- ß- lactamase may be ubiquitous in this 
species. Nevertheless, the strains examined in this thesis from all these 
species did show a multi -resistant profile with MIC60 values approaching, 
and MIC90 values above, the recommended breakpoints. The carbapenems 
and ciprofloxacin showed greatest antibacterial activity, although in several 
strains, these compounds would probably not be effective in vivo. Of great 
interest however, was the observation that the fourth generation 
cephalosporin cefepime showed very good activity against Enterobacter 
(n =9) and Klebsiella (n =11); both species showing MIC90s of lmgil. The 
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suggested breakpoint for this compound is 32mg/1 [213]. A larger number of 
strains would be required to determine whether this observation was 
representative of these species. This compound showed no such activity 
against the other aerobes examined. 
The combination of the ß- lactamase inhibitor clavulanic acid with the 
penicillin amoxycillin did lower the MICb0 and MIC90 values for this 
compound against all organisms tested. However, this effect was most 
marked against the random Bacteroides isolates examined (i1=166), where 
MIC60 and MIC90 values for amoxycillin were 16mg/1 and 128mg/1 (both 
above the breakpoint of 4mg/1), but were reduced to 0.5mg/1 and 4mg/1 
respectively in the presence of amoxycillin and clavulanic acid. In this case, 
the MIC90 for this treatment was below the NCCLS breakpoint of 8mg/1. 
Cefotaxime was the only cephalosporin with MIC60 values of 8mg/1, below 
the breakpoint of 32mg/l. These were the only treatments apart from the 
carbapenems which were effective against these organisms. However, since 
the carbapenems are currently licensed for use only in ITUs, co- amoxyclav 
is the only compound available to general practitioners which showed good 
activity against these organisms with MIC90 values below the breakpoint. 
The carbapenems imipenem and meropenem showed identical MIC60 and 
MIC90 values, both at 0.125mg/1 and 1mg/1 respectively, and were well below 
the breakpoint of 16mg/1. Of the 166 isolates tested, only 1 organism was 
found to be resistant to these agents, with MICs of 16mg/1 for both 
compounds. No imipenem hydrolysis could be detected by a cell -free lysate 
of this organism and thus it was concluded that imipenem resistance 
amongst these isolates was 0.6 %. This value is consistent with other 
surveys which report the incidence of imipenem resistance between 0.1% 
and 4% [157, 172]. However, these reports cannot be compared objectively 
since different groups have used different media and different breakpoints in 
these surveys, with very few strictly adhering to either the 1991 BSAC 
[199] or 1992 NCCLS [176] guidelines. It is possible that several of these 
isolates may harbour a silent metallo -ß- lactamase gene [178, 179], and 
that such a gene could become expressed after repeated exposure to low 
levels of imipenem. 
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A conflict has arisen since different guidelines for susceptibility testing have 
been published by the BSAC [199] and NCCLS [176] which recommend 
different breakpoints for many compounds. One such example is the 
recommended breakpoint for amoxycillin and the ß- lactam / ß- lactamase 
inhibitor combination amoxycillin / clavulanic acid. 
The 1991 BSAC guidelines state that the breakpoint of amoxycillin is 8mg/1 
and the breakpoint of amoxycillin / clavulanic acid is 1mg/1 (against non - 
Pseudomonas aerobes). In this case an eight -fold reduction in MIC in the 
presence of clavulanic acid would be required purely to prevent an apparent 
increase in resistance to this `combination' treatment as opposed to 
`monotherapy'$ with amoxycillin. Whilst in certain cases, the presence of 
clavulanic acid does lower the MIC by this factor, any reduction in MIC 
mediated by this combination will increase the efficacy of this treatment. In 
this scenario, it is quite possible for an organism (hypothetical amoxycillin 
MIC of 4mg/1; mediated by the production of an Ambler class C 
ß- lactamase; resistant to clavulanic acid) to be regarded as resistant to 
amoxycillin / clavulanic acid, but sensitive to amoxycillin by breakpoint. 
Such a difference in breakpoint between these two treatments is too large. 
In addition to this, the BSAC breakpoint for co- amoxyclav is very low, at 
least two dilutions below any other compound, including the carbapenems, 
and is not representative of the physiological concentration of this 
treatment in vivo. 
The 1992 NCCLS breakpoints of these compounds against aerobes are 
both 8mg/1. Use of this guideline will better portray the beneficial effect of 
the presence of the inhibitor clavulanic acid in this treatment. 
' Combination therapy in this instance refers to the combination of amoxycillin / 
clavulanic acid, even though these compounds are administered together in the form of 
Augmentin. The word combination is used solely to differentiate this treatment from 
amoxycillin monotherapy. 
s Amoxycillin is referred to as monotherapy solely to differentiate this treatment from 
the combination of amoxycillin and clavulanic acid. 
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Both of these guidelines recommend the use of IST agar for aerobic 
organisms, and Wilkins - Chalgren agar supplemented with 5% horse blood 
for anaerobic organisms. Nevertheless, several groups have determined 
susceptibilities on other media including DST and Mueller -Hinton agars 
[174, 237, 238]. The use of these agars is known to affect the MIC values 
for several organisms [177, 214, 239], with MIC's generally lower on IST 
than on DST, which are lower than on Mueller -Hinton. This difference was 
initially attributed to the nutritional value of the media, but other factors 
including zinc ion concentration has also been implicated in elevating MICs, 
especially when testing Sten. maltophilia isolates [214]. 
In this thesis, both P. aeruginosa (n =15) and Ent. aerogenes (n =1) isolates 
have been described in which imipenem resistance is mediated not by the 
production of a metallo -ß- lactamase by the hyper- production of a 
ß- lactamase which may belong to Ambler class C, possibly in conjunction 
with a drop in membrane permeability. Since these ß- lactamases could not 
hydrolyse imipenem, the mechanisms of imipenem resistance were not 
examined further, as this type of resistance has been previously reported 
[240 -242]. This resistance was found to be stable in the Ent. aerogenes 
isolate; a 26 day passage lowering the MIC of imipenem by only 2 dilutions. 
The carbapenems were the only ß- lactams with MIC90 values within one 
dilution of the breakpoint, whilst ciprofloxacin was the only compound with 
MIC90s below the breakpoint of 4mg/l, namely 2mg/l. Whilst infections 
involving these organisms can be fatal, the multi- resistant profiles of the 
Burk. cepacia strains examined have serious implications for patients 
suffering from cystic fibrosis. It can be seen from Table 4.3 that these 
strains were resistant not only to the penicillins and cephalosporins, but 
resistance was also observed to both carbapenems and to ciprofloxacin. 
Such organisms are becoming harder to treat in the clinical setting. 
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8.3. Organisms of the Genus Flavobacterium. 
Organisms of the genus Flavobacterium have been recognised as the 
causative agent in several infections, most notably neonatal meningitis. 
8.3.1. Imipenem Hydrolysis by Flavobacterium Isolates. 
The 10 Flavobacterium strains examined in this thesis were all clinical 
specimens originally isolated from several different sites [Table 7.1]. All 10 
of these were isolated before carbapenem antibiotics were licensed for use 
clinically. F. gleum NCTC 10795 was isolated in 1957, nine years before 
Sabath and Abraham described the first metallo -ß- lactamase [164]. The 
small scale cultures of all but two of these strains were able to cause 
significant imipenem hydrolysis. All isolates showed some hydrolytic 
activity against imipenem. The enzymes responsible for this imipenem 
hydrolysis would require further examination to determine whether this 
hydrolysis was mediated by a metallo -ß- lactamase or serine active site 
ß- lactamase. The preliminary data [Table 7.2] indicated that these 
enzymes were sensitive to inhibition with EDTA. The total sample volume 
present in the spectrophotometric cuvette was 150µ1; 50p1 sample, 50µ1 
EDTA and 50µ1 substrate. Whilst the EDTA concentration may have been 
sufficient to effect total zinc sequestration, it is possible that the proteins 
and ions present in the crude cell extract could overwhelm the EDTA (by 
total amount) present. If this were the case, true inhibition levels would be 
greater than those actually observed. 
All metallo -ß- lactamases reported to date have been shown to be sensitive 
to EDTA, but the serine active site carbapenemase from Serratia 
marcescens S6 has also been shown to be sensitive, to this chelator [156]. 
This enzyme was thought to be a metallo -ß- lactamase until its sequence 
was determined [102]. The reason for this inhibition is unclear, but 
demonstrated that EDTA sensitivity alone is not sufficient evidence to 
identify unequivocally such an enzyme as a metallo -ß- lactamase. 
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Nevertheless, this does not detract from the fact that imipenem hydrolysis 
was observed in preparations from all isolates, indicating that all of the 
tested isolates produced a ß- lactamase capable of hydrolysing imipenem. It 
is possible that all Flavobacterium organisms possess a carbapenemase 
gene, and that production of such a carbapenemase, possibly a metallo- 
ß- lactamase may be ubiquitous in this genus. It is currently thought that 
carbapenemase production may be ubiquitous in Aeromonas spp. [163] and 
Sten. maltophilia. The observations made in this thesis considerably 
increases the numbers of organisms producing these enzymes. This leads to 
an increase in the reservoir of ß- lactam resistance determinants which 
could cause treatment failure or could lead to the acquisition of these 
resistance determinants by more clinically important genera, and hence to 
treatment failure in cases involving such organisms. It is also conceivable 
that the presence of such a ß- lactamase producing organism could effect 
treatment failure if colonising the same site as another, more pathogenic 
organism. It has previously been shown that a metallo -ß- lactamase 
producer could confer protection upon another organism which was present 
as part of a mixed infection. In an experimental model, a metallo- 
ß- lactamase producing Bact. fragilis strain was able to confer resistance 
upon a ß- lactamase negative E. coli highly sensitive to ß- lactam antibiotics 
which was colonising the same site [137]. 
8.3.2. F. spiritivoruna NCTC 11388. 
F. spiritivorum NCTC 11388 and F. meningosepticum NCTC 10016 both 
showed similar ß- lactamase profiles by nitrocephin stained IEF, with bands 
of ß- lactamase activity at pI 8.6, 7.6 and 5.4. Whilst cell -free extracts of 
both isolates were able to hydrolyse imipenem spectrophotometrically and 
were sensitive to EDTA inhibition [Table 7.2], it was unclear by IEF alone 
which ß- lactamase was responsible for the carbapenem hydrolysis. 
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F. spiritivorum NCTC 11388 was chosen for further examination as a 
result of its carbapenem MIC values [Table 7.2] and the fact that one band 
could still be visualised by nitrocephin- stained IEF after a 100µM 
BRL 42715 overlay [Figure 7.1]. The whole purification methodology for this 
strain was based upon the deduction that FSP -3 was a metallo- 
ß-lactamase. This deduction proved to be incorrect, once FSP -1 had been 
resolved and assayed separately from the other enzymes. One of the 
difficulties encountered with this isolate was the low level of un- inducible 
ß- lactamase production, which made purification problematic. 
Nevertheless, the carbapenemase FSP -1 exhibited a substrate and 
inhibitor profile indicative of a metallo-13-lactamase. FSP -2 appeared to be a 
serine active ß- lactamase by its substrate and inhibitor profiles, and may 
be SHV- or OXA- derived. Only nitrocephin hydrolysis could be 
unequivocally determined by FSP -3, which remained unaffected by any of 
the clinical or diagnostic ß- lactamase inhibitors tested, including EDTA 
[Figure 7.7]. It is conceivable that this enzyme may not be a ß- lactamase 
as nitrocephin hydrolysis by proteins other than ß- lactamases has been 
reported previously [243]. An improved separation protocol giving a greater 
specific activity would be needed to prove this. 
The only previous report of a metallo -ß- lactamase from an organism of the 
genus Flavobacterium described an enzyme isolated from a strain of 
Flavobacterium odoratum which had a pI of 5.8 [144]. In 1994, Blahova and 
co- workers [191] reported two F. meningosepticum strains able to hydrolyse 
imipenem. However, both strains were consecutive isolates from the same 
patient and had identical antibiograms, and may in fact be a single strain. 
The only other work conducted on these ß- lactamases described partial 
inhibition by EDTA, but as previously stated, this evidence is not sufficient 
to identify an enzyme as a metallo -ß- lactamase. FSP -1, the metallo- 
ß- lactamase described in this thesis from F. spiritivorum NCTC 11388 had 
a pI of 8.6 and a substrate profile distinct from other metallo -ß- lactamases 
described to date [Figure 7.8]. This enzyme is different from the metallo- 
ß- lactamase previously described from an isolate of this genus, and 
suggests that the carbapenemases produced by organisms of the genus 
Flavobacterium are heterogeneous in nature, more so that the 
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carbapenemases described from A. hydrophila, Bact. fragilis or B. cereus 
[Table 1.4]. It is likely that the F. odoratum metallo- ß- lactamase and this 
enzyme are not closely related. 
From this it can be concluded that the FSP -1 ß- lactamase is novel and is 
probably a novel metallo-ß-lactamase. 
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CHAPTER NINE 
Epilogue 
Bacterial resistance to carbapenem antibiotics is rare. Of the possible 
resistance mechanisms, the production of a carbapenemase is the most 
common, and represents the greatest threat to the clinical use of these 
compounds. Both serine active carbapenemases and metallo -ß- lactamases 
have been described from a variety of species. In reports where novel 
carbapenemases have been described, little or no work has been 
undertaken to optimise the purification methodology applied to these 
enzymes. In addition to this, many workers have simply applied an existing 
assay system to the analysis of these enzymes, but added a zinc sulphate 
supplement to increase metallo -ß- lactamase activity, without considering 
any possible inhibitory effect of this supplement on the hydrolytic activity 
of these enzymes. Work undertaken in this thesis redresses this balance 
and also characterises the substrate specific inhibitory effect of zinc on the 
hydrolytic activity of several different carbapenemases, both serine active 
site ß- lactamases and metallo -ß- lactamases. This thesis also describes an 
assay system to determine the most effective ion exchange matrix to purify 
a ß- lactamase. 
Three imipenem resistant Bact. fragilis isolates were found to produce a 
metallo -ß- lactamase which showed biochemical properties indicative of a 
CfiA type metallo -ß- lactamase, but did not appear to be transferable. The 
novel metallo -ß- lactamase FSP -1, from a clinical isolate of F. spiritivorur 
was characterised, and other data presented in this thesis indicate that 
carbapenemase production may be ubiquitous within this genus, suggesting 
that carbapenemase production is more common than previously thought. 
This greatly increases the reservoir of potential carbapenem resistance 
determinants which could potentially lead to treatment failure. 
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Correspondence 
Prophylaxis after splenectomy 
J Antimicrob Chemother 1994; 34: 295 
Sir, 
We read with interest the leading article by 
Read & Finch (1994), which reflected current 
interest by concentrating on the susceptibility 
of splenectomised patients to overwhelming - sepsis caused by Streptococcus pneumoniae 
(Kinnersly, Wilkinson & Srinivasan, 1993; 
McMullin & Johnston, 1993). However it 
should be pointed out, that in one study by 
Ellison & Fabri (1983) S. pneumoniae was 
responsible for only half of all infections after 
splenectomy. Other capsulated organisms are 
-also possible - causes of severe infection; 
especially in children and young adults. 
Attention needs to be drawn to the possibility 
of fatal infection caused by Haemophilus 
influenzae type b. 
This problem was recently met in a young, 
previously fit man aged 19 years who had had 
his spleen removed, because of an accident in 
1989. One evening in December 1993, he 
complained of feeling unwell and of having 
`flu' like symptoms. At about 5 a.m. the 
following morning, when seen by his mother, 
he said he had slept badly and felt sick. She left 
the house and on her return at about 3 p.m. 
found him dead. Post -mortem swabs of 
meninges, nose and upper trachea were taken, 
together with pericardial fluid, heart blood and 
CSF. All specimens yielded a profuse growth 
of H. influenzae type b. 
We believe that this case, like the one 
reported by Teare & O'Riordan (1992), 
reinforces the case for the administration of H. 
influenzae type b vaccine not just to all splenec- 
tomised children who have not yet received it, 
but also to all splenectomised adults (Flegg, 
1994). 
ROBERT C. SPENCER° 
JOHN C. CLARKb 
°Department of Microbiology, 
Royal Hallamshire Hospital, 
Glossop Road, Sheffield SIO 2JF; 
bMedico -Legal Centre 
Watery Street 
Sheffield, S3 7ES, UK 
References 
Ellison, E. C. & Fabri, P. J. (1983). Complications of 
splenectomy. Etiology, prevention and 
management. Surgical Clinics of North America 
63, 1313 -30. 
Flegg, P. J. (1994). Long term management after 
splenectomy. British Medical Journal 308, 131. 
Kinnersley, P., Wilkinson, C. E. & Srinivasan, J. 
(1993). Pneumococcal vaccination after 
splenectomy: survey of hospital and primary care 
records. British Medical Journal 307, 1398 -9. 
McMullin, M. & Johnston, G. (1993). Long term 
management of patients after splenectomy. British 
Medical Journal 307, 1372 -3. 
Teare, L. & O'Riordan, S. (1992). Is splenectomy 
another indication for Haemophilus influenzae 
type b vaccination? Lancet 340, I362. 
Effects of zinc concentration on the 
imipenemase activity of a metallo- ß-lactamáse 
from a Bacteroides fragilis clinical isolate 
J Antimicrob Chemother 1994; 34: 295 -297 
Sir, 
The expression of a serine active chromosomal 
ß- lactamase by organisms from the Bacteroides 
fragilis group is common, conferring resistance 
to several penicillins and cephalosporins. 
However, the production of a metallo-ß- lacta- 
mase is currently thought to represent the 
main threat to the use of carbapenems for 
serious anaerobic clinical infections. It has 
been reported that bacteria from this group 
can produce a variety of metallo -ß- lactamases 
which have the ability to hydrolyse carba- 
penems as well as cephalosporins and penicil- 
lins (Cuchural et al., 1990; Rasmussen, 
Gluzman & Tally, 1991). 
We report an observation made during an 
assay for ß- lactamase activity of an enzyme 
produced by a B. fragilis clinical isolate desig- 
nated JMS -221. This isolate was originally 
isolated at Ninewells hospital, Dundee, from 
the abdominal wounds of a patient with 
myelofibrosis and received from Dr J. Brazier 
(Public Health Laboratory, Cardiff). This 
isolate was positively identified as B. fragilis 

























The assay for ß- lactamase activity was 
conducted at 37 °C on a Perkin -Elmer Lambda 
2 spectrophotometer in 25 mM PIPES buffer 
pH 7.0 made up in MilliQ water, measuring 
the decrease in absorbance of 100 µM 
substrate. Cephaloridine, cefuroxime, cefo- 
taxime, and imipenem were used as substrates, 
all at 100 pM and the decrease in absorbance 
was measured at 255, 260, 265 and 299 nm 
respectively. It has been reported that the type 
of glassware used during the preparation and 
10000 storage steps can greatly affect the concentra- 
tion of zinc in the assay solution (Hawkey et 
al., 1993). To circumvent this, disposable 
glassware was used which had been rinsed -in -- 
MilliQ de- ionized water. and all bottles had 
plastic caps. 
During the assay for ß- lactamase activity 
with imipenem as substrate. it was observed 
that the concentration of zinc sulphate present 
in the assay buffer affected the rate of hydro- 
lysis of imipenem. By extending this observa- 
tion, it was possible to determine an IDSÒ of 
zinc sulphate (concentration required to 
inhibit enzyme activity by 50 %) for this 
enzyme, taking the rate of hydrolysis of 
100 µM imipenem without any added zinc 
sulphate as 100 %. This Ill° was determined as 
1 mM zinc sulphate as shown in the figure, 
which also shows the enzyme activity against 
cephaloridine, cefuroxime. and cefotaxime at 
different concentrations of zinc sulphate. In 
each case. the rate of hydrolysis of 100 µM 
substrate without added zinc sulphate was 
taken as 100% enzyme activity. It was found 
that the effect of zinc sulphate concentration 
on the activity of this metallo -ß- lactamase was 
significantly greater for imipenem than for any 
of the cephalosporins tested. 
The addition of zinc sulphate to the assay 
buffer did not cause any detectable hydrolysis 
of the ß- lactam ring of any of the substrates in 
our assay system despite the fact that ß- lactam 
hydrolysis by Zn2+ ions has been reported 
when present alone or in conjunction with a 
buffer (Benitez et al., 1991). A 5 min pre - 
incubation of the enzyme with the assay buffer 
containing the appropriate zinc concentration 
made negligible difference to the assay as 
compared with no pre- incubation. It was also 
noted that in the experiments with and without 
pre- incubation, the addition of less than 10 pM 
zinc sulphate increased the rate of hydrolysis 
of imipenem to marginally over 100% (data 
not shown) indicating that this may be a more 
appropriate concentration for this assay. 
This work details the identification of a 
Zinc sulphate (gm) 
Figure. The effect of zinc sulphate supplements on 
the activity of the metallo -ß- lactamase produced by 
JMS -221 for various substrates. , Cephaloridine; 
O, cefuroxime; O. cefotaxime; Q imipenem. 
Crude sonicated cell extracts containing the 
enzyme were found to be sensitive to overnight 
dialysis against 25 mM PIPES buffer -pH 7.0 
supplemented with 10 mM EDTA. This dialy- 
sis led to greater than 99% inhibition of the 
enzyme with imipenem and nitrocefin as 
substrates, but had no effect on the activity of 
the TEM -1 ß- lactamase. The activity of the 
B. fragilis enzyme was restored to 22% of the 
original activity by a 10 min pre- incubation of 
the EDTA treated enzyme with 10 mM zinc 
sulphate which, when it was diluted, resulted 
in a final concentration of 167 uM in the assay 
solution. As a result of this observation, and 
the fact that this enzyme was able to hydrolyse 
imipenem, it is proposed that this enzyme is a 
metallo -ß- lactamase. 
The enzyme was partially purified by 
passing a sonicated, cell free extract through a 
Sephadex G75 gel filtration column, with 
25 mM PIPES buffer pH 7.0 supplemented 
with 1 mM zinc sulphate as the elution buffer. 
During all stages of the preparation, 25 mM 
PIPES buffer pH 7.0 supplemented with 1 mM 
zinc sulphate was used as a buffer as it is 
known that metallo -ß- lactamases require zinc 
to maintain enzyme activity (Sabath & 
Abraham, 1966; Davies & Abraham, 1974; 
Felici et al., 1993). The molecular weight of the 
enzyme determined by this gel filtration was 
25,000. Prior to the assay for activity, the 
enzyme was dialysed four times against a 
greater than 100 -fold excess of PIPES buffer 
made up in MilliQ water without the zinc 
sulphate supplement to remove any excess 
Zn2+ ions which were not co- ordinated with 
the enzyme. 
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metallo -ß- lactamase in B. fragilis. We have 
made the novel observation that the concen- 
tration of Zn2+ in the assay buffer affects the 
rate of hydrolysis of imipenem to a signifi- 
cantly greater extent than the hydrolysis of 
cephalosporins. Additional research is 
required to comprehend fully this observation 
and to ascertain whether it applies to other 
metallo -ß- lactamases. As a consequence of 
these investigations, we advise that any initial 
studies on metallo -ß- lactamases should include 
an investigation of the effect of zinc concentra- 
tion on enzyme activity. This will enable an 
appropriate concentration of zinc to be used in 
the kinetic characterization of the enzyme. 
J. G. R. MUNN 
C. J. THOMSON 
S. G. B. AMYES 
Department of Medical Microbiology, 
University of Edinburgh Medical School, 
Teviot Place, 
Edinburgh, EH8 9AG, UK 
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Susceptibility of enterococci to ciprofloxacin 
J Antimicrob Chemother 1994; 34: 297-298 
Sir, 
Ciprofloxacin is widely regarded as having 
only modest antibacterial activity against 
enterococci. Guidelines produced by the 
British Society for Antimicrobial Chemo- 
therapy (BSAC) Working Party (1991) recom- 
mend breakpoint values of > 4 mg /L to define 
resistance and 5 1 mg /L to indicate suscept- 
ibility. As a consequence of this a high propor- 
tion of enterococci are typically found to be of 
moderate susceptibility to ciprofloxacin i.e. 
MIC > 1 < 4 mg /L, (Barry & Jones, 1989). In 
our laboratory we tested 136 consecutive 
clinical isolates of enterococci from a variety 
of sources against ciprofloxacin. Stepwise dilu- 
tions of ciprofloxacin were prepared in 
Diagnostic Sensitivity Test agar (DST) 
(Unipath, Basingstoke, UK) and an inoculum 
of 105 organisms was applied to the agar 
surface. Disc testing was also performed in 
parallel for all strains on DST agar using 
standard methods. Two strengths of disc 
content were used containing 1 and -5 pg cipro- 
floxacin respectively (Mast Laboratories, 
Bootle. UK). The results of the MIC studies 
are shown in the Table. 
The results indicate that this particular 
population of enterococci showed a marked 
bimodal distribution of sensitive and highly 
resistant strains as no single isolate demon- 
strated a MIC of between 4 and > 8 mg /L of 
ciprofloxacin. When these MIC results were 
then compared with antibiotic zone sizes, it 
was found that, perhaps not surprisingly, 
almost all of the enterococci in the "moder- 
ately susceptible" group (66% of the total 
isolates) showed virtually no inhibition to a 
ciprofloxacin 1 pg disc. However, when a 
ciprofloxacin 5 pg disc was tested there was 
excellent discrimination between moderately 
susceptible strains (all isolates produced a zone 
size 15 mm) and resistant isolates which 
showed no zone of inhibition. We believe these 
findings demonstrate that ciprofloxacin 1 Etg 
disc provides '.ittle discrimination when testing 
enterococci and a 5 pg disc produces more 
informative results. . 
We would wish to emphasize that we do not 
advocate ciprofloxacin as a drug of choice 
against enterococci, particularly in serious 
infections. However, there is some evidence 
that it may be clinically appropriate, for 
example, in cases of complicated urinary tract 
infection (Muranaka & Greenwood, 1988). 
Indeed, perhaps the greatest value of testing 
